var title_f39_59_40880="PIP synovitis US in RA";
var content_f39_59_40880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F86268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F86268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Ultrasound image of synovitis of a proximal interphalangeal joint in a patient with rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel shows synovitis (arrowheads) of the third proximal interphalangeal joint (curved arrow) from the dorsal view in a patient with rheumatoid arthritis. Right panel shows positive power Doppler synovitis in the third proximal interphalangeal joint of the same patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40880=[""].join("\n");
var outline_f39_59_40880=null;
var title_f39_59_40881="Patient information: Scarlet fever (The Basics)";
var content_f39_59_40881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83310\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/0/1028\">",
"         Strawberry tongue",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/26/28066\">",
"         Patient information: Sore throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/34/8738\">",
"         Patient information: Strep throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/15/36082\">",
"         Patient information: Sore throat in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Scarlet fever (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/scarlet-fever-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23424206\">",
"      <span class=\"h1\">",
"       What is scarlet fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Scarlet fever is a condition that causes a red rash. People with scarlet fever usually also have a sore throat. This is because scarlet fever is caused by the bacteria that cause a condition called &ldquo;strep throat.&rdquo; A person with scarlet fever has a red rash and usually has strep throat, too. &nbsp;",
"     </p>",
"     <p>",
"      Strep throat is common in children. But not all children with strep throat get scarlet fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424220\">",
"      <span class=\"h1\">",
"       What are the symptoms of scarlet fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rash &ndash; This usually starts on the head and neck and spreads to the body, arms, and legs. It causes:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Red spots that turn white when you press on the skin",
"       </li>",
"       <li>",
"        Small, raised bumps &ndash; Skin might feel rough, like sandpaper.",
"       </li>",
"       <li>",
"        Peeling skin &ndash; This happens when the rash is going away.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bright red tongue with small bumps on it &ndash; Doctors call this a &ldquo;strawberry tongue&rdquo; (",
"        <a class=\"graphic graphic_picture graphicRef83203 \" href=\"mobipreview.htm?1/0/1028\">",
"         picture 1",
"        </a>",
"        ). &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A person with scarlet fever might also have symptoms of strep throat. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A sore throat &ndash; This might start suddenly.",
"       </li>",
"       <li>",
"        White patches in the back of the throat",
"       </li>",
"       <li>",
"        Swollen glands in the neck",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms usually get better in 2 to 5 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424235\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you or your child has a sore throat and rash, call your doctor or nurse. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424250\">",
"      <span class=\"h1\">",
"       Is there a test for scarlet fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will do an exam and look at the rash. He or she can also check for the bacteria that cause strep throat and scarlet fever. The doctor or nurse will run a swab (Q-Tip) along the back of your child&rsquo;s throat, and test it for the bacteria.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424265\">",
"      <span class=\"h1\">",
"       How is scarlet fever treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Scarlet fever is treated with antibiotics. The antibiotics reduce the symptoms of scarlet fever and keep it from spreading to other people.",
"     </p>",
"     <p>",
"      Antibiotics also keep scarlet fever from causing other health problems. In some people, the bacteria that cause scarlet fever can cause a serious disease called &ldquo;acute rheumatic fever.&rdquo; This disease damages the heart and causes other problems. The heart damage gets worse over time.",
"     </p>",
"     <p>",
"      Children between the ages of 5 and 15 are the most likely to get acute rheumatic fever. If your child gets scarlet fever, he or she needs antibiotics. The antibiotics kill the bacteria so they do not cause acute rheumatic fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424280\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/34/8738?source=see_link\">",
"       Patient information: Strep throat in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/26/28066?source=see_link\">",
"       Patient information: Sore throat in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36082?source=see_link\">",
"       Patient information: Sore throat in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/59/40881?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83310 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40881=[""].join("\n");
var outline_f39_59_40881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424206\">",
"      What is scarlet fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424220\">",
"      What are the symptoms of scarlet fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424235\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424250\">",
"      Is there a test for scarlet fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424265\">",
"      How is scarlet fever treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424280\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/0/1028\">",
"      Strawberry tongue",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36082?source=related_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/26/28066?source=related_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40882="Patient information: Ileostomy care (The Basics)";
var content_f39_59_40882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86737\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/17/22802\">",
"          Ileostomy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/13/18653\">",
"           Foods that can affect bowel movements and gas",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/9/38034\">",
"         Patient information: Colectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/38/11875\">",
"         Patient information: Colostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/56/10115\">",
"         Patient information: Crohn's disease in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/31/22002\">",
"         Patient information: Gas and bloating (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/17/42258\">",
"         Patient information: Ulcerative colitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/40/24196\">",
"         Patient information: Crohn's disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ileostomy care (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H85326713\">",
"      <span class=\"h1\">",
"       What is an ileostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ileostomy is an opening in the belly made by a doctor as a way for bowel movements to leave the body. To make an ileostomy, your doctor will do a procedure to make a small opening in your belly. Then he or she will connect your small intestine to this opening (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef86623 \" href=\"mobipreview.htm?22/17/22802\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      An ileostomy is sometimes called a \"stoma,\" which is a medical word that means \"opening.\" After an ileostomy is made, your bowel movements will come out through the stoma into a bag that is attached to your skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326763\">",
"      <span class=\"h1\">",
"       What will my bowel movements be like with an ileostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your bowel movements will be looser and more frequent than they used to be.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326778\">",
"      <span class=\"h1\">",
"       How do I manage my ileostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A special nurse (called an ostomy nurse) will teach you how to manage your ileostomy. He or she will teach you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        When and how to empty the bag that collects your bowel movements",
"       </li>",
"       <li>",
"        When and how to put on a new bag to collect your bowel movements",
"       </li>",
"       <li>",
"        How to check your stoma for problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are different types of ileostomy bags that people can use. With some types of bags, you empty, clean, and reuse them. With other types, you throw them out after each use.",
"     </p>",
"     <p>",
"      You might worry that your bag will leak, or that other people will be able to smell your bowel movements. But these things rarely happen. The bags are made so that they do not leak or smell.",
"     </p>",
"     <p>",
"      Some people have a certain type of ileostomy. They don&rsquo;t use a bag to collect their bowel movements. Instead, they put a tube in their stoma to clean out their bowel movements a few times a day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326793\">",
"      <span class=\"h1\">",
"       What problems can happen with an ileostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen with an ileostomy, either right away or years later. Let your doctor or nurse know if you have any of the following symptoms or problems:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your stoma is swollen or larger than usual.",
"       </li>",
"       <li>",
"        Your stoma is smaller than usual.",
"       </li>",
"       <li>",
"        Your stoma leaks more than usual.",
"       </li>",
"       <li>",
"        You have a rash or sores around your stoma.",
"       </li>",
"       <li>",
"        You have diarrhea.",
"       </li>",
"       <li>",
"        You have sudden belly pain, cramps, or nausea.",
"       </li>",
"       <li>",
"        You are dehydrated. Dehydration is when the body loses too much water. Symptoms of dehydration include not making as much urine or having dark yellow urine, or feeling thirsty, tired, dizzy, or confused.",
"       </li>",
"       <li>",
"        You haven&rsquo;t had any gas or bowel movements for 4 to 6 hours (during the day). These symptoms could mean that your stoma is blocked.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326808\">",
"      <span class=\"h1\">",
"       What should I know about taking medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people have an ileostomy, their body doesn&rsquo;t always absorb medicines normally. Because of this, try to use liquid medicines instead of pills. Do not take pills labeled &ldquo;enteric coated,&rdquo; &ldquo;time release,&rdquo; or &ldquo;extended release.&rdquo; Your body might not absorb these types of pills well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326823\">",
"      <span class=\"h1\">",
"       Do I need to follow a special diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. When people have an ileostomy, their body doesn&rsquo;t always absorb water, vitamins, and salts normally. Because of this, you should drink plenty of fluids to avoid getting dehydrated.",
"     </p>",
"     <p>",
"      You should avoid eating foods that could easily block your intestine or stoma. Some of these foods include popcorn, mushrooms, dried fruit, and foods with skin.",
"     </p>",
"     <p>",
"      The foods you eat can also affect the odor of your bowel movements, and how solid or loose they are. Certain foods can also make you have more gas. Foods that can affect your bowel movements and gas are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef58115 \" href=\"mobipreview.htm?18/13/18653\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326838\">",
"      <span class=\"h1\">",
"       What will my life be like with an ileostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should be able to live an active and normal life with your ileostomy. But many people worry about the following things:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Clothes &ndash; You do not need to wear special clothes. Other people won&rsquo;t be able to see your bag under your clothes.",
"       </li>",
"       <li>",
"        Baths and showers &ndash; You can take a bath or shower with or without your bag on.",
"       </li>",
"       <li>",
"        Sports &ndash; You will probably be able to play most sports. You might want to wear a special belt to protect your bag and keep it in place. Doctors usually recommend that people with an ileostomy not play certain contact sports (such as football) or lift weights.",
"       </li>",
"       <li>",
"        Swimming &ndash; You can swim with your bag on. Make sure to empty your bag before you swim.",
"       </li>",
"       <li>",
"        Sex &ndash; You can have sex. But you might want to wear a special wrap to protect (and hide) your bag during sex.",
"       </li>",
"       <li>",
"        Travel &ndash; When you travel, be sure to bring extra supplies to manage your ileostomy. If you fly, take your supplies in your carry-on luggage.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is normal to feed sad, upset, or worried when you have an ileostomy. If you have these feelings, try to get help. You can talk with a family member, friend, or counselor. You might also find it helpful to go to a support group for people with an ileostomy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H85326853\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=see_link\">",
"       Patient information: Crohn's disease in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=see_link\">",
"       Patient information: Ulcerative colitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/31/22002?source=see_link\">",
"       Patient information: Gas and bloating (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/9/38034?source=see_link\">",
"       Patient information: Colectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=see_link\">",
"       Patient information: Colostomy care (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=see_link\">",
"       Patient information: Crohn's disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/59/40882?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86737 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40882=[""].join("\n");
var outline_f39_59_40882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326713\">",
"      What is an ileostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326763\">",
"      What will my bowel movements be like with an ileostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326778\">",
"      How do I manage my ileostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326793\">",
"      What problems can happen with an ileostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326808\">",
"      What should I know about taking medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326823\">",
"      Do I need to follow a special diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326838\">",
"      What will my life be like with an ileostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85326853\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/17/22802\">",
"       Ileostomy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/13/18653\">",
"        Foods that can affect bowel movements and gas",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/9/38034?source=related_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/31/22002?source=related_link\">",
"      Patient information: Gas and bloating (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40883="AGEP";
var content_f39_59_40883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent nonfollicular pustules superimposed on&nbsp;edematous erythema in a 46-year-old woman&nbsp;with AGEP. A skin biopsy showed intracorneal pustules with numerous neutrophils and neutrophilc infiltration of the epidermis and upper dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Vincent C.B. Lin, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40883=[""].join("\n");
var outline_f39_59_40883=null;
var title_f39_59_40884="Methocarbamol: Pediatric drug information";
var content_f39_59_40884=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methocarbamol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24677?source=see_link\">",
"    see \"Methocarbamol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/1/23572?source=see_link\">",
"    see \"Methocarbamol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Robaxin&reg;;",
"     </li>",
"     <li>",
"      Robaxin&reg;-750",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Robaxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Nonparalytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24677?source=see_link\">",
"      see \"Methocarbamol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tetanus: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (recommended",
"     <b>",
"      only",
"     </b>",
"     for use in tetanus): 15 mg/kg/dose or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose, may repeat every 6 hours if needed; maximum dose: 1.8 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-2 g by direct I.V. injection, which may be followed by an additional 1-2 g by infusion (maximum dose: 3 g total); followed by 1-2 g every 6 hours until NG tube or oral therapy possible; total daily dose of up to 24 g may be needed; injection should not be used for more than 3 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Muscle spasm:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Adolescents &ge;16 years and Adults: 1.5 g 4 times/day for 2-3 days (up to 8 g/day may be used for severe conditions); decrease dose to 4-4.5 g/day as 1 g 4 times/day or 750 mg every 4 hours or 1.5 g 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: Adults: Initial: 1 g; may repeat every 8 hours if oral administration not possible; maximum dose: 3 g/day for 3 consecutive days (except when treating tetanus); may be reinstituted after 2 drug-free days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Clearance is reduced by as much as 40% in patients with renal failure on hemodialysis; avoid use or reduce dosage and monitor closely; do not administer parenteral formulation to patients with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Specific dosing guidelines are not available; clearance may be reduced by as much as 70% in cirrhotic patients",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robaxin&reg;: 100 mg/mL (10 mL) [contains natural rubber/natural latex in packaging, polyethylene glycol 300]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robaxin&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robaxin&reg;-750: 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: May be injected directly I.V. without dilution at a maximum rate of &gt;3 mL/minute; may also be diluted in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W to a concentration of 4 mg/mL and infused more slowly; patient should be in the recumbent position during and for 10-15 minutes after I.V. administration. Monitor closely for extravasation; pH: 3.5-6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Adults: Maximum of 5 mL can be administered into each gluteal region; not recommended for SubQ administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: May be crushed and mixed with food or liquid if needed.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Prior to dilution, store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of muscle spasm associated with acute painful musculoskeletal conditions (eg, tetanus) (FDA approved in ages &ge;16 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methocarbamol may be confused with mephobarbital",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Robaxin&reg; may be confused with ribavirin, Skelaxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Robaxin [U.S., Canada, Great Britain, Greece, Spain] may be confused with Rubex brand name for ascorbic acid [Ireland]; doxorubicin [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, flushing, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, confusion, coordination impaired (mild), dizziness, drowsiness, fever, headache, insomnia, lightheadedness, sedation, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema,  pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, metallic taste, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions including anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methocarbamol or any component; renal impairment (injectable formulation)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use injectable form cautiously in patients with suspected or known seizure disorders; use with caution in myasthenia gravis patients receiving pyridostigmine; use oral formulation with caution in patients with renal or hepatic impairment; monitor these patients closely; may cause CNS depression which may impair physical or mental abilities; use with caution when used with other sedative drugs or ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral solution for injection is hypertonic, avoid extravasation. Use of injection in patients with impaired renal function is contraindicated due to the polyethylene glycol vehicle which, in large amounts, may be irritating to the kidneys by increasing pre-existing acidosis and urea retention in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridostigmine: Methocarbamol may diminish the therapeutic effect of Pyridostigmine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. The manufacturer notes that fetal and congenital abnormalities have been rarely reported following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13926240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor closely for extravasation (I.V. administration).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS depressant with sedative and skeletal muscle relaxant effects; exact mechanism of action is unknown",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 46% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via dealkylation and hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within &sim;1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance: Adults: 0.2-0.8 L/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/1/23572?source=see_link\">",
"      see \"Methocarbamol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; urine may darken to brown, black, or green",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12593 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40884=[""].join("\n");
var outline_f39_59_40884=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194398\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060295\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060287\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194375\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194360\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060298\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060291\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060297\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194436\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194434\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060302\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060286\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060285\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194369\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194372\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194384\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13926240\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060284\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060300\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060301\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060293\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24677?source=related_link\">",
"      Methocarbamol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/1/23572?source=related_link\">",
"      Methocarbamol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40885="Middle phalanx fractures";
var content_f39_59_40885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Middle phalanx fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40885/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40885/contributors\">",
"     Rebecca Bassett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40885/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40885/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40885/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40885/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/59/40885/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finger fractures are among the most common injuries managed by primary care and emergency clinicians. An understanding of basic finger anatomy and common injury patterns provides the basis for diagnosing and treating these injuries.",
"   </p>",
"   <p>",
"    Fractures of the middle phalanx will be discussed here. Finger anatomy, other common finger injuries, and thumb injuries are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38390?source=see_link\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomy of special importance to middle phalanx fractures is described below; a more detailed discussion of finger anatomy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proximal interphalangeal (PIP) joint and the distal interphalangeal (DIP) joint form the articulations of the middle phalanx (",
"    <a class=\"graphic graphic_figure graphicRef51990 \" href=\"mobipreview.htm?4/46/4838\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51038 \" href=\"mobipreview.htm?5/32/5642\">",
"     figure 2",
"    </a>",
"    ). These joints are stabilized by a volar plate, extensor apparatus, capsule, and collateral ligaments. Just proximal to the PIP joint, the flexor digitorum superficialis tendon splits to allow for the flexor digitorum profundus (FDP) to travel through its center (",
"    <a class=\"graphic graphic_figure graphicRef50968 \" href=\"mobipreview.htm?18/23/18801\">",
"     figure 3",
"    </a>",
"    ). The FDP then passes along the palmar surface of the middle phalanx and attaches to the distal phalanx. The FDP enables DIP joint flexion.",
"   </p>",
"   <p>",
"    The flexor digitorum superficialis (FDS) attaches to the palmar surface of the middle phalanx and is the primary flexor of the PIP joint. Deep to the flexor tendons the volar plate provides stability against hyperextension.",
"   </p>",
"   <p>",
"    On the dorsal surface, the extensor tendon central slip passes over the PIP joint and inserts on the base of the middle phalanx, while the lateral bands proceed distally, attaching to the base of the distal phalanx. Fractures at the proximal base of the middle phalanx can cause an avulsion of the insertion of the extensor tendon central slip. If unrecognized, a boutonniere deformity usually develops (",
"    <a class=\"graphic graphic_figure graphicRef63093 \" href=\"mobipreview.htm?13/54/14180\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the shaft of the middle phalanx are commonly caused by a direct blow to the dorsum of the hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1\">",
"     1",
"    </a>",
"    ]. Less commonly, injuries occur from an axial load or twisting mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the shaft of the middle phalanx present with pain and swelling, generally following trauma to the dorsum of the finger. Ecchymosis may be present.",
"   </p>",
"   <p>",
"    During the initial physical examination, the clinician should focus on identifying any complicating factors that require urgent treatment, including: open injury, neurovascular deficits, malalignment or dislocation, and tendon dysfunction.",
"   </p>",
"   <p>",
"    The neurovascular status of fingers is evaluated using two-point discrimination and capillary refill time. Although values for both these tests increase with age and certain disease states (eg, diabetes), normal two-point discrimination is approximately 4 to 5 mm, while normal capillary refill is generally less than two seconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Middle phalanx fractures are commonly associated with tendon or soft tissue injuries. The complex tendon anatomy in the region of the middle phalanx can lead to variations in fracture patterns, joint immobility, and fracture instability (",
"    <a class=\"graphic graphic_figure graphicRef80728 \" href=\"mobipreview.htm?10/4/10308\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation for deformity or rotation of the phalanx should be performed with the fingers in extension and flexion (",
"    <a class=\"graphic graphic_picture graphicRef73269 graphicRef71612 \" href=\"mobipreview.htm?4/2/4134\">",
"     picture 1A-B",
"    </a>",
"    ). Careful examination of the PIP and DIP joints is mandatory. The flexor and extensor mechanisms of the PIP and DIP joints should be evaluated to rule out associated tendon injuries (",
"    <a class=\"graphic graphic_picture graphicRef60190 graphicRef71895 \" href=\"mobipreview.htm?15/4/15430\">",
"     picture 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58818 graphicRef73661 \" href=\"mobipreview.htm?22/63/23541\">",
"     picture 3A-B",
"    </a>",
"    ). Careful evaluation of the extensor tendon is necessary to rule out central slip injuries, which can lead to a boutonniere deformity. The palmar surface of the finger should be examined for damage to the flexor tendon or volar plate. Collateral ligaments are evaluated by placing a varus and valgus stress on the DIP and PIP joints (",
"    <a class=\"graphic graphic_picture graphicRef69449 \" href=\"mobipreview.htm?38/34/39456\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AP, lateral, and oblique radiographs are obtained to evaluate the middle phalanx (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56068 \" href=\"mobipreview.htm?13/48/14081\">",
"     image 1",
"    </a>",
"    ). Transverse fractures can occur proximally or distally and require evaluation for displacement and angulation. Proximal transverse shaft fractures may present in an apex dorsal position, if the flexor digitorum profundus pulls the distal fragment volarly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. Distal transverse fractures may present in an apex volar position if the flexor digitorum superficialis pulls the proximal fragment volarly.",
"   </p>",
"   <p>",
"    Oblique and spiral fractures are evaluated for shortening or rotation and are often unstable due to the forces exerted by the various tendon and ligament insertions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75328 \" href=\"mobipreview.htm?11/18/11566\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54342 \" href=\"mobipreview.htm?35/3/35901\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70099 \" href=\"mobipreview.htm?30/8/30862\">",
"     image 4",
"    </a>",
"    ). Intraarticular fractures are commonly associated with soft tissue trauma, such as volar plate injuries, extensor central slip or terminal slip injuries, and collateral ligament tears (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77404 \" href=\"mobipreview.htm?30/40/31374\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56889 \" href=\"mobipreview.htm?15/31/15870\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63484 \" href=\"mobipreview.htm?37/5/37982\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55860 \" href=\"mobipreview.htm?41/59/42942\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hand or orthopedic surgeon should be consulted emergently for any open fracture and any fracture associated with a tendon or nerve injury.",
"   </p>",
"   <p>",
"    Comminuted fractures, rotational fractures, intraarticular fractures, and displaced or angulated fractures that cannot maintain their reduction should all be referred to a hand or orthopedic surgeon. Most spiral and oblique fractures involve rotation or shortening and are unstable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. They should also be referred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nondisplaced fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondisplaced stable fractures of the middle phalanx without angulation are treated by buddy taping them to an adjacent finger (",
"    <a class=\"graphic graphic_picture graphicRef79535 \" href=\"mobipreview.htm?21/8/21635\">",
"     picture 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. If the ring finger is involved, it should be buddy taped to the little finger. Short-term immobilization with a dorsal (",
"    <a class=\"graphic graphic_picture graphicRef53670 \" href=\"mobipreview.htm?37/10/38063\">",
"     picture 6",
"    </a>",
"    ) or volar finger splint (",
"    <a class=\"graphic graphic_picture graphicRef76059 \" href=\"mobipreview.htm?31/41/32415\">",
"     picture 7",
"    </a>",
"    ) or a toad splint (",
"    <a class=\"graphic graphic_picture graphicRef65838 \" href=\"mobipreview.htm?12/0/12288\">",
"     picture 8",
"    </a>",
"    ) can be used for added protection or pain control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Displaced or angulated fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed reduction often produces satisfactory results for angulated or minimally displaced fractures of the middle phalanx. A digital block is used for local anesthesia. Proximal shaft fractures often present in an apex dorsal position, while distal fractures present in an apex volar position. Reduction is performed by applying longitudinal traction, and then using three-point pressure to bring the distal fragment into alignment with the proximal fragment (",
"    <a class=\"graphic graphic_picture graphicRef68434 \" href=\"mobipreview.htm?38/15/39154\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61259 \" href=\"mobipreview.htm?38/58/39841\">",
"     picture 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. If the fracture is displaced in an apex volar position, flexion of the DIP joint can help realign the distal fragment.",
"   </p>",
"   <p>",
"    Following reduction, the injured finger should be immobilized in an ulnar or radial gutter splint with buddy taping to an adjacent finger (",
"    <a class=\"graphic graphic_figure graphicRef59409 \" href=\"mobipreview.htm?10/0/10240\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Proper positioning in the splint is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wrist in 20 to 30 degrees of extension",
"     </li>",
"     <li>",
"      MCP joints in 70 to 90 degrees of flexion",
"     </li>",
"     <li>",
"      PIP and DIP joints flexed 5 to 10 degrees",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased flexion of the PIP joint may be helpful for maintaining reduction in more proximal fractures of the middle phalanx with significant apex dorsal angulation. Flexed positioning decreases the force exerted by the flexor digitorum superficialis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is not as protective, a dorsal finger splint with buddy taping may be used instead of a gutter splint using the same joint positioning. This approach should not be used if patient compliance is in doubt or if the patient is required to perform any lifting or strenuous work with their hands.",
"   </p>",
"   <p>",
"    Once splinted, post-reduction radiographs are obtained to ensure the reduction is adequate. No more than 1 or 2 mm of displacement or shortening is acceptable. Up to ten degrees of angulation is acceptable but no amount of rotation is permitted. The patient should be referred to a hand or orthopedic surgeon if adequate reduction cannot be maintained. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for surgical referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nondisplaced fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondisplaced fractures should be reevaluated by physical examination and radiographs within one week injury to check for displacement, angulation, or rotational deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. If no malalignment is detected, buddy taping is continued for a total of approximately four to six weeks, until clinical healing has occurred. Range of motion exercises to restore normal mobility at the DIP, PIP, and MCP joints should be encouraged while buddy taping is continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finger should be examined every one to two weeks until range of motion and finger function is normal. Radiographs can be obtained three to four weeks after the first follow-up appointment to ensure healing, but are not necessary unless malalignment or inadequate clinical healing occurs (eg, pain persists or function is compromised). Frequently, radiographic healing lags behind clinical healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Displaced or angulated fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displaced or angulated middle phalanx fractures are treated with four weeks of splinting. Repeat examinations and radiographs should be performed with the splint in place one week following the injury, and every one to two weeks thereafter. Total time in the gutter splint should not exceed four weeks to prevent stiffness and loss of motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1\">",
"     1",
"    </a>",
"    ]. After four weeks, buddy taping is used to provide stability.",
"   </p>",
"   <p>",
"    Once the fracture has maintained a stable position for a minimum of three weeks, the splint is removed. Buddy taping is applied for four to six weeks for further protection, but range of motion exercises are begun. If there is significant swelling or loss of motion, formal physical therapy under expert supervision should be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/8\">",
"     8",
"    </a>",
"    ]. Thereafter, range of motion and function are evaluated every two weeks until normal function is achieved. Radiographs can be obtained every four to eight weeks until complete fracture healing is evident; full radiographic healing can take up to 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nondisplaced fractures can return to play or work once pain is controlled. Buddy taping is needed for a minimum of four to six weeks thereafter, and a protective splint should be used for any higher risk activities during this period.",
"   </p>",
"   <p>",
"    Displaced fractures should remain in a gutter splint for three to four weeks, until radiographs demonstrate that the fracture has maintained a stable position and evidence of early healing is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. After the gutter splint has been removed, the patient may return to noncontact activities, with buddy taping for protection, for an additional four to six weeks. If the patient's work or athletic activities involve heavy lifting or the risk of forceful trauma to the finger, then return should be delayed until plain x-rays demonstrate significant healing (ie, substantial callus present at fracture site). This will likely require six to twelve weeks in a healthy adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle phalanx fractures complicated by shortening, angulation, or rotation can lead to malrotation of the finger and abnormal mechanics. Failure to recognize intraarticular involvement or prolonged use of splinting can lead to stiffness and loss of motion at the PIP or DIP joint. Nonunion is a rare complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, soft tissue injuries may accompany the fracture and lead to deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40885/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Injury to the central extensor slip may result in a Boutonniere deformity. Volar plate disruption may lead to a \"swan neck\" deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/5/3155?source=see_link\">",
"       \"Patient information: Finger fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Middle phalanx fractures occur most commonly from a blow to the dorsum of the hand but may occur from an axial load or twisting injury. They present with tenderness and swelling; ecchymosis may be present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial physical examination should focus on identifying any complicating factors that require urgent treatment, including: open injury, neurovascular deficits, malalignment or dislocation, and tendon dysfunction. A neurovascular examination including two-point discrimination and capillary refill should be performed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Middle phalanx fractures are commonly associated with tendon injuries. All middle phalanx fractures should be evaluated carefully for evidence of rotation, shortening, or angulation. Transverse fractures may present in an apex volar or apex dorsal position. Spiral or oblique fractures are often unstable and should be reassessed regularly looking for rotation and shortening. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate consultation with a hand surgeon should be obtained for any open fracture and any fracture associated with a tendon or nerve injury. Comminuted fractures, rotational fractures, intraarticular fractures, and displaced or angulated fractures that cannot maintain their reduction require referral. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nondisplaced middle phalanx fractures are treated with finger splinting or buddy taping. Minimally displaced fractures are reduced and initially treated in a gutter splint. Proper splinting, positioning of the finger, and follow-up are described in the text. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Eiff P, Hatch R, Calmbach W. Finger fractures. In: Fracture Management for Primary Care, 2nd, Saunders, Philadelphia 2003. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/2\">",
"      Schriger DL, Baraff L. Defining normal capillary refill: variation with age, sex, and temperature. Ann Emerg Med 1988; 17:932.",
"     </a>",
"    </li>",
"    <li>",
"     Henry M. Fractures and dislocations of the hand. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/4\">",
"      Kozin SH, Thoder JJ, Lieberman G. Operative treatment of metacarpal and phalangeal shaft fractures. J Am Acad Orthop Surg 2000; 8:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/5\">",
"      Oetgen ME, Dodds SD. Non-operative treatment of common finger injuries. Curr Rev Musculoskelet Med 2008; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/6\">",
"      Capo JT, Hastings H 2nd. Metacarpal and phalangeal fractures in athletes. Clin Sports Med 1998; 17:491.",
"     </a>",
"    </li>",
"    <li>",
"     Wheeless Textbook of Orthopedics www.wheelessonline.com (Accessed on March 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/8\">",
"      Cannon NM. Rehabilitation approaches for distal and middle phalanx fractures of the hand. J Hand Ther 2003; 16:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/9\">",
"      McCue FC 3rd, Meister K. Common sports hand injuries. An overview of aetiology, management and prevention. Sports Med 1993; 15:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40885/abstract/10\">",
"      Freiberg A, Pollard BA, Macdonald MR, Duncan MJ. Management of proximal interphalangeal joint injuries. J Trauma 1999; 46:523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 209 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-DE299E3F9D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40885=[""].join("\n");
var outline_f39_59_40885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nondisplaced fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Displaced or angulated fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nondisplaced fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Displaced or angulated fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/209|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/48/14081\" title=\"diagnostic image 1\">",
"      Normal finger radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/18/11566\" title=\"diagnostic image 2\">",
"      AP xray of middle phalanx oblique fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/3/35901\" title=\"diagnostic image 3\">",
"      Lateral xray of middle phalanx oblique fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/8/30862\" title=\"diagnostic image 4\">",
"      Spiral fracture of the middle phalanx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/40/31374\" title=\"diagnostic image 5\">",
"      Middle phalanx fracture involving DIP joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/31/15870\" title=\"diagnostic image 6\">",
"      Middle phalanx fracture of proximal volar plate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/5/37982\" title=\"diagnostic image 7\">",
"      Middle phalanx fracture with impaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/59/42942\" title=\"diagnostic image 8\">",
"      Middle phalanx fracture with impaction lateral xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/209|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4838\" title=\"figure 1\">",
"      Wrist hand bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/32/5642\" title=\"figure 2\">",
"      Functional anatomy of the finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/23/18801\" title=\"figure 3\">",
"      Finger tendons expanded view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/54/14180\" title=\"figure 4\">",
"      Extensor hood injury of finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/4/10308\" title=\"figure 5\">",
"      Middle phalanx fracture displacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/0/10240\" title=\"figure 6\">",
"      Gutter splints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/209|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/37/40528\" title=\"picture 1A\">",
"      Examination metacarpal malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/20/39232\" title=\"picture 1B\">",
"      Metacarpal fracture with malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/0/14337\" title=\"picture 2A\">",
"      PIP extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/12/39104\" title=\"picture 2B\">",
"      PIP flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/32/26112\" title=\"picture 3A\">",
"      Examination of finger DIP joint extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/0/21504\" title=\"picture 3B\">",
"      Examination of finger DIP joint flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/34/39456\" title=\"picture 4\">",
"      Finger varus valgus stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/8/21635\" title=\"picture 5\">",
"      Finger buddy taping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/10/38063\" title=\"picture 6\">",
"      Finger dorsal splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/41/32415\" title=\"picture 7\">",
"      Finger volar splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/0/12288\" title=\"picture 8\">",
"      Finger toad splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/15/39154\" title=\"picture 9\">",
"      Phalanx fracture traction and reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/58/39841\" title=\"picture 10\">",
"      Phalanx fracture reduction 3 point technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/5/3155?source=related_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40886="Thyroid gland blood supply";
var content_f39_59_40886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid gland blood supply",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Overall anatomic relationships of the thyroid and surrounding structures. Note the course of the inferior thyroid artery, behind and perpendicular to the carotid artery. The superior thyroid artery and external branch of the superior laryngeal nerve run in close approximation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Surgical Anatomy of the Thyroid, Parathyroid, and Adrenal Glands. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40886=[""].join("\n");
var outline_f39_59_40886=null;
var title_f39_59_40887="Intellectual disability (mental retardation) in children: Management; outcomes; and prevention";
var content_f39_59_40887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Penelope Pivalizza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40887/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/59/40887/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intellectual disability (ID) is a static encephalopathy with multiple etiologies that encompasses a broad spectrum of functioning, disability, and strengths. The term is synonymous with and is now preferred over the older term, mental retardation. The term global developmental delay is usually used to describe children younger than age five with significant cognitive deficits, because IQ testing is less reliable in this age group. A variety of other terms are used outside of the United States (",
"    <a class=\"graphic graphic_table graphicRef57206 \" href=\"mobipreview.htm?6/47/6908\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ID is an important public health issue because of its prevalence and the need for extensive support services. Its management requires early diagnosis and intervention, coupled with access to health care and educational resources.",
"   </p>",
"   <p>",
"    The management, outcomes, and prevention of intellectual disability will be presented here. The definition, causes, clinical presentation, diagnosis, and evaluation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall goals of management of intellectual disability (ID) are to strengthen areas of reduced function, provide ongoing family support, to prevent or minimize further cognitive-adaptive deterioration relative to peers and promote optimal functioning in society. Interventions should begin early and be sustained. Goals should be appropriate and achievable.",
"   </p>",
"   <p>",
"    The approach should be collaborative and multidisciplinary. In the teen years, an emphasis should be placed on vocational goals, including social adaptation, and vocational professionals should be part of the multidisciplinary team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ID require ongoing health surveillance similar to normal children. Developmental, academic, and psychosocial progress should be monitored. Slower developmental progress should be expected in children with more severe cognitive-adaptive disability.",
"   </p>",
"   <p>",
"    Evaluation of nutritional status by a dietitian may be helpful to ensure a well-balanced diet. However, there is no evidence that dietary or other alternative treatments (eg, high doses of fat-soluble vitamins) are effective, and these should be avoided because excessive doses can have toxic effects.",
"   </p>",
"   <p>",
"    Vigilant surveillance should be maintained to detect and prevent abuse and neglect. Tools such as the Family Psychosocial Screen may be helpful to screen families for concerns of abuse and maternal depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link&amp;anchor=H11#H11\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'Assessment of psychosocial risks and protective factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most individuals with ID require a broad range of interventions that should be applied early to improve short-term and long-term outcomes. Some of these are indicated below.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Speech and language therapy",
"     </li>",
"     <li>",
"      Occupational therapy",
"     </li>",
"     <li>",
"      Physical therapy and rehabilitation, including mobility and postural support",
"     </li>",
"     <li>",
"      Family counseling and support",
"     </li>",
"     <li>",
"      Behavioral intervention",
"     </li>",
"     <li>",
"      Educational assistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parent support, information, and advocacy are available through community organizations such as the",
"    <a class=\"external\" href=\"file://www.thearc.org/\">",
"     Arc",
"    </a>",
"    (formerly Association for Retarded Citizens), Family-to-Family Health Information and Education Centers,",
"    <a class=\"external\" href=\"file://www.autism-society.org/\">",
"     Autism Society of America",
"    </a>",
"    , and support groups corresponding to specific genetic syndromes or conditions (eg, Fragile X, Down syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specific interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an underlying cause is identified, it should be promptly treated. Conditions in which further disability can be prevented include phenylketonuria, hypothyroidism, and hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, associated conditions should be treated in order to maximize functioning. These include cataracts, vision and hearing impairments, congenital heart disease, seizures, and constipation. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Lead screening should be obtained for possible exposure and reexposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ID due to specific conditions may have characteristic sleep disorders. As examples, Smith Magenis syndrome is associated with insomnia. Patients with Prader-Willi or Down syndrome are at risk for obstructive sleep apnea. These children usually require sleep-related behavior interventions or counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Behavior intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavior interventions are usually needed to improve socialization skills and behavioral functioning in children with ID. These should be individualized and applied consistently to encourage appropriate thinking, expression, adaptive function, conduct, and environmental manipulation. Interventions should be appropriate to the child's level of functioning (particularly language functioning) rather than chronological age. Desirable behaviors should be positively reinforced and restraining or punitive aversive approaches should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavior management techniques are selected according to the child's development, displayed problem behavior or a desired behavior and the child's responsiveness to management techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/2\">",
"     2",
"    </a>",
"    ]. Specific techniques may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active intervention to reduce antecedents (triggers) of problem behaviors",
"     </li>",
"     <li>",
"      Reinforcement of acceptable behavior by providing positive attention (\"time in\" attention) or desired reinforcer (appropriate treat or preferred activity)",
"     </li>",
"     <li>",
"      Purposeful \"ignoring\" of behaviors to encourage their non-use (as long as the behavior is not dangerous)",
"     </li>",
"     <li>",
"      Redirecting attention to extinguish problem behaviors",
"     </li>",
"     <li>",
"      Reinforcing behaviors incompatible with problem behaviors (eg, placing hands in an appropriate position or activity that replaces their use in a problem behavior)",
"     </li>",
"     <li>",
"      Prompt removal of the child from an activity when a targeted problem behavior occurs (\"time out\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Behavioral goals and psychotherapy interventions for the child and family should focus on understanding, the positive use of strengths, building social skills and problem solving, self-esteem, communication strategies, and independence. Interventions should be pertinent to the child&rsquo;s needs and abilities, behavioral phenotype, antecedents, psychiatric disorder, and child-school-family environmental conflicts, perceptions, and expectations. Promotion of good self-esteem and independence improves quality of life and reduces unwanted behaviors. The child should also be taught how to resist peer pressure and avoid exploitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/3\">",
"     3",
"    </a>",
"    ]. For adolescents, individualized teaching should include issues of sexuality, transition to adult life, and preparation for independent community living. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Transition planning'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Group psychotherapy may be a useful adjunct to individualized sessions for school-aged children who have sufficient communication and cognitive functioning to participate in a group setting; six or seven year age-equivalent functioning is usually minimally needed. In general, this should be part of a comprehensive treatment program and involves a trained therapist working in a community setting, with techniques adapted for the developmental skill level. Group therapy is most useful for adolescents and particularly for training in social skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mental disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for mental disorders that may be associated with ID include family counseling, education, and habilitative techniques that may be modified for the developmental level of functioning, and psychopharmacologic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/3\">",
"     3",
"    </a>",
"    ]. Some psychiatric behaviors, such as aggression or self-injury, may place the child or others at risk of imminent harm. These require emergent evaluation to exclude medical and environmental causes such as hypoxia, pain, toxins, infection, and abuse or trauma, and may need medication, temporary restraint, or hospitalization.",
"   </p>",
"   <p>",
"    The use of psychopharmacologic therapy is similar in children with or without ID. However, little evidence is available to direct the use of these medications in young children. Thus, a therapeutic trial may be indicated to assess whether the therapy is successful in an individual patient.",
"   </p>",
"   <p>",
"    The use of medications should be part of a clear comprehensive psychosocial treatment plan that includes behavioral baseline functioning, goals, and evidence-based intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with disruptive behavior, such as aggression, should be evaluated for possible causes, including psychosis, mood disorders,",
"    <span class=\"nowrap\">",
"     abuse/trauma,",
"    </span>",
"    or disruptive behavioral disorder, prior to prescribing medication.",
"   </p>",
"   <p>",
"    Prior to initiating pharmacotherapy, the clinician and caregivers should agree upon measurable goals. In the absence of a positive response, the accuracy of the underlying psychiatric diagnosis should be reconsidered, along with factors such as compliance with medications and effects on targeted symptoms.",
"   </p>",
"   <p>",
"    Initial treatment should use the lowest recommended dose, and the patient should be monitored for a response before adjustments are made. Medication regimes should be simple, using the fewest possible doses. Follow-up evaluations should be made at least every three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to be aware of potential side effects, although it is not known if they are increased in children with ID. Medications to control behaviors often have negative effects on attention, concentration, and learning, and may adversely affect quality of life.",
"   </p>",
"   <p>",
"    Clinicians should also be alert to idiosyncratic responses to medications. As examples, patients with ID may have increased sensitivity to the disinhibiting effects of sedative-hypnotics, and children with Down syndrome may be especially sensitive to anticholinergic medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Residential setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the majority of individuals with ID live in community settings and are not institutionalized. This setting can be successful if appropriate individualized health care and resource supports are provided. However, the risk of mortality appears to be greater when individuals with ID are transferred from institutions into community care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Residential services are available but are scarce and costly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transition planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transition planning to facilitate the transition from childhood to adulthood, including to adult health services, should begin at or by age 12 years in youth with special needs such as ID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Early individualized discussions may address issues of vocation, independent",
"    <span class=\"nowrap\">",
"     living/functioning,",
"    </span>",
"    independent decision-making or guardianship, care coordination, sexual reproduction, life expectancy, health insurance, eligibility for adult community-based",
"    <sup>",
"    </sup>",
"    services, medical comanagement by different specialists, advance directives, and communication preferences of the child or youth with ID. The child or youth with ID should be involved as much as possible in the decision-making process, and his or her level of understanding should be assessed and documented.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    A transition plan should be documented by age 14 years and reviewed annually thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/7\">",
"     7",
"    </a>",
"    ]. A transition plan may include the assessment of transition readiness, realistic goal setting, focused interventions, and anticipated timelines; the transition plan is used to implement and monitor the transition process until 18 years of age or the time of actual transition.",
"    <strong>",
"    </strong>",
"    Transition-related resources for professionals include educational guide books, evaluation tools and checklists. Such tools are available for download at the following sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.mahec.net/quality/chat.aspx?a=10\">",
"       Carolina Health and Transition Project",
"      </a>",
"      (CHAT) &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://jaxhats.ufl.edu/hcp_resources.php\">",
"       Jacksonville Health and Transition Services",
"      </a>",
"      (JaxHATS)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.waisman.wisc.edu/cedd/youth.php\">",
"       University of Wisconsin Waisman Center",
"      </a>",
"      , including a",
"      <a class=\"external\" href=\"file://www.waisman.wisc.edu/wrc/pdf/pubs/PG.pdf\">",
"       pocket health guide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.gottransition.org/\">",
"       National Health Care Transition Center",
"      </a>",
"      : Got Transition",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.medicalhomeinfo.org/how/care_delivery/transitions.aspx\">",
"       National Center for Medical Home Implementation",
"      </a>",
"      Transitions page",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transition includes assistance with adjustment from school to work or other adult activity. According to the Individuals with Disabilities Education Act (IDEA), the Individualized Education Plan (IEP) for students must include a transition plan by 16 years of age. The student should be involved in the development of the plan and student advocacy and self-determination should be encouraged. When the youth actually transitions to the adult service provider, a health record and medications summary with an individualized collaborative care plan should accompany him or her. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27737?source=see_link&amp;anchor=H17#H17\">",
"     \"Children with special health care needs\", section on 'Transitioning: The special-needs child grows up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LEGISLATIVE MANDATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, federal legislation supports a range of services for children with ID. The Individuals with Disabilities Education Act (IDEA) provides for early intervention and special education for children with disabilities from birth to 21 years of age. According to the Rehabilitation, Comprehensive Services and Developmental Disabilities Amendments of 1975 (PL 95-602 of 1978), individuals are considered to have disabilities if they have mental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical impairment occurring before 22 years of age that results in substantial functional limitation in at least three areas of life activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complex Patient Protection and Affordable Care Act (PPACA) (Public Law 111 &ndash; Publ 148 &ndash; Mar 23, 2010) is expected to reform health care coverage and remove the exclusion of preexisting conditions in 2014; youth with ID and their families need assistance in understanding its application and impact on their needs in the context of other programs such as Medicaid, Title V, Supplemental Security Income (SSI), and Social Security Disability Income (SSDI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Early intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early intervention is available for children identified before three years of age who have or are at risk of having disabilities, which are broadly defined. Children are eligible for services if they have developmental delay or certain medical, genetic, or surgical conditions (eg, Down syndrome and cerebral palsy). Children who may be at risk of developmental delay without early intervention include low birth weight infants or those with prenatal exposure to illicit drugs. Early intervention provides evaluation and individualized comprehensive services for the disabilities, including preventive measures to avoid secondary disabilities. Services are usually provided in the home setting. However, services are applied variably at the discretion of states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Educational and supportive services are available for the child and family. Interventions for the child include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Case management",
"     </li>",
"     <li>",
"      Speech and language therapy",
"     </li>",
"     <li>",
"      Occupational and physical therapy",
"     </li>",
"     <li>",
"      Psychological services",
"     </li>",
"     <li>",
"      Health services, including hearing and vision",
"     </li>",
"     <li>",
"      Nutrition counseling",
"     </li>",
"     <li>",
"      Assistive technology (which may include tape-recorded texts, reading scanners, or voice-activated computer programs)",
"     </li>",
"     <li>",
"      Medical diagnostic services",
"     </li>",
"     <li>",
"      Transportation and other assistive technology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interventions for the family include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Counseling",
"     </li>",
"     <li>",
"      Training",
"     </li>",
"     <li>",
"      Home visitation",
"     </li>",
"     <li>",
"      Social services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A child may be referred by a parent or professional to the appropriate local agency for comprehensive evaluation of needs and coordination of multidisciplinary services. The family involvement should participate in the development of an Individualized Family Service Plan (IFSP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Special education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the IDEA, special education and related services are provided for children from three to 21 years of age. All children with disabilities are mandated to receive a comprehensive education in the least restrictive environment, with priority given to the most severely impaired children. IDEA requires the states to identify and evaluate eligible children and generate an Individualized Education Plan (IEP) annually, with measurable and appropriate goals.",
"   </p>",
"   <p>",
"    The legislation includes due process so that parents may participate actively in their child's education. Requirements for the participation of physicians and the extent of their participation vary among states. When it is not required by the state, parents may choose to obtain a physician's evaluation and assessment for developmental and other associated conditions and to identify medical needs and interventions. It is often helpful for the child and family to have a physician advocate who can act as an intermediary with state agencies.",
"   </p>",
"   <p>",
"    Special education services offered by the school may include training in social skills, assistance in self-help, vocational training, behavioral assistance, and academic program modifications. Children may be placed in a special education class or provided resource classes or an aide. Principles of least restrictive environment and inclusion must be applied. Not all children can participate in regular academic classes, but, depending upon the extent of disability, they may be included in many other activities such as home room, physical education, lunch, recess, art, or music.",
"   </p>",
"   <p>",
"    Other educational settings are available for children who are unable to attend regular classes. These include a self-contained special education class with adaptive, self-help life skills training, a specialized day school, or, in rare cases, a residential institutional placement. The state is responsible for reimbursement, and the extent of the school's responsibility for related services, such as nursing, is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, according to the IDEA improvement act of 2004, after 16 years of age, an Individualized Transition Plan must be included in the student's annual IEP. This includes vocational planning and provisions for including the patient in decision-making, when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome for ID is variable and depends upon the etiology, associated conditions, and environmental and social factors. As examples, biomedical disorders (eg, Down syndrome or metabolic abnormalities) may be associated with a range of function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduced lifespan. Associated conditions such as seizure disorders and motor-sensory handicaps may limit adaptation, function, and long-term outcomes. Comorbid psychological factors, such as mental health disorders, may impair communication abilities and social functioning, and affect the child's profile of intellectual strengths and weaknesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Environmental factors also affect the natural history and outcome of ID. These include the availability and appropriate provision of services, such as education and rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/9\">",
"     9",
"    </a>",
"    ]. A child's course may also be affected by social factors such as caregiver support, expectations, attitudes, socioeconomic characteristics and social opportunities.",
"   </p>",
"   <p>",
"    Traditionally, long-term outcomes of ID have been grouped according to DSM categories of levels of severity. However, many children initially diagnosed with ID may acquire adaptive function skills over time and no longer meet these diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/9\">",
"     9",
"    </a>",
"    ]. According to the DSM definitions, the following outcomes are expected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mild ID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with mild ID typically have a developmental velocity of one-half to two-thirds the average rate, accomplishing third to sixth grade level reading skills by late adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/12\">",
"     12",
"    </a>",
"    ]. However, some adults are functionally illiterate. Social play and extracurricular interests may be similar to those of younger children.",
"   </p>",
"   <p>",
"    The long-term outcome of mild ID is related both to cognitive functioning as well as adaptive and personal social skills; the latter play a critical role in the capacity for independent living and occupational outcome. Some mildly affected individuals can work at regular occupations, and many live independently. However, many need sheltered employment and assisted living or group homes. Many marry and become parents, although raising children is challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Moderate ID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with moderate ID typically develop at one-third to one-half the expected rate of normal children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/12\">",
"     12",
"    </a>",
"    ]. School based academic and social development gains are slow. Affected children may learn to read essential words and signs such as \"stop\", \"exit\", or \"danger\". Reading at a first to third grade level can be accomplished with educational services. In general, teaching is needed for daily living skills.",
"   </p>",
"   <p>",
"    Long-term outcomes in moderate ID depend upon the extent and presence of comorbidities. Most affected individuals can reside in a group home in a community setting. The majority need sheltered or supportive employment positions, although some can perform unskilled work. Few are able to marry and raise children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Severe ID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticipated rate of developmental progress for children with severe ID is approximately one-quarter to one-third of the expected rate. Speech development may be delayed until four to five years of age, or may never occur. Some individuals are able to learn to read survival words such as \"danger,\" \"exit,\" and \"stop.\" The majority require training in social and self-help daily living skills in high school.",
"   </p>",
"   <p>",
"    Adults without prohibitive comorbid conditions may be able to work in sheltered settings and, if not behaviorally disruptive, reside in a group home. The majority need assistance with daily living and adult social skills. In general, severely affected individuals do not marry or raise children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Profound ID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with profound ID develop at less than one-quarter of the typical rate. They need comprehensive assistance that is tailored to their physical needs. Those with comorbid medical conditions may need additional supportive equipment. Some benefit from training in self-help skills. Most need high school classes in life skills and assistance in all aspects of daily living. Profoundly affected individuals cannot acquire reading skills.",
"   </p>",
"   <p>",
"    Long-term outcomes of individuals with profound ID are highly variable. Some are totally dependent, while others are able to dress and feed themselves, accomplish basic speech and language skills, and have friendships with others. In general, placement depends upon medical needs, comorbidities, and behavioral characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The life expectancy of children with profound ID varies with cause and individual mobility. Among children who were immobile and tube fed, 80 percent died by 10 years of age, with most deaths before age four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/13\">",
"     13",
"    </a>",
"    ]. The cause of death in the majority of cases was respiratory disease. Most children who were mobile but nonambulatory survived to at least 20 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most causes of ID cannot be prevented. When possible, strategies should be implemented to reduce the risk of ID, to detect treatable conditions such as phenylketonuria (PKU) and hypothyroidism, to minimize the extent of potential disability, and to improve the functioning of affected individuals. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Specific interventions'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention is aimed at preventing conditions that may cause ID. Examples of interventions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of prenatal exposure to alcohol or other toxins",
"     </li>",
"     <li>",
"      Use of prenatal multivitamins, especially",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"     </li>",
"     <li>",
"      Appropriate prenatal care",
"     </li>",
"     <li>",
"      Newborn screening programs for metabolic disease",
"     </li>",
"     <li>",
"      Routine childhood immunizations",
"     </li>",
"     <li>",
"      Use of car seats and restraints",
"     </li>",
"     <li>",
"      Prevention of motor vehicle accidents, violence, and other trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic forms of ID could be addressed by the following measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provision of clinical genetics services to facilitate accurate genetic diagnosis and counseling when a genetic disorder is suspected or diagnosed in a child with ID. This is especially important for those with a family history of ID. Genetic counseling may enable estimation of recurrence risks and facilitate informed decision-making about reproductive options in the future.",
"     </li>",
"     <li>",
"      Pre-implantation genetic diagnosis (PGD) and prenatal diagnosis may be possible for some forms of genetic ID where an accurate laboratory diagnosis has been established in an affected member of the family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prevention is directed at treating an underlying condition to reduce potential cognitive-adaptive dysfunction. Interventions include lead surveillance in a child at risk for lead exposure, dietary restriction in metabolic diseases such as phenylketonuria or galactosemia, and thyroid hormone replacement in a hypothyroid child. Treatment of associated conditions including vision and hearing impairment, seizures, and other co-morbid medical disorders, may improve outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tertiary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tertiary interventions are aimed at maximizing function and quality of life by attempting to reduce functional disability. This approach includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40887/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early identification of affected individuals",
"     </li>",
"     <li>",
"      Access to and provision of appropriate comprehensive services and resources",
"     </li>",
"     <li>",
"      Treatment of comorbid conditions",
"     </li>",
"     <li>",
"      Prevention and treatment of psychosocial disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25336217\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall goals of management of intellectual disability (ID) are to strengthen areas of reduced function, to prevent or minimize further cognitive-adaptive deterioration relative to peers, and to promote optimal functioning in society. Interventions should begin early and be sustained. The approach should be collaborative and multidisciplinary. Depending on the individual&rsquo;s needs, intervention may include speech and language therapy, occupational therapy, physical therapy and rehabilitation, family counseling and support, behavioral intervention, and educational assistance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavior interventions are usually needed to improve social and behavioral functioning in children with ID. These should be individualized and applied consistently. Desirable behaviors should be positively reinforced and restraining or punitive aversive approaches should be avoided. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Behavior intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions for mental disorders that may be associated with ID include family counseling, education, and psychopharmacologic therapy. The use of medications should be part of a clear comprehensive psychosocial treatment plan that includes behavioral baseline functioning, goals, and evidence-based intervention. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mental disorders'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      In the United States, federal legislation supports a range of services for children with ID. The Individuals with Disabilities Education Act (IDEA) provides for early intervention and special education for children with disabilities from birth to 21 years of age. All children with disabilities are mandated to receive a comprehensive education in the least restrictive environment, using an Individualized Education Plan (IEP), with measurable and appropriate goals. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Legislative mandates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transition planning discussion should begin at or by 12 years of age, with a written transition plan in the child's medical record by 14 years of age. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Transition planning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome for ID is variable and depends upon the etiology, co-morbidity, associated conditions, severity of the disability, and environmental and social factors. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with mild ID typically have a developmental velocity of one-half to two-thirds of the rate of typical children, accomplishing third to sixth grade level reading by late adolescence.",
"     </li>",
"     <li>",
"      Children with moderate ID typically develop at one-third to one-half of the expected rate. Reading at a first to third grade level can be accomplished.",
"     </li>",
"     <li>",
"      Children with severe ID develop at one-quarter to one-third of the expected rate. Speech development may be delayed until four to five years of age, or may not occur.",
"     </li>",
"     <li>",
"      Children with profound ID develop at less than one-quarter of the expected rate. They need comprehensive assistance that is tailored to their physical needs. Their life expectancy varies with their mobility. &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prevention of ID is aimed at preventing causative conditions, such as prenatal exposures (for example, to alcohol) and metabolic disorders detectable by neonatal screening programs. Secondary prevention of ID is directed at treating an underlying condition to reduce potential cognitive-adaptive dysfunction, such as treatment and surveillance for lead toxicity, congenital hypothyroidism, and metabolic diseases. Tertiary prevention refers to measures to maximize function and quality of life in an individual with ID. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prevention'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20924532\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Geoffrey Miller, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Zuromski ES. The Management of Mental Retardation. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven Press, New York 1992. p.119.",
"    </li>",
"    <li>",
"     Nassau JH, Buchanan GM, High PC. Behavior Management. In: Developmental-Behavioral Pediatrics, 4th, Levine MD, Carey WB, Crocker AC (Eds), Saunders Elsevier, Philadelphia 2009. p.856.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/3\">",
"      Szymanski L, King BH. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999; 38:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/4\">",
"      Szymanski L, King BH. Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Mental Retardation and Comorbid Mental Disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1999; 38:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/5\">",
"      Kastner T, Nathanson R, Friedman DL. Mortality among individuals with mental retardation living in the community. Am J Ment Retard 1993; 98:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/6\">",
"      Shavelle R, Strauss D. Mortality of persons with developmental disabilities after transfer into community care: a 1996 update. Am J Ment Retard 1999; 104:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/7\">",
"      American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians, et al. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics 2011; 128:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/8\">",
"      Stein DS, Blum NJ, Barbaresi WJ. Developmental and behavioral disorders through the life span. Pediatrics 2011; 128:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/9\">",
"      Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2003; 60:367.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     Palfrey, JS. Legislation for the education of children with disabilities. in: Developmental-Behavioral Pediatrics, 4th ed, Levine, MD, Carey WB, Crocker, AC (Eds), Saunders Elsevier, Philadelphia 2009. p.972.",
"    </li>",
"    <li>",
"     Accardo PM, Capute AJ. Mental Retardation. In: Developmental Disabilities in Infancy and Childhood, 2nd, Capute AJ, Accardo PM (Eds), Paul Brookes, Baltimore 1996. p.211.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40887/abstract/13\">",
"      Eyman RK, Grossman HJ, Chaney RH, Call TL. The life expectancy of profoundly handicapped people with mental retardation. N Engl J Med 1990; 323:584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6191 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40887=[""].join("\n");
var outline_f39_59_40887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25336217\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specific interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Behavior intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mental disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Residential setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transition planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LEGISLATIVE MANDATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Early intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Special education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mild ID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Moderate ID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Severe ID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Profound ID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tertiary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25336217\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20924532\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6191|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/47/6908\" title=\"table 1\">",
"      Intel disabil terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=related_link\">",
"      Microdeletion syndromes (chromosomes 1 to 11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40888="Overview of maternal mortality";
var content_f39_59_40888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of maternal mortality",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Haywood L Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Maria J Small, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40888/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/59/40888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 358,000 women died globally in 2008 as a result of pregnancy-related conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although maternal mortality rates remain elevated in many areas, maternal mortality decreased from approximately 526,000 pregnancy-related deaths globally in 1980. Declines in maternal mortality have been associated with improved access to education, higher incomes, increased availability of skilled birth attendants, and decreased pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1\">",
"     1",
"    </a>",
"    ]. Many studies report an increase in maternal mortality ratios in the United States; improved identification of pregnancy-related deaths and changes in coding and classification may account for most of this rise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, increases in maternal age, body mass index, and co-morbidities have increased and may also account for part of this rise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911359\">",
"    <span class=\"h1\">",
"     MATERNAL MORTALITY WORLDWIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developing countries bear a disproportionate share of maternal deaths: 99 percent occur in developing countries compared to 1 percent in more developed nations (",
"    <a class=\"graphic graphic_figure graphicRef71683 \" href=\"mobipreview.htm?33/17/34070\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50498 \" href=\"mobipreview.htm?20/4/20556\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Sub-Saharan Africa and South Asia accounted for 87 percent of global maternal deaths in 2008 and 50 percent of all deaths occurred in six nations: India, Nigeria, Pakistan, Afghanistan, Ethiopia, and the Democratic Republic of Congo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For the poorest nations, such as Afghanistan and Somalia, the lifetime risk of dying as a result of pregnancy or childbirth is 1 in 11 and 1 in 14, respectively, whereas in the industrialized nations of Northern Europe, the lifetime risk ranges from 1 in 7600 to 11,400 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of maternal mortality attributable to the various causes of maternal death also varies worldwide (",
"    <a class=\"graphic graphic_figure graphicRef86824 \" href=\"mobipreview.htm?23/22/23919\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Code of Diseases (ICD-10) definitions for maternal death and its subclassifications are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Maternal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Late maternal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The death of a woman from direct or indirect obstetrical causes more than 42 days, but less than one year, after termination of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1728169\">",
"    <span class=\"h2\">",
"     Pregnancy related death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the cause of death. These deaths may be from accidental or incidental causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Direct and indirect obstetric death",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37833512\">",
"    <span class=\"h3\">",
"     Direct obstetric death",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct obstetric death results from obstetric complications of pregnancy, from interventions, omissions, incorrect treatment, or from chain of events resulting from pregnancy, labor, delivery, or postpartum conditions.",
"   </p>",
"   <p>",
"    In low and middle income countries, direct obstetric deaths account for 75 to 80 percent of maternal deaths. Hemorrhage, sepsis, and hypertensive disorders",
"    <span class=\"nowrap\">",
"     (preeclampsia/eclampsia)",
"    </span>",
"    are the leading causes of direct obstetric death in",
"    <span class=\"nowrap\">",
"     developing/low",
"    </span>",
"    and middle income countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In",
"    <span class=\"nowrap\">",
"     developed/higher",
"    </span>",
"    income countries, direct obstetric deaths also account for most maternal deaths; however, thromboembolic events are a leading cause of direct maternal mortality in these countries since deaths due to hemorrhage and sepsis are less common and cesarean delivery is more common in countries with well-equipped hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/8-13\">",
"     8-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37833519\">",
"    <span class=\"h3\">",
"     Indirect obstetric death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms nonmaternal, nonobstetrical, and indirect maternal death are used interchangeably with indirect obstetric death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/7\">",
"     7",
"    </a>",
"    ]. An indirect obstetric death results from preexisting disease (eg, diabetes, cardiac disease, malaria, tuberculosis, HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/11\">",
"     11",
"    </a>",
"    ]) or a new disease that develops during pregnancy and is unrelated to pregnancy-related conditions, but is aggravated by the physiologic effects of pregnancy (eg, influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/11\">",
"     11",
"    </a>",
"    ]). Maternal deaths from indirect causes, or conditions antedating pregnancy, but aggravated by pregnancy, account for 20 to 25 percent of maternal deaths.",
"   </p>",
"   <p>",
"    While conditions such as asthma and systemic lupus erythematosus are relatively common diseases in women, death during pregnancy from these conditions is uncommon unless associated with hypertension-related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maternal mortality ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal mortality ratio refers to the number of maternal deaths during a given time period per 100,000 live births. This is the most commonly used measure of maternal mortality and serves as an indicator of the risk for death once a woman has become pregnant. The denominator is live births rather than all pregnancies because of the difficulty in ascertaining the number of miscarriages and abortions in the population.",
"   </p>",
"   <p>",
"    In 2008, the maternal mortality ratio for the world was 260 maternal deaths per 100,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/2\">",
"     2",
"    </a>",
"    ]. The ratio for the United States was approximately 24 maternal deaths per 100,000 live births (adjusted for underreporting and misclassification) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/14\">",
"     14",
"    </a>",
"    ]; maternal mortality ratios for other countries are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef50498 \" href=\"mobipreview.htm?20/4/20556\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maternal mortality rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal mortality rate is defined as the number of maternal deaths in a given period per 100,000 women of reproductive age (15 to 49 years of age) during the same time period. Since the frequency of pregnancy in women of childbearing age is a factor in calculating this rate, it is altered by differences in the frequency of pregnancy or birth in the population even though the risk of maternal death per",
"    <span class=\"nowrap\">",
"     pregnancy/birth",
"    </span>",
"    remains unchanged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lifetime risk of maternal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of maternal death takes into account the cumulative probability of dying as a result of pregnancy across a woman's reproductive years. It is calculated by multiplying the maternal mortality rate by the length of the reproductive period (approximately 35 years) [1- (1-maternal mortality rate)] [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/15\">",
"     15",
"    </a>",
"    ]. In 2008, the lifetime risk of maternal death was highest in Afghanistan (1 in 11) and sub-Saharan Africa (1 in 31), and lowest in developed countries (1 in 4300) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ASCERTAINMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of high quality, population-based data is one of the challenges of measuring maternal mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1,16-18\">",
"     1,16-18",
"    </a>",
"    ]. Maternal deaths are relatively rare events, even in countries where maternal mortality rates are high. Thus, sample sizes must be large to estimate both maternal mortality risks and contributors to maternal deaths.",
"   </p>",
"   <p>",
"    Globally, several measures and surveillance methods are used to ascertain the magnitude of maternal mortality in a given region. These include medical certification in vital registration, household surveys (including sisterhood method), census records, and reproductive age mortality studies (RAMOS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/5\">",
"     5",
"    </a>",
"    ]. Although many of these methods are imprecise, they provide some baseline information on the causes and magnitude of maternal deaths. Resource poor countries often apply their limited resources toward implementation of processes to decrease maternal mortality, rather than toward improvement of surveillance programs.",
"   </p>",
"   <p>",
"    In the United States, the Centers for Disease Control Pregnancy Mortality Surveillance System (PMSS) combines data from state health departments, maternal mortality review committees, media, and individual providers, in addition to",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    death certificates, to provide the best available assessment of maternal mortality in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vital registration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few developing countries have resources necessary to employ vital registration systems to assess levels and trends in maternal mortality. In developed countries, information about maternal mortality is determined primarily from vital registrations of deaths by causes. Nevertheless, maternal mortalities are still under-reported and frequently misclassified. In one study from the United States, 38 percent of maternal deaths were unreported on death certificates and at least 50 percent of maternal deaths were unreported among women who were undelivered at the time of death, experienced a fetal death or therapeutic abortion, died more than a week after delivery, or died as a result of a cardiovascular disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/16\">",
"     16",
"    </a>",
"    ]. Confidential enquiries, such as the longstanding British surveillance system, are often used to determine the extent of misclassification of maternal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Direct household surveys",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas where vital registration data are not available or reliable, household surveys provide an alternative method of maternal mortality assessment. However, surveys for direct estimation of maternal death are expensive and require large sample sizes to provide statistically reliable estimates. The sisterhood method is the most common method for household survey.",
"   </p>",
"   <p>",
"    The sisterhood method asks four simple questions about survival of the respondents' adult sisters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How many sisters have you ever had, born to the same mother, who ever reached the age 15 (or who were ever married), including those who are now dead?",
"     </li>",
"     <li>",
"      How many of these sisters reaching age 15 are alive now?",
"     </li>",
"     <li>",
"      How many of these sisters are dead?",
"     </li>",
"     <li>",
"      How many of these dead sisters died during pregnancy or during childbirth, or during the six weeks after the end of the pregnancy?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In high-fertility populations, this methodology is useful because sample size requirements (and thus costs) can be reduced. At high levels of maternal mortality (over 500 maternal deaths per 100,000 live births), a sample size of 4000 households or less is acceptable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/23\">",
"     23",
"    </a>",
"    ]. The method is not appropriate for use in settings where the total fertility rate is less than four children per family; in areas of significant migration, civil strife, or war; or where other social disruptions exist.",
"   </p>",
"   <p>",
"    Because deaths occurring over a large interval of time are being documented, the overall estimate of maternal mortality is determined for a period of 10 to 12 years before the survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/23\">",
"     23",
"    </a>",
"    ]. This method is still useful since maternal mortality generally changes slowly. Furthermore, it provides some data for settings where there are no alternative means of generating estimates.",
"   </p>",
"   <p>",
"    Demographic health surveys may also employ the indirect sisterhood approach, which utilizes more in-depth questions. The indirect sisterhood method relies on fewer assumptions than the original sisterhood method, but requires a larger sample size; information gathering and analyses are also more complex. This method also does not provide a current estimate of maternal mortality, but the greater specificity of information allows for calculation of ratios for seven years prior to the survey.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reproductive Age Mortality Studies (RAMOS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RAMOS method involves investigation of the cause of death for all women of reproductive age. It has been used to calculate the degree of misclassification of maternal deaths in countries with and without well-developed vital registration systems. Multiple methods and sources are applied to obtain a comprehensive sample. In countries without vital registration systems, interviews with household members and medical providers enable further classification of deaths as possibly maternal. This method is one of the most complete determinations of maternal deaths; however, it can be complicated and time-consuming to perform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Verbal autopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Where medical classification of cause of death is limited or unavailable, some studies establish cause of death using verbal autopsy methodology. However, the reliability and validity of this method for determining the cause of death have not been established. The method may fail to address certain maternal deaths, such as first trimester deaths (ectopic, abortion-associated) or medical causes resulting from complications of terminations (eg, sepsis) and indirect causes (eg, HIV infection).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Census",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dicennial census level data may include questions on household deaths during an established reference period followed by more detailed questions that identify maternal deaths based on timing of death in relation to pregnancy, similar to verbal autopsy methodology. The advantage of this method is that it can generate national data relative to household characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Death certificate data",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, a 2003 revision of the death certificate added questions to connect death certificates and ICD-10 coding. This revision expanded direct and indirect maternal deaths to also include \"late maternal deaths\" and \"pregnancy-related deaths\" (eg, not pregnant within past year; pregnant at time of death; not pregnant, but pregnant within 42 days of death; not pregnant, but pregnant 43 days to one year before death; unknown if pregnant within last year). The addition of these questions resulted in increased ascertainment of maternal deaths, particularly indirect, late maternal deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even with these additions, state surveillance programs suggest that maternal death is underreported in the United States. A study in Maryland found that check boxes on death certificates were effective in identifying pregnancy-associated deaths resulting from maternal causes, but were far less effective in identifying deaths resulting from nonmaternal causes, such as homicide, accidental death, and substance abuse, which represented three of the four leading causes of pregnancy-associated death in Maryland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Near miss maternal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal mortality is rare in high-income (HI) nations, while near miss maternal mortalities and severe maternal morbidities are more frequent occurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. Therefore, near miss maternal mortalities, or severe obstetric morbidities, can be used to provide information on the quality of maternity care for women experiencing life-threatening events during pregnancy and as indirect indicators in the evaluation of maternal deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Near miss maternal mortalities represent events that would have resulted in a maternal death during pregnancy and childbirth if not for significant medical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/29\">",
"     29",
"    </a>",
"    ]. Criteria for near miss maternal mortality vary across institutions and among nations, but are most commonly described in terms of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multisystem failure or severe organ system dysfunction (eg, respiratory, renal failure)",
"     </li>",
"     <li>",
"      Need for major",
"      <span class=\"nowrap\">",
"       intervention(s)/resuscitation",
"      </span>",
"      (eg, hysterectomy, intubation, intensive care unit admission, transfusion)",
"     </li>",
"     <li>",
"      Serious category of disease (eg, severe hemorrhage, eclampsia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since there are more near misses than deaths, the larger number of cases provides more analyzable data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Assessment of near misses provides meaningful information regarding determinants of severe obstetric morbidity, and may show trends in management and outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/33,36\">",
"     33,36",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Examination of these events may provide insight into system problems in areas with high maternal mortality ratios and system",
"    <span class=\"nowrap\">",
"     successes/effective",
"    </span>",
"    interventions in areas with low ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. In addition, interviews with surviving women provide valuable information (eg, poor care or poor access to care) that may have led to the near miss but is not easily ascertained from interviews with family members or through record review after a maternal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/33,37\">",
"     33,37",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    In the United States, the Department of Health and Human Services (HHS), American",
"    <span class=\"nowrap\">",
"     College/Congress",
"    </span>",
"    of Obstetricians and Gynecologists (ACOG), Association of Maternal Child Health Programs (AMCHP) and the Department of Health and Human",
"    <span class=\"nowrap\">",
"     Services/Health",
"    </span>",
"    Resources Services Administration (HRSA) provide useful surveillance resources to direct formation of maternal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    review committees, such as a guidebook with appendices of forms to assist with data abstraction and coding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/38\">",
"     38",
"    </a>",
"    ]. The proceedings of these committees should have protection by state statute to protect them from liability or discovery. Their findings may enable development of referral systems for appropriate transfer or consultation, in addition to providing education and feedback on management of scenarios or cases that result in high near miss maternal morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116982881\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In low income countries, other benchmark or process indicators, such as the number of deliveries with skilled attendants and minimum cesarean delivery rate have been proposed as proxy measures for health system progress in maternal mortality reduction efforts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28761?source=see_link\">",
"     \"Approaches to reduction of maternal mortality in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Delays in seeking and receiving care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"Three Delays\" model has been widely applied in the global context to understand and investigate complex social, cultural, and medical events contributing to maternal deaths. The delays leading to maternal death include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delay in the decision to seek care (eg, unrecognized life-threatening illness, women needing to seek permission from family members before obtaining care)",
"     </li>",
"     <li>",
"      Delay in arrival to an appropriate medical care facility (eg, poor or no transportation, long distance from care facility)",
"     </li>",
"     <li>",
"      Delay in receiving adequate care once a woman arrives to medical facility (eg, unrecognized or under-treated life-threatening condition, inadequate facilities for severity of disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This framework enables assessment of patient, provider, and",
"    <span class=\"nowrap\">",
"     social/cultural",
"    </span>",
"    practices which contribute to maternal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Specific etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most maternal deaths are considered preventable (",
"    <a class=\"graphic graphic_figure graphicRef80185 \" href=\"mobipreview.htm?5/63/6143\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1\">",
"     1",
"    </a>",
"    ]. Pregnancy-related conditions are the second most common cause of death for women age 15 to 44 years worldwide and account for about 15 percent of deaths in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, the frequencies of some other major causes of death in this age group are",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    (19.2 percent), tuberculosis (6.4 percent), suicide (4.7 percent), traffic accidents (3.7 percent), respiratory infection (3.4 percent), ischemic heart disease (2.9 percent), fires (2.9 percent), stroke (2.2 percent), and violence (1.7 percent). Breast cancer is among the top 10 causes of female death in this age group in middle and high income countries, accounting for 2.6 and 7.9 percent of deaths, respectively. Cervical cancer is the leading cause of gynecologic-related cancer deaths in low income countries, but is not one of the top 10 causes of death.",
"   </p>",
"   <p>",
"    Trauma is a major contributor to maternal mortality, and, in the United States, it is the leading cause of pregnancy-associated maternal death or death that may be causally related to pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/42\">",
"     42",
"    </a>",
"    ]. Despite the magnitude of trauma-related maternal deaths, these deaths are excluded from most national maternal mortality ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/5\">",
"     5",
"    </a>",
"    ]. Motor vehicle accidents are the leading cause of trauma-related maternal death, followed by violence and assault (homicide). In parts of the United States, however, homicide is the leading cause of trauma-related maternal death, followed by falls and suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The National Violent Death Reporting System reported 94 pregnancy-associated suicides and 139 pregnancy-associated homicides in the US from 2003 to 2007, yielding maternal death rates of 2.0 and 2.9 deaths per 100,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/45\">",
"     45",
"    </a>",
"    ]. These mortality rates are higher than those for obstetrical hemorrhage,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    and amniotic fluid embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=see_link\">",
"     \"Trauma in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     By geographic region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes and frequencies of maternal mortality vary by geographic region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1,46\">",
"     1,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Africa and Asia, hemorrhage (30.8 to 33.9 percent) is the leading direct obstetric cause of maternal mortality, followed by hypertensive disorders (9.7 percent).",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      is emerging as a significant contributor to maternal mortality in Sub-Saharan Africa, accounting for approximately 9 percent of all maternal deaths in this region overall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/2\">",
"       2",
"      </a>",
"      ]. In Botswana, over three-quarters of maternal deaths are due to HIV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/2\">",
"       2",
"      </a>",
"      ]. Universal access to antiretroviral therapy could avert many of these deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Latin America and the Caribbean, hypertensive disorders are the leading cause of maternal death, followed by obstructed labor (13.4 percent).",
"     </li>",
"     <li>",
"      In most high income countries, complications of hypertensive disorders are the leading cause of maternal death (16.1 percent), followed by pulmonary embolism (14.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, pulmonary embolism is responsible for 1 to 1.5 deaths per 100,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/8,9,12,13,48\">",
"     8,9,12,13,48",
"    </a>",
"    ]. Pulmonary embolism (both thrombotic and amniotic) accounts for about 20 percent of maternal deaths and is the leading cause of maternal death, but hemorrhage (12.5 percent) and complications of hypertensive disorders, such as",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    (12.3 percent) are not far behind [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"     48",
"    </a>",
"    ]. Maternal deaths from hemorrhage and hypertensive disorders have declined, while maternal deaths due to other disorders have increased. The most common of these disorders are non-cardiovascular medical conditions (13.2 percent), cardiovascular conditions (12.4 percent), cardiomyopathy (11.5 percent), infection (10.7 percent), and cerebrovascular accident (6.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"     48",
"    </a>",
"    ]. Obesity, which is increasing in prevalence globally, contributes to an increased risk for venous thromboembolism-related maternal death and deaths associated with cesarean delivery, preeclampsia, and cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     By fetal/newborn status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes and frequencies of maternal mortality also vary according to",
"    <span class=\"nowrap\">",
"     fetal/newborn",
"    </span>",
"    status (live birth, stillbirth, undelivered) in one population based study of pregnancy-related mortality in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most (60 percent) maternal deaths occurred after a live birth. For women who died after live birth, the leading causes of death were pulmonary embolism (21 percent), hypertension (19 percent), and \"other medical conditions\" (17 percent).",
"     </li>",
"     <li>",
"      By comparison, the leading causes of maternal mortality after a stillbirth were hemorrhage (21 percent), hypertension (20 percent), and infection (19 percent).",
"     </li>",
"     <li>",
"      After spontaneous or induced abortion, the leading causes of maternal death were infection (34 percent), hemorrhage (22 percent), and \"other medical conditions\" (16 percent).",
"     </li>",
"     <li>",
"      Undelivered women were most likely to die from \"other medical conditions\" (34 percent) and pulmonary embolism (25 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     WHEN DO MATERNAL DEATHS OCCUR?",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States from 1998 to 2005, 3 percent of maternal deaths occurred after spontaneous or induced abortion, 4 percent occurred after ectopic pregnancies, 15 percent occurred antepartum, and 77 percent occurred postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"     48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The most common cause of first trimester pregnancy related death in the United States is ectopic pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. Although the incidence of ectopic pregnancy has increased, there has been a 90 percent decrease in the case fatality (from 35.5 maternal deaths per 10,000 ectopic pregnancies in 1970 to 3.8 per 10,000 in 1989) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a preterm or term birth, approximately one-third of maternal deaths occur within 24 hours of delivery, approximately one-half occur during the first 2 to 42 days postpartum, and the remainder occur from 43 to 365 days postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/49\">",
"     49",
"    </a>",
"    ]. About 50 percent of deaths from pulmonary emboli occur within 24 hours postpartum and 68 percent of hemorrhage-related deaths occur within 48 hours postpartum. Cardiomyopathy is a common cause of late maternal deaths, with 45 percent occurring 43 to 365 days postpartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DEMOGRAPHIC RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     African-American race",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, there is significant disparity in maternal mortality for African-American women compared to white women (in 2005: 38.7 versus 10.7 pregnancy-related deaths per live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"     48",
"    </a>",
"    ]. This is one of the largest perinatal health disparities in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. Increasing educational level is protective against maternal death; however, at all educational levels, pregnancy-related mortality ratios for black women are three to four times higher than ratios for white women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/49,53\">",
"     49,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women receiving any prenatal care have lower maternal death risks than those who receive no care. For African-American women, the benefit of prenatal care is attenuated: the reduction in maternal death associated with prenatal care is greater for white women than for African-American women who receive prenatal care. The reasons for this disparity in United States maternal mortality are unclear and under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Advancing maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of death for older women is several-fold higher than for younger women across ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"     48",
"    </a>",
"    ]. For women over 39 years of age, there is a six-fold increase in risk for maternal death compared to women 15 to 19 years of age.",
"   </p>",
"   <p>",
"    This disparity is even more pronounced in African Americans of advanced maternal age. The risk of death for African-American women over 39 years of age is 10 times that of African-American women 15 to 19 years of age, whereas the risk of death for white women over 39 years of age is about 6 times that of white women 15 to 19 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9605925\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR MATERNAL MORTALITY REDUCTION IN HIGH INCOME COUNTRIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for maternal mortality reduction in the United States and other high income countries are based, in part, on confidential inquiries of maternal deaths and evaluations of &lsquo;near miss&rsquo; maternal mortalities.",
"   </p>",
"   <p>",
"    In the United States, deficient medical care, medical co-morbidities, and social circumstances appear to be strong contributors to maternal mortality, especially for African American women who continue to have a higher case-fatality rate than Caucasian women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48,53\">",
"     48,53",
"    </a>",
"    ]. Pregnancy-related mortality is three to four times higher among American women and this relationship is maintained independent of presence of early entry to prenatal care, maternal age, socioeconomic status, and parity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"     48",
"    </a>",
"    ]. As such, in the United States, better use of resources, rather than lack of resources, is a major focus for reducing maternal mortality. These efforts have focused on team and individual training; simulations and drills; development of protocols, guidelines and checklists; use of information technology; and education. For example, deaths from obstetric hemorrhage can be reduced through development of protocols, drills, and teamwork [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. It has been estimated that more than half of all maternal deaths in the United States can be prevented through early diagnosis and appropriate medical care of pregnancy complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other risk factors for maternal death in the United States include preexisting cardiovascular conditions and cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/57\">",
"     57",
"    </a>",
"    ]. Preconception counseling for women with medical comorbidities, such as those with heart conditions, reduces risk of maternal death for avoidance of pregnancy for those at highest risk and through multi-disciplinary management during pregnancy and postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=see_link\">",
"     \"Reducing adverse obstetrical outcomes through safety sciences\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33369?source=see_link\">",
"     \"Operating room safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, maternal obesity is a risk factor for maternal death as it is associated with multiple serious maternal and pregnancy complications. The risk of maternal mortality related to obesity may be modifiable through risk reduction interventions, such as tertiary care management of women with severe obesity, availability of specialized equipment, and postpartum interventions for maternal weight reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6898587\">",
"    <span class=\"h2\">",
"     Recommendations of national organizations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6898602\">",
"    <span class=\"h3\">",
"     Joint Commission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Joint Commission suggests the following actions to help hospitals reduce the risk of maternal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good communication between all members of the health care delivery team, as well as consultants, the patient, and the patient&rsquo;s family is essential.",
"     </li>",
"     <li>",
"      Educate clinicians who care for women with underlying medical conditions about the potential additional risks if pregnancy occurs. Discuss these risks during preconceptional care and counseling, and discuss the use of appropriate contraception. Refer high-risk patients to obstetricians with expertise in caring for these patients and with access to a broad range of specialized services.",
"     </li>",
"     <li>",
"      Promptly identify changes in the mother&rsquo;s vital signs and clinical condition and develop written protocols and drills for responding with best practices as soon as her condition appears to be worsening. Use drills to train staff in the protocols, to refine local protocols, and to identify and fix system problems that would prevent optimal care. Common scenarios are management of severe hypertension or hypotension, treatment of pulmonary edema in preeclampsia, and early response to postpartum hemorrhage.",
"     </li>",
"     <li>",
"      Make pneumatic compression devices available for patients undergoing cesarean delivery who are at high risk for pulmonary embolism. Evaluate patients who are at high risk for thromboembolism for postpartum low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Educate emergency room personnel about the possibility that a woman may be pregnant or may have recently been pregnant, regardless of her presenting complaint.",
"     </li>",
"     <li>",
"      Staff and the patient&rsquo;s family should seek additional assistance when they have concerns about the patient&rsquo;s condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6898609\">",
"    <span class=\"h3\">",
"     UK Confidential Enquiries Commission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom had similar recommendations, and included access to professional interpreter services for ethnic minorities, an emphasis on prevention and treatment of infection, consistent reporting of serious incidents and maternal deaths, and performance of autopsies by pathologists with expertise in this area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40888/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6898471\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR MATERNAL MORTALITY REDUCTION IN LOW INCOME COUNTRIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28761?source=see_link\">",
"     \"Approaches to reduction of maternal mortality in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal mortality, while uncommon in high income countries, is a significant contributor to death in women in low income countries. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The International Code of Diseases (ICD-10) provides several definitions for classification of maternal death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The biggest hurdle to understanding the impact of maternal death on global society is the lack of standardized documentation of deaths. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ascertainment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delays in seeking and receiving",
"      <span class=\"nowrap\">",
"       medical/obstetrical",
"      </span>",
"      care are the root causes of maternal death. These &lsquo;delays&rsquo; are related to patient, provider, and",
"      <span class=\"nowrap\">",
"       social/cultural",
"      </span>",
"      factors. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Delays in seeking and receiving care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of maternal death are directly related to pregnancy (pulmonary embolism, hemorrhage, sepsis, and hypertensive disease). Trauma, including homicide and motor vehicle accidents, is the most common cause of pregnancy-associated maternal death or death that may be causally related to pregnancy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Specific etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In high income countries, optimum use of available resources is a major focus for maternal mortality reduction efforts. (See",
"      <a class=\"local\" href=\"#H9605925\">",
"       'Recommendations for maternal mortality reduction in high income countries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/1\">",
"      Hogan MC, Foreman KJ, Naghavi M, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375:1609.",
"     </a>",
"    </li>",
"    <li>",
"     Trends in maternal mortality: 1990 to 2008",
"Estimates developed by WHO, UNICEF, UNFPA and The World Bank file://www.who.int/reproductivehealth/publications/monitoring/9789241500265/en/index.html (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/3\">",
"      Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991-1997. Obstet Gynecol 2003; 101:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/4\">",
"      MacKAy AP, Berg CJ, Liu X, et al. Changes in pregnancy mortality ascertainment: United States, 1999-2005. Obstet Gynecol 2011; 118:104.",
"     </a>",
"    </li>",
"    <li>",
"     AbouZahar, C, Wardlaw, T. Maternal Mortality in 2000: estimates developed by WHO, UNICEF and UNFPA. WHO. 2003. Geneva, Switzerland.",
"    </li>",
"    <li>",
"     International statistical classification of Diseases and Related Health Problems, Tenth Revision (ICD 10). Geneva, Switzerland, World Health Organization 1992.",
"    </li>",
"    <li>",
"     Say, L, Inuoe, M, Mills, S, Suzuki, E. Maternal mortality 2005: Estimates developed by WHO, UNICEF, UNFPA, and the World Bank 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/8\">",
"      Franks AL, Atrash HK, Lawson HW, Colberg KS. Obstetrical pulmonary embolism mortality, United States, 1970-85. Am J Public Health 1990; 80:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/9\">",
"      Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/10\">",
"      Pagel C, Lewycka S, Colbourn T, et al. Estimation of potential effects of improved community-based drug provision, to augment health-facility strengthening, on maternal mortality due to post-partum haemorrhage and sepsis in sub-Saharan Africa: an equity-effectiveness model. Lancet 2009; 374:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/11\">",
"      Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/12\">",
"      James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/13\">",
"      Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359:2025.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau.. Child Health USA 2008-2009, Rockville, Maryland 2009.",
"    </li>",
"    <li>",
"     Maternal mortality and related concepts. VItal and Health Statistics. Dept of Health and Human Services. February 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/16\">",
"      Horon IL. Underreporting of maternal deaths on death certificates and the magnitude of the problem of maternal mortality. Am J Public Health 2005; 95:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/17\">",
"      Graham WJ, Ahmed S, Stanton C, et al. Measuring maternal mortality: an overview of opportunities and options for developing countries. BMC Med 2008; 6:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/18\">",
"      Donati S, Senatore S, Ronconi A, Regional maternal mortality working group. Maternal mortality in Italy: a record-linkage study. BJOG 2011; 118:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/19\">",
"      de Swiet M. Maternal mortality: confidential enquiries into maternal deaths in the United Kingdom. Am J Obstet Gynecol 2000; 182:760.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis, G, Drise, J, Botting, B, Carson, C, et al. Why mothers die: Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 1997-1999. London (UK): Department of Health on behalf of the controller of Her majesty's Stationery Office; 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/21\">",
"      Geller SE, Rosenberg D, Cox SM, et al. The continuum of maternal morbidity and mortality: factors associated with severity. Am J Obstet Gynecol 2004; 191:939.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis, G. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mother's lives: reviewing maternal deaths to make childhood safer, 2003-2005. London (UK): CEMACH; 2007.",
"    </li>",
"    <li>",
"     www.who.org/reproductive-health/publications/rht_97_28/RHT_97_28_chapter2.en.html. (Accessed August 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/24\">",
"      MacKay AP, Berg CJ, Duran C, et al. An assessment of pregnancy-related mortality in the United States. Paediatr Perinat Epidemiol 2005; 19:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/25\">",
"      Horon IL, Cheng D. Effectiveness of pregnancy check boxes on death certificates in identifying pregnancy-associated mortality. Public Health Rep 2011; 126:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/26\">",
"      Ronsmans C, Graham WJ, Lancet Maternal Survival Series steering group. Maternal mortality: who, when, where, and why. Lancet 2006; 368:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/27\">",
"      Mantel GD, Buchmann E, Rees H, Pattinson RC. Severe acute maternal morbidity: a pilot study of a definition for a near-miss. Br J Obstet Gynaecol 1998; 105:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/28\">",
"      Wilson RE, Salihu HM. The paradox of obstetric \"near misses\": converting maternal mortality into morbidity. Int J Fertil Womens Med 2007; 52:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/29\">",
"      Say L, Pattinson RC, G&uuml;lmezoglu AM. WHO systematic review of maternal morbidity and mortality: the prevalence of severe acute maternal morbidity (near miss). Reprod Health 2004; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/30\">",
"      van Roosmalen J, Zwart J. Severe acute maternal morbidity in high-income countries. Best Pract Res Clin Obstet Gynaecol 2009; 23:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/31\">",
"      Filippi V, Brugha R, Browne E, et al. Obstetric audit in resource-poor settings: lessons from a multi-country project auditing 'near miss' obstetrical emergencies. Health Policy Plan 2004; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/32\">",
"      Geller SE, Rosenberg D, Cox SM, Kilpatrick S. Defining a conceptual framework for near-miss maternal morbidity. J Am Med Womens Assoc 2002; 57:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/33\">",
"      Pattinson RC, Hall M. Near misses: a useful adjunct to maternal death enquiries. Br Med Bull 2003; 67:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/34\">",
"      Geller SE, Cox SM, Kilpatrick SJ. A descriptive model of preventability in maternal morbidity and mortality. J Perinatol 2006; 26:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/35\">",
"      Geller SE, Cox SM, Callaghan WM, Berg CJ. Morbidity and mortality in pregnancy: laying the groundwork for safe motherhood. Womens Health Issues 2006; 16:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/36\">",
"      Mantel GD, Buchmann E, Rees H, Pattinson RC. Severe acute maternal morbidity: a pilot study of a definition for a near-miss. Br J Obstet Gynaecol 1998; 105:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/37\">",
"      Filippi V, Ganaba R, Baggaley RF, et al. Health of women after severe obstetric complications in Burkina Faso: a longitudinal study. Lancet 2007; 370:1329.",
"     </a>",
"    </li>",
"    <li>",
"     Bacak SJ, Berg CJ, Desmaris J, Hutchins E, Locke E (Eds). State Maternal Mortality Review: Accomplishments of Nine states, CDC, Atlanta 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/39\">",
"      Thaddeus S, Maine D. Too far to walk: maternal mortality in context. Soc Sci Med 1994; 38:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/40\">",
"      Barnes-Josiah D, Myntti C, Augustin A. The \"three delays\" as a framework for examining maternal mortality in Haiti. Soc Sci Med 1998; 46:981.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Ten leading causes of death in women aged 15&ndash;44 years by country income group, 2004. file://www.who.int/gender/women_health_report/womenandhealth_report_chart_chp4_table1.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/42\">",
"      Chang J, Berg CJ, Saltzman LE, Herndon J. Homicide: a leading cause of injury deaths among pregnant and postpartum women in the United States, 1991-1999. Am J Public Health 2005; 95:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/43\">",
"      Fildes J, Reed L, Jones N, et al. Trauma: the leading cause of maternal death. J Trauma 1992; 32:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/44\">",
"      Harper M, Parsons L. Maternal deaths due to homicide and other injuries in North Carolina: 1992-1994. Obstet Gynecol 1997; 90:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/45\">",
"      Palladino CL, Singh V, Campbell J, et al. Homicide and suicide during the perinatal period: findings from the National Violent Death Reporting System. Obstet Gynecol 2011; 118:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/46\">",
"      South Africa Every Death Counts Writing Group, Bradshaw D, Chopra M, et al. Every death counts: use of mortality audit data for decision making to save the lives of mothers, babies, and children in South Africa. Lancet 2008; 371:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/47\">",
"      Anema A, Au-Yeung CG, Joffres M, et al. Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Res Ther 2011; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/48\">",
"      Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/49\">",
"      Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/50\">",
"      Berg CJ, Harper MA, Atkinson SM, et al. Preventability of pregnancy-related deaths: results of a state-wide review. Obstet Gynecol 2005; 106:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/51\">",
"      Goldner TE, Lawson HW, Xia Z, Atrash HK. Surveillance for ectopic pregnancy--United States, 1970-1989. MMWR CDC Surveill Summ 1993; 42:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). State-specific maternal mortality among black and white women--United States, 1987-1996. MMWR Morb Mortal Wkly Rep 1999; 48:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/53\">",
"      Tucker MJ, Berg CJ, Callaghan WM, Hsia J. The Black-White disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. Am J Public Health 2007; 97:247.",
"     </a>",
"    </li>",
"    <li>",
"     The Joint Commission. Sentinel Event Alert. Preventing Maternal Death. Issue 44. January 2010. file://www.jointcommission.org/assets/1/18/SEA_44.PDF (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     California Maternal Quality Care Collaborative, Hemorrhage Taskforce. Improving Healthcare Response to Obstetric Hemorrhage Toolkit. Palo Alto; CMQCC; 2010. www.cmqcc.org/ob_hemorrhage (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/56\">",
"      Berg CJ, Atrash HK, Koonin LM, Tucker M. Pregnancy-related mortality in the United States, 1987-1990. Obstet Gynecol 1996; 88:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/57\">",
"      Berg CJ, Harper MA, Atkinson SM, et al. Preventability of pregnancy-related deaths: results of a state-wide review. Obstet Gynecol 2005; 106:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/58\">",
"      Gelson E, Gatzoulis MA, Steer P, Johnson MR. Heart disease--why is maternal mortality increasing? BJOG 2009; 116:609.",
"     </a>",
"    </li>",
"    <li>",
"     The Joint Commission. Sentinel Event Alert. Preventing Maternal Death. Issue 44. January 2010. file://www.jointcommission.org/assets/1/18/SEA_44.PDF (Accessed on March 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40888/abstract/60\">",
"      Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 Suppl 1:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6713 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40888=[""].join("\n");
var outline_f39_59_40888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1911359\">",
"      MATERNAL MORTALITY WORLDWIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Maternal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Late maternal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1728169\">",
"      Pregnancy related death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Direct and indirect obstetric death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37833512\">",
"      - Direct obstetric death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37833519\">",
"      - Indirect obstetric death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maternal mortality ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maternal mortality rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lifetime risk of maternal death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ASCERTAINMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vital registration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Direct household surveys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reproductive Age Mortality Studies (RAMOS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Verbal autopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Census",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Death certificate data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Near miss maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116982881\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Delays in seeking and receiving care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Specific etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      By geographic region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      By fetal/newborn status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      WHEN DO MATERNAL DEATHS OCCUR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DEMOGRAPHIC RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      African-American race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Advancing maternal age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9605925\">",
"      RECOMMENDATIONS FOR MATERNAL MORTALITY REDUCTION IN HIGH INCOME COUNTRIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6898587\">",
"      Recommendations of national organizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6898602\">",
"      - Joint Commission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6898609\">",
"      - UK Confidential Enquiries Commission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6898471\">",
"      RECOMMENDATIONS FOR MATERNAL MORTALITY REDUCTION IN LOW INCOME COUNTRIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6713|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/17/34070\" title=\"figure 1\">",
"      Global maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/22/23919\" title=\"figure 2\">",
"      Variation in causes of maternal mortality worldwide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/63/6143\" title=\"figure 3\">",
"      Causes maternal death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6713|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/4/20556\" title=\"table 1\">",
"      Maternal mortality ratio",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28761?source=related_link\">",
"      Approaches to reduction of maternal mortality in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33369?source=related_link\">",
"      Operating room safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=related_link\">",
"      Reducing adverse obstetrical outcomes through safety sciences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=related_link\">",
"      Trauma in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40889="Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents";
var content_f39_59_40889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Madhusmita Misra, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40889/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/59/40889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus (T1DM), one of the most common chronic diseases in childhood, is caused by insulin deficiency following destruction of the insulin-producing pancreatic beta cells. It most commonly presents in childhood, but one-fourth of cases are diagnosed in adults. T1DM remains the most common form of diabetes in childhood, accounting for approximately two-thirds of new diagnoses of diabetes in patients &le;19 years of age in the United States, despite the increasing rate of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, presentation, and diagnosis of T1DM in children and adolescents are presented here. The pathogenesis of T1DM and the management and complications of childhood T1DM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment and management of individuals presenting during infancy with hyperglycemia also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link\">",
"     \"Neonatal hyperglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of childhood type 1 diabetes (T1DM) varies based upon geography, age, gender, family history, and ethnicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Geographical variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of childhood T1DM varies worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In Europe and China, the risk appears to rise as the geographical latitude (distance from the equator) increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], but this North-South variation is not found in the United States, even after adjusting for racial and ethnic variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/10\">",
"     10",
"    </a>",
"    ]. When people relocate from a region of low to high incidence, their risk of developing T1DM also increases, suggesting a causative role for environmental factor(s). However, wide variations in incidence occur between neighboring areas of similar latitude, suggesting the presence of other contributing risk factors and demonstrating the complexity of the pathogenesis of T1DM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The highest reported incidences of T1DM occur in Finland and Sardinia (37 to 45 per 100,000 children younger than the age of 15 years). Rates in these countries are almost 400 times that of Venezuela and parts of China, which have the lowest incidence (0.1 to 0.5 per 100,000 children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the incidence of T1DM in non-Hispanic white children and adolescents is 23.6 per 100,000 per year, and the prevalence is 2.0 per 1000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/12\">",
"     12",
"    </a>",
"    ]. Rates are substantially lower in other racial or ethnic groups (",
"    <a class=\"graphic graphic_table graphicRef51817 \" href=\"mobipreview.htm?21/60/22476\">",
"     table 1",
"    </a>",
"    ). Parts of Canada, such as Newfoundland, have a higher incidence (36 per 100,000 per year) than the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/13\">",
"     13",
"    </a>",
"    ], whereas the incidence in Quebec is lower, at 15 per 100,000 per year in children younger than 15 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age and gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of presentation of childhood onset T1DM has a bimodal distribution, with one peak at four to six years of age and a second in early puberty (10 to 14 years of age) (",
"    <a class=\"graphic graphic_figure graphicRef88297 \" href=\"mobipreview.htm?4/28/4558\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Overall, about 45 percent of children present before 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most autoimmune diseases are more common in females, there appears to be no gender difference in the overall incidence of childhood T1DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/18\">",
"     18",
"    </a>",
"    ]. However, in select populations, T1DM occurs more frequently in males. As an example, older males of European origin (&ge;13 years of age) are more likely to develop T1DM than females of similar age and geographic location, with an approximate 3:2 male to female ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The same 3:2 male to female ratio also was reported in children younger than six years of age in an observational study from Massachusetts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22151378\">",
"    <span class=\"h2\">",
"     Time trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of childhood type 1 disease is rising worldwide, with reported increases of 2 to 5 percent per year in Europe, the Middle East, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. In the United States, the overall incidence of T1DM also appears to be rising in most age and ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/18,27\">",
"     18,27",
"    </a>",
"    ]. The reasons for the increasing incidence are unknown.",
"   </p>",
"   <p>",
"    The rise appears to be primarily in younger children. A report using data from 17 European countries revealed an annual rate increase of 5.4, 4.3, and 2.9 percent for the age groups 0 to 4, 5 to 9, and 10 to 14 years, respectively, over a 15-year period from 1989 to 2003; the overall increase was 3.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/26\">",
"     26",
"    </a>",
"    ]. If these trends continue, the number of new cases of T1DM mellitus in children younger than five years of age may double in some regions between 2005 and 2020, and prevalent cases in children under 15 years will rise by 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/26\">",
"     26",
"    </a>",
"    ]. Data reported from Philadelphia show that the incidence in children less than five years of age increased by 70 percent between 1985 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/28\">",
"     28",
"    </a>",
"    ]. The trend towards younger age of onset is not seen in all populations: One study from Sweden has reported increases in age at diagnosis for children born in or after 2000, reversing the previous trend [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/29\">",
"     29",
"    </a>",
"    ]. Similarly, a study from New Zealand documented a trend towards older age at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821065\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both genetic and environmental factors contribute to the risk of developing type 1 diabetes mellitus (T1DM). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of developing T1DM is significantly increased in close relatives of a patient with T1DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No family history &ndash; 0.4 percent",
"     </li>",
"     <li>",
"      Offspring of an affected mother &ndash; 1 to 4 percent",
"     </li>",
"     <li>",
"      Offspring of an affected father &ndash; 3 to 8 percent",
"     </li>",
"     <li>",
"      Offspring with both parents affected &ndash; reported as high as 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Non-twin sibling of affected patient &ndash; 3 to 6 percent",
"     </li>",
"     <li>",
"      Dizygotic twin &ndash; 8 percent",
"     </li>",
"     <li>",
"      Monozygotic twin &ndash; 30 percent within 10 years of diagnosis of the first twin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/35\">",
"       35",
"      </a>",
"      ], and 65 percent concordance by age 60 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, there also are ethnic differences in incidence of T1DM. In a study that sampled several large multiethnic populations between 2002 and 2005, the highest incidence was seen in non-Hispanic white youth, followed by African American, Hispanic, Asian-Pacific Islanders, and American Indians (22.6, 15.7, 13.8, 7.4, and 2.97 cases per 100,000 children 10 to 19 years old, respectively) (",
"    <a class=\"graphic graphic_table graphicRef51817 \" href=\"mobipreview.htm?21/60/22476\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/12\">",
"     12",
"    </a>",
"    ]. Of note, Hispanic populations of Puerto Rican origin have a markedly higher incidence rate than those of Mexican or South American descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations of familial and ethnic risk factors are most likely the consequences of gene polymorphisms in the major histocompatibility complex (MHC) or other genetic susceptibility regions. Details regarding genetic susceptibility and the genes that increase the risk of T1DM are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of type 1 diabetes mellitus\", section on 'Genetic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In genetically susceptible individuals, exposure to one or more environmental agents appears to trigger an immune response that ultimately causes destruction of the insulin-producing pancreatic beta cells. Identification of these factors should lead to a better understanding of the pathogenesis of the disease and aid in developing strategies to prevent T1DM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of type 1 diabetes mellitus\", section on 'Environmental factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=see_link\">",
"     \"Prevention of type 1 diabetes mellitus\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Reports have linked each of the following factors to an increased risk of T1DM; however, none of these associations have been verified and many have been contradicted by other studies. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Viral infections, particularly enterovirus infections",
"     </li>",
"     <li>",
"      Immunizations",
"     </li>",
"     <li>",
"      Diet, especially exposure to cow's milk at an early age",
"     </li>",
"     <li>",
"      Higher socioeconomic status",
"     </li>",
"     <li>",
"      Obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vitamin D deficiency",
"     </li>",
"     <li>",
"      Perinatal factors such as maternal age, history of preeclampsia, and neonatal jaundice. Low birth weight decreases the risk of developing T1DM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seasonal variation has been suggested in some studies, with a higher reported incidence of T1DM in colder as compared to warmer months, particularly in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, another study did not find a seasonal variation in girls and reported a higher incidence in the summer months for boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more complete description of environmental factors and their potential link to T1DM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of type 1 diabetes mellitus\", section on 'Environmental factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood type 1 diabetes mellitus (T1DM) can present in several different ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Classic new onset",
"     </li>",
"     <li>",
"      Diabetic ketoacidosis",
"     </li>",
"     <li>",
"      Silent (asymptomatic) incidental discovery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Classic new onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia without acidosis is the most common presentation of childhood T1DM in most populations. Patients typically present with the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyuria &ndash; Polyuria occurs when the serum glucose concentration rises significantly above 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      exceeding the renal threshold for glucose, which leads to increased urinary glucose excretion. Glycosuria causes osmotic diuresis (ie, polyuria) and hypovolemia. Polyuria may present as nocturia, bedwetting, or daytime incontinence in a previously continent child. In children who are not toilet trained, parents may note an increased frequency of wet diapers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diapers that are unusually heavy (wet).",
"     </li>",
"     <li>",
"      Polydipsia &ndash; Polydipsia is due to enhanced thirst because of increased serum osmolality from hyperglycemia and hypovolemia. Despite the hypovolemia, patients may not have the classic signs of dry mucus membranes or decreased skin turgor. &nbsp;",
"     </li>",
"     <li>",
"      Weight loss &ndash; Weight loss is a result of hypovolemia and increased catabolism. Insulin deficiency in diabetic children impairs glucose utilization in skeletal muscle and increases fat and muscle breakdown. Initially, appetite is increased, but over time, children are more thirsty than hungry, and ketosis leads to nausea and anorexia, contributing to weight loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with these symptoms usually present in the ambulatory setting appearing slightly ill, with vague complaints, such as weight loss and lethargy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ]. In a study from Ireland, the mean duration of symptoms before presentation was 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/46\">",
"     46",
"    </a>",
"    ]. The classic symptoms of polyuria and polydipsia are present in more than 90 percent of patients, but these are not always the initial complaints and may become apparent only after obtaining a careful history (eg, nocturia and bedwetting, increased frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unusually wet diapers, and persistent thirst). Weight loss is a presenting symptom in about half of children.",
"   </p>",
"   <p>",
"    Other presentations include perineal candidiasis, which is a relatively common presenting symptom in young children and in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ]. Visual disturbances are common because of alterations in the osmotic milieu of the lens, and to a lesser extent the aqueous and vitreous humors leading to changes in refractive index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/47\">",
"     47",
"    </a>",
"    ]. Children with longstanding hyperglycemia may present with cataracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diabetic ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (hyperglycemia and ketoacidosis) is the second most common form of presentation for T1DM in most populations. Symptoms are similar but usually more severe than those of patients without acidosis. In addition to polyuria, polydipsia, and weight loss, patients with ketoacidosis may present with a fruity-smelling breath and neurologic findings including drowsiness and lethargy. DKA can be misinterpreted as an acute vomiting illness because classic pediatric symptoms of dehydration (decreased urination) are masked by the polyuria that is associated with glycosuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported frequency of diabetic ketoacidosis (DKA) as the initial presentation for childhood T1DM is approximately 35 percent, but varies from 15 to 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Young children (&lt;six years of age) or those from an adverse socioeconomic background are more likely to have DKA as their initial presentation of T1DM. Among children younger than three years, more than half had DKA as the initial presentation of T1DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Epidemiology'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Children with DKA require hospitalization, rehydration, and insulin replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Silent presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children will be diagnosed with T1DM before the onset of clinical symptoms. This presentation is least common and typically occurs in children who have another close family member with T1DM and are being closely monitored. The diagnosis often is made by either a family member or clinician with a high index of suspicion. Children with an affected close family member also may undergo pancreatic autoantibody screening to assess risk for the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/52\">",
"     52",
"    </a>",
"    ], although this is currently not a clinical care recommendation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32087?source=see_link\">",
"     \"Prediction of type 1 diabetes mellitus\"",
"    </a>",
"    .) The diagnosis is made based upon an elevated blood glucose concentration using the criteria outlined below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of disorders can cause hyperglycemia during infancy. Although autoimmune classic T1DM can occur in the first year of life, neonatal diabetes is uncommonly, if ever, autoimmune in nature. This rare disorder is caused by one of several genetic defects in pancreatic development or beta cell function. (See",
"    <a class=\"local\" href=\"#H4821788\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link&amp;anchor=H12#H12\">",
"     \"Neonatal hyperglycemia\", section on 'Neonatal diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger children are more vulnerable to dehydration compared with older children because they are less able to compensate for pathologic processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ] by obtaining fluids and increasing fluid intake to replace ongoing urinary losses. In addition, children younger than six years of age are more likely to present with DKA because health care personnel and families less often suspect diabetes in this age group, leading to a prolonged duration of illness and more severe metabolic decompensation before diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21,46,51,53,54\">",
"     21,46,51,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children in this age group also have polydipsia and polyuria, but these symptoms are difficult to detect if the child is in diapers or is nonverbal and unable to communicate thirst. Therefore, it is often difficult to recognize these symptoms of hyperglycemia in young children, especially those younger than two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ]. A history or presence of prolonged or recurrent candidal infection (usually in the diaper area) is an important clue that should raise suspicion about the possibility of diabetes mellitus in young children. Candidal infection was present at diagnosis in a significant proportion of children younger than six years with T1DM, and especially in those younger than two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These patients often have been seen by a clinician for nonspecific complaints before the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"     21",
"    </a>",
"    ]. In this vulnerable age group, a high index of suspicion is required for early diagnosis. When a young child presents for evaluation of dehydration, abdominal pain, or fatigue, the clinician should include diabetes in the differential diagnosis and consider measuring serum glucose and testing for glycosuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus (T1DM) is one of several different types of diabetes mellitus. The initial step is to diagnose diabetes. The second step is to differentiate T1DM from other causes of diabetes based upon the clinical presentation of the patient and laboratory studies. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Type 1 versus type 2 diabetes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Other causes of diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821743\">",
"    <span class=\"h2\">",
"     Diagnostic criteria for diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus is diagnosed based upon one of the following four signs of abnormal glucose metabolism (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting plasma glucose &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on more than one occasion. Fasting is defined as no caloric intake for at least eight hours.",
"     </li>",
"     <li>",
"      Random venous plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in a patient with classic symptoms of hyperglycemia",
"     </li>",
"     <li>",
"      Plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      measured two hours after a glucose load of 1.75",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      (maximum dose of 75 g) in an oral glucose tolerance test (OGTT). Most children and adolescents are symptomatic and have plasma glucose concentrations well above &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      thus, OGTT is seldom necessary to diagnose T1DM.",
"     </li>",
"     <li>",
"      Glycated hemoglobin (A1C) &ge;6.5 percent (using an assay that is certified by the National Glycohemoglobin Standardization Program). This criterion is more useful in the diagnosis of type 2 diabetes mellitus (T2DM) in adults, and should be confirmed by hyperglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These diagnostic criteria based upon the guidelines of the American Diabetes Association (ADA) are similar to those used in adults with diabetes. Unless unequivocal symptomatic hyperglycemia is present, the diagnosis should be confirmed by repeat testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A1C measures the percent of hemoglobin A bound to glucose in a non-enzymatic reaction, and is an indication of average blood sugar levels for 10 to 12 weeks before the time of measurement. A1C &ge;6.5 percent is now an accepted criterion for diagnosis of diabetes in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/56\">",
"     56",
"    </a>",
"    ]. However, its diagnostic utility in children is less well established than in adults. Although values &ge;6.5 percent are diagnostic of diabetes, levels &lt;6.5 percent do not exclude diabetes. Of note, in one study from Germany, all children with symptomatic new-onset T1DM had a glycated hemoglobin &ge;6.35 percent, whereas those with transient hyperglycemia had A1C values ranging from 4.5 to 6.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/57\">",
"     57",
"    </a>",
"    ]. Individuals with abnormal hemoglobins or rapid destruction of red blood cells may have a measured A1C that does not accurately reflect their average blood sugar values. The accuracy of measurements in individuals with abnormal hemoglobins will improve with use of improved techniques for assessing A1C and with standardization of A1C measurements. For example, hemoglobin variants and derivatives interfere very minimally with the commercially available boronate-affinity chromatography technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/58\">",
"     58",
"    </a>",
"    ]. However, rapid turnover of hemoglobin will still affect the reported level. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Glycosuria is suggestive of diabetes, but not diagnostic. For example, patients with renal glucosuria or Fanconi syndrome will present with glycosuria but have normal plasma glucose concentration. Similarly, the presence of islet-specific autoantibodies supports the diagnosis of T1DM, as discussed in the next section, but is not sufficient to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Type 1 versus type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;T1DM is characterized primarily by insulin deficiency, whereas type 2 diabetes (T2DM) is characterized primarily by insulin resistance with relative insulin deficiency. As the incidence of T2DM increases in children and adolescents, it becomes increasingly important to distinguish type 1 from type 2 disease, because long-term management differs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    No set of criteria or diagnostic test can consistently distinguish between T1DM and T2DM. Therefore, differentiating between the two types is based upon a combination of the clinical presentation and history, often supported by laboratory studies (",
"    <a class=\"graphic graphic_table graphicRef59370 \" href=\"mobipreview.htm?31/15/31997\">",
"     table 3",
"    </a>",
"    ). &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Clinical characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body habitus &ndash; Patients with T2DM are usually obese (body mass index [BMI] &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age and gender). In contrast, children with T1DM are usually not obese and often have a recent history of weight loss, although up to 25 percent are overweight (BMI &ge;85",
"      <sup>",
"       th",
"      </sup>",
"      to 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &ndash; Patients with T2DM generally present after the onset of puberty, whereas those with T1DM often present at an earlier age. About 45 percent of children with T1DM present before 10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/18\">",
"       18",
"      </a>",
"      ]. By contrast, almost all cases of T2DM present after 10 years of age (",
"      <a class=\"graphic graphic_figure graphicRef88297 \" href=\"mobipreview.htm?4/28/4558\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Age and gender'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin resistance &ndash; Patients with T2DM frequently have acanthosis nigricans (a sign of insulin resistance), hypertension, dyslipidemia, and polycystic ovary syndrome (in girls). These findings are less likely in children with T1DM. As an example, in studies in the United States, 50 to 90 percent of youth diagnosed with T2DM have acanthosis nigricans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/2,60\">",
"       2,60",
"      </a>",
"      ]. Among those clinically diagnosed with T1DM, up to 25 percent have biochemical evidence of insulin resistance, and about 12 percent have acanthosis nigricans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/60\">",
"       60",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Family history &ndash; Up to 10 percent of patients with T1DM have an affected close relative, whereas 75 to 90 percent of those with T2DM have an affected close relative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/2,61\">",
"       2,61",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory testing &ndash; The following laboratory tests are often helpful in differentiating between T1DM and T2DM. We suggest including them in the evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies &ndash; Although there is no specific test to distinguish between the two types of diabetes, T1DM is suggested by the presence of serum islet-specific pancreatic autoantibodies, glutamic acid decarboxylase (GAD), the 40K fragment of tyrosine phosphatase (IA2),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insulin, and zinc transporter 8 (ZnT8). However, the absence of pancreatic autoantibodies does not rule out the possibility of T1DM. Up to 30 percent of individuals with the classical appearance and presentation of T2DM have positive autoantibodies and may have a slowly progressive type of autoimmune diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"       \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Insulin and C-peptide levels &ndash; High fasting insulin and C-peptide levels suggest T2DM. Levels are inappropriately low or in the normal range relative to the concomitant plasma glucose concentration in T1DM. At presentation, insulin and C-peptide levels may be suppressed by severe hyperglycemia and illness. It is usually best to assess these levels after the newly diagnosed patient has recovered from acute illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin deficiency in T1DM most commonly results from autoimmune destruction of pancreatic beta cells and is referred to as type 1A diabetes (approximately 85 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients with clinical features of T1DM but without detectable autoantibodies are categorized as having type 1B diabetes (approximately 15 percent). In these patients, there is no evidence of autoimmune beta-cell destruction and no other cause has been identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients may have mixed features, and are difficult to classify. As an example, in a registry study in the United States, pediatric diabetes was classified based upon the presence or absence of beta cell autoimmunity and the presence or absence of insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40889/abstract/60\">",
"     60",
"    </a>",
"    ]. More than 70 percent of patients fell into traditional categories of autoimmune and insulin sensitive T1DM (55 percent) or nonautoimmune and insulin resistant T2DM (16 percent). An additional 20 percent had both autoimmunity and insulin resistance, a pattern typical for obese patients with T1DM. The remaining 10 percent of patients were insulin sensitive in the absence of islet cell autoimmunity, most of whom were clinically categorized as T1DM (ie, type 1B diabetes), and the remainder as T2DM (suggesting that these patients need additional evaluation for the possibility of monogenic diabetes, formerly referred to as maturity onset diabetes of the young [MODY]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Distinguishing type 1 from type 2 diabetes'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Other causes of diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821788\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4821796\">",
"    <span class=\"h2\">",
"     Other causes of hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the previously healthy child, diabetes mellitus is by far the most common cause of clinically significant hyperglycemia. Other considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Critically ill patients &ndash; Patients with septic shock or other critical illnesses often have abnormalities in glycemic control, leading to either hypoglycemia or hyperglycemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13354?source=see_link&amp;anchor=H18270361#H18270361\">",
"       \"Septic shock: Ongoing management after resuscitation in children\", section on 'Manage glucose abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medication &ndash; Children receiving intravenous infusions containing glucose, or who require treatment with acute high-dose glucocorticoid administration for illnesses like asthma, may have random elevations in blood glucose that revert to normal after treatment is complete.",
"     </li>",
"     <li>",
"      Neonatal hyperglycemia &ndash; Causes of hyperglycemia in a neonate include excessive glucose infusion, prematurity, stress, sepsis, drugs, and transient or permanent neonatal diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link\">",
"       \"Neonatal hyperglycemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other causes of diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;T1DM is distinguished from other diseases that cause diabetes by patient characteristics, history, and laboratory studies. This approach is similar to that used to differentiate type 1 from type 2 diabetes discussed above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Type 1 versus type 2 diabetes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following diseases that cause diabetes are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diseases of the exocrine system &ndash; Cystic fibrosis, hereditary hemochromatosis, and chronic pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H20#H20\">",
"       \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Diseases of the exocrine pancreas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endocrine abnormalities in glucose regulation &ndash; Cushing syndrome, growth-hormone excess, glucagon-secreting tumors, catecholamine excess in pheochromocytoma. With the exception of Cushing syndrome, these are all extremely rare. This possibility should be evaluated in patients presenting with Cushingoid features (such as central obesity, facial plethora, dorsocervical fat pad, and delayed linear growth). This is usually best accomplished by measuring 24-hour urinary cortisol excretion or 11 PM or midnight salivary cortisol two or more times, but may require additional testing. It is important to recognize that children with Cushing syndrome may not manifest the classic features seen in adults. However, a deceleration of growth velocity despite increasing weight should raise concern for Cushing syndrome in a growing child. It is very rare for a child with Cushing syndrome to present with hyperglycemia, although relatively common in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Glucose intolerance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced diabetes &ndash; A number of drugs (eg, glucocorticoids, HIV protease inhibitors,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , L-asparaginase, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) and atypical antipsychotic agents can impair glucose tolerance by inhibiting insulin secretion, increasing hepatic glucose production, or causing insulin resistance (",
"      <a class=\"graphic graphic_table graphicRef67257 \" href=\"mobipreview.htm?10/40/10891\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link&amp;anchor=H36#H36\">",
"       \"Pathogenesis of type 2 diabetes mellitus\", section on 'Drug-induced hyperglycemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monogenic diabetes (formerly referred to as maturity onset diabetes of the young, or MODY) &ndash; Monogenic diabetes is a clinically heterogeneous disorder characterized by non-insulin dependent diabetes presenting at a young age, with autosomal dominant transmission and lack of autoantibodies. Many different genetic abnormalities have been identified, each leading to a different type of disease. Monogenic diabetes should be considered in a patient presenting with non insulin-dependent diabetes at a young age (&lt;25 years), with autosomal dominant transmission and lack of islet autoantibodies. The diagnosis of monogenic diabetes is made by performing diagnostic genetic testing by direct sequencing of the gene. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H9#H9\">",
"       \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Maturity onset diabetes of the young'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Neonatal diabetes mellitus &ndash; Neonatal diabetes is a rare cause of hyperglycemia in infants. It can be transient or permanent, and usually is caused by mutations in one of several genes that encode proteins that affect the function of the pancreatic beta-cell (eg, proteins that are subunits of the ATP-sensitive potassium channel). Most of the infants are small for gestational age, and they present with weight loss, volume depletion, hyperglycemia, and glucosuria with or without ketonuria and ketoacidosis. The natural history and management of diabetes in these infants depends on the genetic defect, as discussed in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link&amp;anchor=H12#H12\">",
"       \"Neonatal hyperglycemia\", section on 'Neonatal diabetes mellitus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"       \"Patient information: My child has diabetes: How will we manage? (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"       \"Patient information: Giving your child insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus (T1DM) is the result of insulin deficiency caused by destruction of the pancreatic beta cells. T1DM is one of the most common chronic diseases of childhood. It accounts for approximately two-thirds of all cases of diabetes in patients &le;19 years of age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of childhood T1DM varies worldwide, ranging from 0.1 to 37 per 100,000 children younger than the age of 15 years. In the United States, the incidence of T1DM in non-Hispanic white children and adolescents is 23.6 per 100,000 annually; rates are substantially lower in other racial or ethnic groups (",
"      <a class=\"graphic graphic_table graphicRef51817 \" href=\"mobipreview.htm?21/60/22476\">",
"       table 1",
"      </a>",
"      ). The age of presentation has a bimodal distribution with peaks at four to six years of age and between 10 and 14 years of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there appears to be no overall gender difference in the incidence of childhood T1DM, in select populations (eg, European adolescents), there seems to be an increased risk for males (3:2 male to female ratio). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Age and gender'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of T1DM is moderately increased in children with an affected close relative, which is most likely due to gene polymorphisms in the major histocompatibility complex (MHC) and other susceptibility areas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetic susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although exposure to an environmental agent(s) in genetically susceptible individuals appears to trigger the destruction of the insulin-producing pancreatic beta cell, no factor(s) has been definitively identified. (See",
"      <a class=\"local\" href=\"#H4821065\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"       \"Pathogenesis of type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Childhood T1DM usually presents with the classic signs and symptoms resulting from hyperglycemia including polyuria, polydipsia, weight loss, and lethargy. Diabetic ketoacidosis is often the initial presentation for T1DM, especially in children younger than six years of age, and in children of all ages with poor access to health care. Children also may be identified by screening for the disease before the onset of symptoms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32087?source=see_link\">",
"       \"Prediction of type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of diabetes is based upon any one of four detected abnormalities of glucose metabolism (",
"      <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4821743\">",
"       'Diagnostic criteria for diabetes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"       \"Diagnosis of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fasting plasma glucose &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on at least two occasions",
"     </li>",
"     <li>",
"      Symptoms of hyperglycemia and a plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      measured two hours after a standard glucose load in an oral glucose tolerance test (OGTT).",
"     </li>",
"     <li>",
"      Hemoglobin A1C &ge;6.5 percent &ndash; This criterion is more useful in the diagnosis of type 2 diabetes mellitus (T2DM) in adults and should be confirmed by hyperglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T1DM often can be distinguished from other causes of diabetes, such as T2DM, by clinical presentation and laboratory studies. Although no one diagnostic test can distinguish between the two types of diabetes, T1DM is suggested by the presence of serum autoantibodies to islet cells, glutamic acid decarboxylase (GAD65), the 40K fragment of tyrosine phosphatase (IA2), insulin, zinc transporter 8 (ZnT8), and by low or inappropriately normal fasting C-peptide and insulin levels with concomitant hyperglycemia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Type 1 versus type 2 diabetes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Other causes of diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of T1DM is often missed in young children because it is not considered, and because it may be difficult to recognize the symptoms of hyperglycemia in this age group. Children younger than two years of age are particularly likely to have a delay in diagnosis. In these patients, a history or presence of prolonged candidal infection should prompt consideration of diabetes mellitus and measurement of blood and urine glucose concentrations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Young children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/1\">",
"      Lipton RB, Drum M, Burnet D, et al. Obesity at the onset of diabetes in an ethnically diverse population of children: what does it mean for epidemiologists and clinicians? Pediatrics 2005; 115:e553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/2\">",
"      Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/3\">",
"      Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med 2006; 160:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/4\">",
"      SEARCH for Diabetes in Youth Study Group, Liese AD, D'Agostino RB Jr, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/5\">",
"      Silink M. Childhood diabetes: a global perspective. Horm Res 2002; 57 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/6\">",
"      Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/7\">",
"      Rosenbauer J, Herzig P, von Kries R, et al. Temporal, seasonal, and geographical incidence patterns of type I diabetes mellitus in children under 5 years of age in Germany. Diabetologia 1999; 42:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/8\">",
"      Yang Z, Wang K, Li T, et al. Childhood diabetes in China. Enormous variation by place and ethnic group. Diabetes Care 1998; 21:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/9\">",
"      Waldh&ouml;r T, Schober E, Karimian-Teherani D, et al. Regional differences and temporal incidence trend of Type I diabetes mellitus in Austria from 1989 to 1999: a nationwide study. Diabetologia 2000; 43:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/10\">",
"      Liese AD, Lawson A, Song HR, et al. Evaluating geographic variation in type 1 and type 2 diabetes mellitus incidence in youth in four US regions. Health Place 2010; 16:547.",
"     </a>",
"    </li>",
"    <li>",
"     Plotnick LP, Klingensmith GJ, Silverstein JH, et al. Diabetes mellitus. In: Principles and Practice of Pediatric Endocrinology, Kappy MS, Allen DB, Geffner ME (Eds), Charles C Thomas, Springfield 2005. p.635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/12\">",
"      Bell RA, Mayer-Davis EJ, Beyer JW, et al. Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/13\">",
"      Newhook LA, Curtis J, Hagerty D, et al. High incidence of childhood type 1 diabetes in the Avalon Peninsula, Newfoundland, Canada. Diabetes Care 2004; 27:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/14\">",
"      Legault L, Polychronakos C. Annual incidence of type 1 diabetes in Qu&eacute;bec between 1989-2000 in children. Clin Invest Med 2006; 29:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/15\">",
"      Felner EI, Klitz W, Ham M, et al. Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. Pediatr Diabetes 2005; 6:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/16\">",
"      Durruty P, Ruiz F, Garc&iacute;a de los R&iacute;os M. Age at diagnosis and seasonal variation in the onset of insulin-dependent diabetes in Chile (Southern hemisphere). Diabetologia 1979; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/17\">",
"      Elamin A, Omer MI, Zein K, Tuvemo T. Epidemiology of childhood type I diabetes in Sudan, 1987-1990. Diabetes Care 1992; 15:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/18\">",
"      Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/19\">",
"      Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001; 44:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/20\">",
"      Harjutsalo V, Sj&ouml;berg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/21\">",
"      Quinn M, Fleischman A, Rosner B, et al. Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. J Pediatr 2006; 148:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/22\">",
"      Mamoulakis D, Galanakis E, Bicouvarakis S, et al. Epidemiology of childhood type I diabetes in Crete, 1990-2001. Acta Paediatr 2003; 92:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/23\">",
"      Karvonen M, Pitk&auml;niemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 1999; 22:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/24\">",
"      Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/25\">",
"      Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987; 317:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/26\">",
"      Patterson CC, Dahlquist GG, Gy&uuml;r&uuml;s E, et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/27\">",
"      Vehik K, Hamman RF, Lezotte D, et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care 2007; 30:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/28\">",
"      Lipman TH, Levitt Katz LE, Ratcliffe SJ, et al. Increasing Incidence of Type 1 Diabetes in Youth: Twenty years of the Philadelphia Pediatric Diabetes Registry. Diabetes Care 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/29\">",
"      Berhan Y, Waernbaum I, Lind T, et al. Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden. Diabetes 2011; 60:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/30\">",
"      Derraik JG, Reed PW, Jefferies C, et al. Increasing incidence and age at diagnosis among children with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand). PLoS One 2012; 7:e32640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/31\">",
"      Tillil H, K&ouml;bberling J. Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients. Diabetes 1987; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/32\">",
"      Steck AK, Barriga KJ, Emery LM, et al. Secondary attack rate of type 1 diabetes in Colorado families. Diabetes Care 2005; 28:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/33\">",
"      Guo SW, Tuomilehto J. Preferential transmission of type 1 diabetes from parents to offspring: fact or artifact? Genet Epidemiol 2002; 23:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/34\">",
"      Tuomilehto J, Podar T, Tuomilehto-Wolf E, Virtala E. Evidence for importance of gender and birth cohort for risk of IDDM in offspring of IDDM parents. Diabetologia 1995; 38:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/35\">",
"      Olmos P, A'Hern R, Heaton DA, et al. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia 1988; 31:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/36\">",
"      Redondo MJ, Jeffrey J, Fain PR, et al. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 2008; 359:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/37\">",
"      Lipman TH, Chang Y, Murphy KM. The epidemiology of type 1 diabetes in children in Philadelphia 1990-1994: evidence of an epidemic. Diabetes Care 2002; 25:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/38\">",
"      Kibirige M, Metcalf B, Renuka R, Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003; 26:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/39\">",
"      Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001; 44:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/40\">",
"      O'Connell MA, Donath S, Cameron FJ. Major increase in Type 1 diabetes: no support for the Accelerator Hypothesis. Diabet Med 2007; 24:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/41\">",
"      Zalloua PA, Terwedow H, Shbaklo H, et al. Host and environmental factors defining the epidemiology of type 1 diabetes mellitus in a group of Lebanese children and young adults. J Pediatr Endocrinol Metab 2003; 16:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/42\">",
"      Imkampe AK, Gulliford MC. Trends in Type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991-2008. Diabet Med 2011; 28:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/43\">",
"      Moltchanova EV, Schreier N, Lammi N, Karvonen M. Seasonal variation of diagnosis of Type 1 diabetes mellitus in children worldwide. Diabet Med 2009; 26:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/44\">",
"      Roche EF, Lewy H, Hoey HM, Laron Z. Differences between males and females in the seasonality of birth and month of clinical onset of disease in children with type 1 diabetes mellitus in Ireland. J Pediatr Endocrinol Metab 2003; 16:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/45\">",
"      Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005; 52:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/46\">",
"      Roche EF, Menon A, Gill D, Hoey H. Clinical presentation of type 1 diabetes. Pediatr Diabetes 2005; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/47\">",
"      Sonmez B, Bozkurt B, Atmaca A, et al. Effect of glycemic control on refractive changes in diabetic patients with hyperglycemia. Cornea 2005; 24:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/48\">",
"      Falck A, Laatikainen L. Diabetic cataract in children. Acta Ophthalmol Scand 1998; 76:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/49\">",
"      Datta V, Swift PG, Woodruff GH, Harris RF. Metabolic cataracts in newly diagnosed diabetes. Arch Dis Child 1997; 76:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/50\">",
"      Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/51\">",
"      Klingensmith GJ, Tamborlane WV, Wood J, et al. Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr 2013; 162:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/52\">",
"      Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004; 27:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/53\">",
"      Mallare JT, Cordice CC, Ryan BA, et al. Identifying risk factors for the development of diabetic ketoacidosis in new onset type 1 diabetes mellitus. Clin Pediatr (Phila) 2003; 42:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/54\">",
"      Neu A, Willasch A, Ehehalt S, et al. Ketoacidosis at onset of type 1 diabetes mellitus in children--frequency and clinical presentation. Pediatr Diabetes 2003; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/55\">",
"      Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/56\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/57\">",
"      Ehehalt S, Gauger N, Blumenstock G, et al. Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence. Pediatr Diabetes 2010; 11:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/58\">",
"      Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/59\">",
"      Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/60\">",
"      Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/61\">",
"      Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40889/abstract/62\">",
"      Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5816 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40889=[""].join("\n");
var outline_f39_59_40889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Geographical variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age and gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22151378\">",
"      Time trends",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4821065\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Classic new onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Silent presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4821743\">",
"      Diagnostic criteria for diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Type 1 versus type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4821788\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4821796\">",
"      Other causes of hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other causes of diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5816\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5816|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/28/4558\" title=\"figure 1\">",
"      Incidence of diabetes in youth by age group",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5816|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/60/22476\" title=\"table 1\">",
"      Diab prevalence youth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/3/28731\" title=\"table 2\">",
"      ADA criteria for diagnosis diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/15/31997\" title=\"table 3\">",
"      Type 1 vs type 2 DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/40/10891\" title=\"table 4\">",
"      Drug induced diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32087?source=related_link\">",
"      Prediction of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13354?source=related_link\">",
"      Septic shock: Ongoing management after resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40890="Heparin-induced thrombocytopenia";
var content_f39_59_40890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heparin-induced thrombocytopenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40890/contributors\">",
"     Steven Coutre, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40890/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/59/40890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/59/40890/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/59/40890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is a well-recognized complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, usually occurring within the first 10 days after heparin treatment has started [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/1\">",
"     1",
"    </a>",
"    ]. There are two forms of heparin-induced thrombocytopenia (HIT) (",
"    <a class=\"graphic graphic_table graphicRef50170 \" href=\"mobipreview.htm?20/45/21211\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common form of thrombocytopenia, of no clinical consequence (type I",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia), is typically characterized by a slight fall in platelet count that occurs within the first two days after heparin initiation and often returns to normal with continued heparin administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2\">",
"       2",
"      </a>",
"      ]. The mechanism of the thrombocytopenia is nonimmune and appears to be due to a direct effect of heparin on platelet activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The less common and more serious form (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia, type II; HIT-II) is an immune-mediated disorder characterized by the formation of antibodies against the heparin-platelet factor 4 complex. This disorder has also been called heparin-associated immune thrombocytopenia, heparin-associated thrombocytopenia and thrombosis (HITT), and white clot syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,5\">",
"       2,5",
"      </a>",
"      ]. White clot syndrome refers to platelet-rich arterial thrombosis (rather than fibrin-rich venous thrombosis), which occurs with high frequency in patients who develop this disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the remainder of this review, the term HIT will refer only to the immune form (ie, type II). The clinical manifestations, diagnosis, prevention, and treatment of HIT will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,6-10\">",
"     2,6-10",
"    </a>",
"    ]. The clinical use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and low molecular weight heparin is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical assessment of immune-mediated HIT suggests a frequency of 0.2 to 5.0 percent in patients exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for more than four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/11-16\">",
"     11-16",
"    </a>",
"    ], with an overall incidence of 2.6 percent noted in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/11\">",
"     11",
"    </a>",
"    ]. The incidence is closer to 0.2 percent for those treated with unfractionated heparin (UFH) for less than four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of importance, two prospective observational studies showed a surprisingly high incidence of thrombocytopenia in patients treated with either unfractionated or low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for &ge;4 days, with 15 percent of patients showing a &gt;50 percent reduction in baseline platelet counts in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/19\">",
"     19",
"    </a>",
"    ] and 42 percent in the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three factors in addition to longer duration of therapy that are most strongly associated with the development of HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/16,18,21,22\">",
"     16,18,21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH) rather than low molecular weight (LMW) heparin",
"     </li>",
"     <li>",
"      Surgical rather than medical patients",
"     </li>",
"     <li>",
"      Female rather than male patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following observations illustrate these relationships:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of data from seven prospective studies, the risk of HIT was higher following the use of UFH than LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (RR 5.3; 95% CI 2.8-9.9), higher in surgical than medical patients (RR 3.2; 95% CI 2.0-5.4), and higher in females than males (RR 2.4; 95% CI 1.4-4.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/16\">",
"       16",
"      </a>",
"      ]. The highest risk for HIT was seen in female surgical patients receiving UFH (RR 17; 95% CI 4.2-72).",
"     </li>",
"     <li>",
"      The difference in risk between UFH and LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was illustrated in a meta-analysis of randomized and prospective nonrandomized studies, mostly in patients undergoing orthopedic surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/11\">",
"       11",
"      </a>",
"      ]. The risk of HIT was 2.6 percent with UFH and 0.2 percent with LMW heparin. One trial, for example, randomly assigned 665 patients to therapy with either UFH or LMW heparin for prophylaxis after hip surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/12\">",
"       12",
"      </a>",
"      ]. Immune-mediated thrombocytopenia developed in 2.7 percent of patients treated with UFH, but none of those receiving LMW heparin. The incidence of heparin-dependent IgG antibodies was also higher in the patients receiving UFH (7.8 versus 2.2 percent). Similar results have been reported in patients with neurologic disorders treated with these two forms of heparin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies are more likely to form in patients undergoing cardiac surgery (reported incidence of antibodies as high as 15 to 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]) than in orthopedic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/17,24,26\">",
"       17,24,26",
"      </a>",
"      ]. However, among those in whom antibodies do form, orthopedic patients are more likely to develop HIT than those undergoing cardiac surgery (",
"      <a class=\"graphic graphic_table graphicRef82161 \" href=\"mobipreview.htm?18/2/18475\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/24,27\">",
"       24,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of HIT after LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may be increased in those with prior exposure to heparin therapy. This was suggested in a prospective cohort study in 1754 consecutive medical patients treated with LMW heparin in which the overall incidence of HIT was 0.8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/28\">",
"       28",
"      </a>",
"      ]. HIT was significantly more frequent in those with prior exposure to UFH or LMW heparin (1.7 versus 0.3 percent, OR 4.9; 95% CI 1.5-16).",
"     </li>",
"     <li>",
"      In a study using the database of the National Hospital Discharge Survey, HIT was found to be rare among patients &lt;40 years of age as well as in women following delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most patients developing HIT have received IV or SQ",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy for a thrombotic event or for prophylaxis, the amount of heparin required to cause HIT can be quite small. Occasional patients have developed this disorder after exposure to as little as 250 units from a heparin flush or after the use of heparin-coated catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibody formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or other sulfated oligosaccharides for four or more days can trigger an antibody response (",
"    <a class=\"graphic graphic_figure graphicRef50473 \" href=\"mobipreview.htm?28/43/29375\">",
"     figure 1",
"    </a>",
"    ). These IgG, IgM, and IgA antibodies are provoked not by heparin alone, but by the highly immunogenic complex of heparin and platelet factor 4 (PF4), a heparin-neutralizing protein contained in the alpha granules of platelets, which is released from the platelet upon its activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. A region separate from the heparin-binding domain of PF4 is required to form the epitope recognized by many HIT antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/36\">",
"     36",
"    </a>",
"    ]. Binding of these antibodies to PF4 absorbed onto polystyrene in the absence of heparin suggests that the involved epitope may be due to a conformational change within PF4 brought on by surface immobilization on polystyrene, a suitable linear polyanion, or, in vivo, by the action of heparin, heparan, or chondroitin sulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/33,37-39\">",
"     33,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, naturally-occurring",
"    <span class=\"nowrap\">",
"     anti-PF4/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"    </span>",
"    antibodies are present in 3 to 8 percent of the normal population. It has thus been suggested that preimmunization by antigens mimicking",
"    <span class=\"nowrap\">",
"     PF4/heparin",
"    </span>",
"    complexes, such as PF4 complexes with negatively-charged polysaccharides on the surface of bacteria, such as may be present in patients with periodontal disease, may be responsible for the rapid appearance of these antibodies following treatment with heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -PF4 complex, once formed, binds to an activated platelet surface and is recognized by the Fab region of the HIT antibody, forming a heparin-PF4-antibody complex on the platelet surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/32,42\">",
"     32,42",
"    </a>",
"    ]. The Fc portion of this bound IgG further activates the same or adjacent platelets through the Fc gamma RIIA receptors on the platelet surface, leading to additional platelet activation with further release of PF4, creating a positive feedback loop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activated platelets with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -PF4-antibody complex attached to their surface undergo aggregation and are removed prematurely from the circulation leading to thrombocytopenia (HIT); it also leads to the generation of procoagulant platelet-derived microparticles, frequently resulting in thrombin generation and thrombosis (HITT) (",
"    <a class=\"graphic graphic_figure graphicRef50473 \" href=\"mobipreview.htm?28/43/29375\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/44\">",
"     44",
"    </a>",
"    ]. The antibody complex may also activate microvascular endothelial cells, resulting in augmented release of interleukin-6, von Willebrand factor, and other adhesion molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/45\">",
"     45",
"    </a>",
"    ]. PF4 can also bind heparan sulfate on vascular endothelial cells; subsequent binding of the pathologic antibody to this PF4-heparan sulfate complex can injure the endothelium, which further promotes thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/32,45\">",
"     32,45",
"    </a>",
"    ]. It is not clear whether these antibodies can be associated with thrombosis in the absence of relative or absolute thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are several mechanisms associated with drug-induced thrombocytopenia, HIT is distinct among them in being associated with platelet activation. This may explain why HIT is uniquely associated with thrombosis rather than bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary studies, which will require confirmation, suggest that the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -PF4-antibody complex may promote thrombosis by a number of other mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      By inducing the production of tissue factor by monocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      By inhibiting activated protein C generation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A transgenic mouse model of HIT is now available, which may shed more light on the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/51\">",
"     51",
"    </a>",
"    ]. Highly immunogenic complexes of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with other positively charged proteins (eg, protamine, lysozyme) have been detected in animal model systems and in human subjects following cardiopulmonary bypass surgery, although their clinical significance is unclear at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disease variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Why some of these antibodies cause clinical HIT, occasionally after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been stopped, while others do not, is poorly understood. Potential explanations for these observations include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/33,53\">",
"     33,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antigenicity of PF4-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      complexes is related to the concentration of PF4 on the platelet surface. Binding of HIT IgG occurs only over a narrow molar ratio of reactants, being optimal at 1 molecule of the PF4 tetramer to 1 molecule of unfractionated heparin.",
"     </li>",
"     <li>",
"      Large antigenic complexes between PF4 and glycosaminoglycans (GAG) may also form on the surface of platelets independent of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . These antigenic",
"      <span class=\"nowrap\">",
"       GAG/PF4",
"      </span>",
"      complexes can contribute to initial antibody formation in the absence of heparin and such HIT antibodies may also be augmented in the presence of heparin.",
"     </li>",
"     <li>",
"      Patients with high total and surface PF4 may therefore be at the highest risk for development of clinical HIT when exposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/54\">",
"       54",
"      </a>",
"      ], or after heparin has been discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the binding of HIT antibodies to these",
"    <span class=\"nowrap\">",
"     PF4/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"    </span>",
"    complexes occurs only over a narrow molar ratio of reactants, high concentrations of heparin, such as those used in cardiopulmonary bypass, disrupt antigen formation by depleting surface-bound PF4. This prevents thrombocytopenia induced by the HIT antibody, potentially explaining the low incidence of clinical HIT despite the high incidence of antibodies in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/53\">",
"     53",
"    </a>",
"    ]. A discussion of testing in the presence of both low and high concentrations of heparin is below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnostic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic and patient-specific interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variability in the clinical manifestations and complications of HIT might also arise from interactions between the various systems involved in the pathogenesis of HIT (eg, antigen and antibody variables) and clinical variables in the patient. Thus, evidence has been presented for involvement of the following patient-specific factors in the genesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of HIT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prothrombotic state of the patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polymorphisms of platelet glycoproteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polymorphisms of the receptor for the Fc portion of IgG which deal with HIT antibody clearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severity of trauma and need for major surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Onset and degree of thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune-mediated HIT is associated with a fall in the platelet count of &gt;50 percent that typically occurs 5 to 10 days after the initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef56493 \" href=\"mobipreview.htm?31/36/32334\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,60\">",
"     2,60",
"    </a>",
"    ]. Onset after two weeks is unusual, an observation that correlates with serologic studies showing that heparin-dependent antibodies usually develop between days five to eight after exposure to heparin, but rarely later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/12,61\">",
"     12,61",
"    </a>",
"    ]. Earlier onset of HIT may be seen if the patient had been treated with heparin in the previous one to three months and still has circulating HIT antibodies (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Early onset HIT'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a fall in the platelet count greater than 50 percent due to immune-mediated HIT is rarely severe, with platelet counts typically",
"    <span class=\"nowrap\">",
"     &gt;20,000/microL",
"    </span>",
"    and a median platelet count nadir of about",
"    <span class=\"nowrap\">",
"     60,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. As a result, spontaneous bleeding is unusual. This is in contrast to other immune-mediated thrombocytopenias (eg, immune [idiopathic] thrombocytopenic purpura or post-transfusion purpura) where patients often present with platelet counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    and clinical bleeding (",
"    <a class=\"graphic graphic_figure graphicRef72370 \" href=\"mobipreview.htm?19/27/19901\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Delayed onset HIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed-onset HIT, in which thrombocytopenia and thrombosis occur after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been withdrawn, has been increasingly described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In one study, HIT was described in 12 patients an average of nine days (range: 5 to 19 days) after heparin was withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/66\">",
"     66",
"    </a>",
"    ]. These patients had high titer platelet-activating antibodies that exhibited increased heparin-dependent as well as heparin-",
"    <strong>",
"     independent",
"    </strong>",
"    platelet activation, perhaps explaining why this complication arose after all heparin should have been cleared from the body.",
"   </p>",
"   <p>",
"    One possible explanation of this phenomenon is that the unusually high antibody levels react with platelet-associated PF4 bound to non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    glycosaminoglycans (eg, chondroitin sulfate), rather than to heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/33,68\">",
"     33,68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Disease variability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The incidence of this phenomenon is not known, although in a retrospective study from three hospitals, there were an estimated 260 patients with HIT and 14 cases of delayed-onset HIT, occurring at a median time of 14 days (range: 9 to 40 days) after onset of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/67\">",
"     67",
"    </a>",
"    ]. The following criteria were used to diagnose delayed-onset HIT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and discharge from the hospital after a reasonably benign course, during which time HIT went unrecognized.",
"     </li>",
"     <li>",
"      Re-presentation with objectively proven venous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arterial thrombosis, with thrombocytopenia developing after reexposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Positive serologic tests for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On readmission, 11 of the 14 cases were treated with unfractionated or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , resulting in a prompt decrease in platelet counts, often with overt clinical deterioration. Three of the 11 patients reexposed to heparin died. After HIT was recognized as the cause of the thromboembolic episodes, heparin was stopped",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patients received alternative anticoagulants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ), with ultimate recovery in the remaining patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Early onset HIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early onset of HIT (median time of platelet fall 10.5 hours after the start of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    administration), may be seen in approximately 30 percent of patients with persistent antibodies due to heparin therapy within the previous one to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/60,69,70\">",
"     60,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiac surgery patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major decrease in the platelet count of approximately 40 to 50 percent occurs universally during the first 72 hours following cardiac surgery, due at least in part to prolonged contact of platelets with the artificial surface of the extracorporeal circuit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. These patients usually receive large amounts of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , a setting in which the incidence of HIT antibodies is as high as 25 to 70 percent by immunoassay and 4 to 20 percent by platelet activation assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/24,25,74,75\">",
"     24,25,74,75",
"    </a>",
"    ]. Since several other potential causes of thrombocytopenia are often present, it is difficult to determine whether or not HIT is present in these patients.",
"   </p>",
"   <p>",
"    While this question has not been satisfactorily settled, the presence of a",
"    <strong>",
"     secondary",
"    </strong>",
"    fall in the platelet count &ge;50 percent that begins between the fifth and tenth postoperative day appears to be highly predictive of HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/72,73,76,77\">",
"     72,73,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical problem associated with HIT is thrombosis, both venous and arterial. The precise mechanism of this hypercoagulable state is unknown, although the release of procoagulants from activated platelets has been postulated as a primary event. Other theories include the generation of platelet microparticles, fragments of the platelet membrane that are released and can serve as catalysts for clotting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/78\">",
"     78",
"    </a>",
"    ]. Since HIT antibodies also bind to heparan sulfate on the surface of endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/32\">",
"     32",
"    </a>",
"    ], thrombosis may result from endothelial cell activation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased tissue factor and thrombin generation due to endothelial cell injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/44,45,79\">",
"     44,45,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which thrombosis occurs can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of UFH versus LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in 665 patients following hip surgery, 8 of 9 patients with HIT developed a thrombotic event (seven venous and one arterial) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/12\">",
"       12",
"      </a>",
"      ]. The frequency of thrombosis was much higher than in those who did not develop HIT (89 versus 18 percent).",
"     </li>",
"     <li>",
"      A retrospective review of 127 patients with serologically confirmed HIT found that venous and arterial thrombosis occurred in 78 and 18 patients (61 and 14 percent), respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/80\">",
"       80",
"      </a>",
"      ]. Approximately one-half of patients with HIT were recognized only after they had a complicating thrombotic event. Of the patients initially recognized with isolated thrombocytopenia, the subsequent 30-day risk of thrombosis was 53 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for thromboprophylaxis or treatment, the initial sign of HIT is usually the development of thrombocytopenia. If such a patient develops an initial or recurrent thrombotic event, the presence of thrombocytopenia suggests that it is due to HIT rather than failure of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H57#H57\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Heparin-induced thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major manifestations of venous thrombosis are deep vein thrombosis (DVT) and pulmonary embolism. In the study cited above, pulmonary embolism was the most common life-threatening event, occurring in 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other manifestations of venous thrombosis include venous limb gangrene (distal ischemic necrosis following deep vein thrombosis) and cerebral sinus thrombosis. In one report, eight patients with deep vein thrombosis developed venous limb gangrene and full-thickness skin necrosis after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was stopped in response to a diagnosis of HIT and initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/82\">",
"     82",
"    </a>",
"    ]. The histologic appearance of the lesion was different from that seen with warfarin-induced necrosis and the patients were not deficient in the natural anticoagulants protein C, protein S or antithrombin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/83\">",
"     83",
"    </a>",
"    ]. However, the patients with venous limb gangrene had a much higher INR than the 58 patients who did not develop gangrene (median INR 5.8 versus 3.1), suggesting a contribution from acquired protein C deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"     \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper extremity DVT has also been described in HIT, but is less common than lower extremity DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/84\">",
"     84",
"    </a>",
"    ]. In a retrospective study of 260 patients with antibody-positive HIT, 14 episodes of upper extremity DVT were observed (5.4 percent); all occurred in patients with central venous catheters (CVC) and at the CVC site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial thrombosis, although less common, can lead to a variety of clinical manifestations including stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], myocardial infarction, acute limb ischemia from peripheral arterial occlusion, or organ infarction (mesentery, kidney). Since the arterial circulation is a high flow, high shear rate environment, thrombi tend to be platelet-rich. These clots are \"white\" due to the presence of platelet aggregates, hence the name \"white clot syndrome\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin necrosis at the site of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    injections is a well-described complication of treatment with unfractionated or LMW heparin, and should immediately suggest the presence of HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/87-92\">",
"     87-92",
"    </a>",
"    ]. Affected patients have heparin-dependent antibodies but may not develop thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected areas are usually fat-rich, such as the abdomen, as in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced necrosis; however, the distal extremities and the nose can also be involved. The appearance of erythema is followed by purpura and hemorrhage leading to necrosis. Although the lesions appear similar to warfarin-induced skin necrosis, deficiencies of the natural anticoagulants are not present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other unusual complications of HIT include adrenal hemorrhage secondary to adrenal vein thrombosis, and transient global amnesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Suspecting HIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in establishing a diagnosis of HIT is suspecting the presence of this syndrome. Any one of the following scenarios should raise the possibility of HIT in a patient begun on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy within the preceding 5 to 10 days, or in a patient receiving prolonged treatment with low molecular weight heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,95-97\">",
"     2,95-97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of otherwise unexplained thrombocytopenia",
"     </li>",
"     <li>",
"      Venous or arterial thrombosis associated with thrombocytopenia",
"     </li>",
"     <li>",
"      A platelet count that has fallen 50 percent or more from a prior value, even if absolute thrombocytopenia is not present",
"     </li>",
"     <li>",
"      Necrotic skin lesions at",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      injection sites",
"     </li>",
"     <li>",
"      Acute systemic (anaphylactoid) reactions (eg,",
"      <span class=\"nowrap\">",
"       fever/chills,",
"      </span>",
"      tachycardia, hypertension, dyspnea, cardiopulmonary arrest) occurring after IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      bolus administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of HIT is initially made on clinical grounds, because the assays with the highest sensitivity and specificity may not be readily available and have a slow turnaround time.",
"   </p>",
"   <p>",
"    The most specific diagnostic tests for HIT include serotonin release assays,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced platelet aggregation assays, and solid phase immunoassays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,98\">",
"     2,98",
"    </a>",
"    ]. Patients with HIT also have elevated platelet- associated IgG levels, but this is a nonspecific finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Serotonin release assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 14C-serotonin release assay remains the gold standard among the diagnostic tests for HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/100\">",
"     100",
"    </a>",
"    ]. Platelets from normal donors are radiolabeled with 14C-serotonin. The platelets are then washed and patient serum is added along with either high or low",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    concentrations. A positive test is the release of 14C-serotonin when therapeutic (0.1",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    concentrations of heparin are used, rather than high (100",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    concentrations. This concentration dependence reflects the fact that the binding of HIT IgG occurs only over a narrow molar ratio of reactants. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The serotonin release assay has been clinically validated in a prospective randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/12\">",
"     12",
"    </a>",
"    ], and has a sensitivity and specificity of &gt;95 percent when performed by experienced laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/8,101\">",
"     8,101",
"    </a>",
"    ]. A positive serotonin release assay was strongly associated with thrombocytopenia beginning five or more days after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    exposure (odds ratio 78). The disadvantages of this test are high cost due to the use of radioactive material and the technical demands of the assay.",
"   </p>",
"   <p>",
"    An assay in which the released serotonin is quantitated via a commercially available ELISA has been described, with a sensitivity and specificity of 100 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/102\">",
"     102",
"    </a>",
"    ]. However, this assay is not generally available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Heparin-induced platelet aggregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the platelet aggregation assay, either washed normal donor platelets or platelet-rich plasma (PRP) is added to serum or platelet-poor plasma from a patient with suspected HIT and platelet aggregation is measured. Aggregation should be measured with no added",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as one control, as well as with low (0.1 to 0.3",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    heparin concentrations and high (10 to 100",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    heparin concentrations. A positive test would include low background aggregation with no added heparin, aggregation with the addition of a low concentration of heparin, and absent aggregation with high heparin concentrations.",
"   </p>",
"   <p>",
"    The platelet aggregation test is quite specific (&gt;90 percent) but suffers from lack of sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/103\">",
"     103",
"    </a>",
"    ]. Some authors claim that the use of washed normal donor platelets rather than PRP increases the sensitivity to approximately 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Solid phase immunoassay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The solid phase ELISA immunoassay is different from the first two tests, since it is not a functional assay.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    -PF4 complexes or polyanion-PF4 complexes are coated on a microtiter plate and patient serum is added. If heparin-dependent antibodies are present in the serum sample, they will bind the complex, which can be identified by adding a second antibody.",
"   </p>",
"   <p>",
"    This is a very sensitive assay (91 to &gt;97 percent); a negative test strongly suggests the absence of HIT, while the clinical utility of a positive test remains to be determined, since many patients with a positive ELISA test (ie, an optical density at 405 nm greater than a predetermined cut-off value) do not have platelet-activating antibodies and do not develop clinical HIT (presence of antiphospholipid antibodies, systemic lupus erythematosus, pseudothrombocytopenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/39,105-113\">",
"     39,105-113",
"    </a>",
"    ]. Accordingly, this test has a low specificity of 74 to 86 percent.",
"   </p>",
"   <p>",
"    Solid phase immunoassay for HIT has a high negative predictive value (&gt;95 percent), but its positive predictive value is only moderate, varying from 50 to 93 percent depending upon, among other factors, the population being studied and the timing of the platelet fall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,107,108,114\">",
"     2,107,108,114",
"    </a>",
"    ]. The specificity of the test may be improved by one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/115\">",
"     115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assaying only for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -PF4-IgG antibodies since, in a number of studies, assays for the presence of antibodies of the IgM and IgA class were not as specific for diagnosing clinical HIT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/109,116-120\">",
"       109,116-120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Addition of a high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      confirmatory procedure. Inhibition of a positive ELISA result by 50 percent or more in the presence of excess heparin (100",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      has been considered confirmatory of heparin-dependent antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/121\">",
"       121",
"      </a>",
"      ], although this step has not been consistently reliable in cardiac surgery patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/122,123\">",
"       122,123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consideration of the magnitude of the optical density result. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Defining test positivity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Results in dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of a positive solid phase immunoassay for HIT antibodies in dialysis patients has varied considerably (eg, zero to 18 percent); the significance of such antibodies is unclear. This issue was studied in a group of 740 renal failure patients receiving either hemodialysis or peritoneal dialysis and followed for a median duration of 3.6 years. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/124\">",
"     124",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive ELISA test (optical density &gt;0.4 OD units) was seen in 76 patients (10.3 percent). When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      neutralization was employed, tests were considered positive in 66 of the 76 cases (8.9 percent).",
"     </li>",
"     <li>",
"      Thrombocytopenia was noted in only nine patients (1.2 percent), all of whom also had a positive ELISA test, compatible with a clinical diagnosis of HIT. One of these nine patients had a venous thromboembolic event (0.1 percent).",
"     </li>",
"     <li>",
"      Immunoassay positivity in the absence of thrombocytopenia did not predict for development of thrombocytopenia or for arterial or venous thromboembolic events, vascular access occlusion, or mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because immunoassay positivity in these patients in the absence of thrombocytopenia did not predict for development of significant clinical endpoints, it was concluded that dialysis patients should not be monitored for the presence of HIT antibodies in the absence of thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Defining test positivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strength of a positive immunoassay (ie, its optical density (OD) at 405 nm) provides useful information regarding the likelihood of HIT, with an optical density &gt;1.0 more likely to be associated with platelet-activating antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,109,111,119,125,126\">",
"     2,109,111,119,125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was directly approached in one study by determining the risk of a strongly-positive serotonin release assay (SRA, &ge;50 percent serotonin release) for five different categories of OD reactivity using both a commercial and an in-house solid phase immunoassay. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/111\">",
"     111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      OD &lt;0.40 &mdash; SRA positive in 0.0 to 0.1 percent",
"     </li>",
"     <li>",
"      OD 0.40 to &lt;1.00 &mdash; SRA positive in 1 to 5 percent",
"     </li>",
"     <li>",
"      OD 1.00 to &lt;1.40 &mdash; SRA positive in 18 to 30 percent",
"     </li>",
"     <li>",
"      OD 1.40 to &lt;2.00 &mdash; SRA positive in 19 to 46 percent",
"     </li>",
"     <li>",
"      OD &gt;2.00 &mdash; SRA positive in 89 to 100 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on their results, the authors concluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/111\">",
"     111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A weak-positive test result (ie, an OD in the range of 0.40 to &lt;1.00) was strong evidence",
"      <strong>",
"       against",
"      </strong>",
"      the diagnosis of HIT, with a probability of HIT of &le;5 percent.",
"     </li>",
"     <li>",
"      The probability that a positive test result indicated the presence of platelet-activating HIT antibodies did not reach a threshold of &gt;50 percent, meaning that the diagnosis of HIT was more likely than not, until the OD reached a value of &ge;1.40. This threshold may be considerably higher in cardiothoracic bypass patients receiving unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For a very strongly positive immunoassay result (ie, OD &gt;2.00), the probability of detecting platelet-activating antibodies was approximately 90 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single institution study evaluated the relationship between the strength of a positive ELISA immunoassay and the 30-day probability of developing a thrombotic event in 318 consecutive hospitalized patients with clinically suspected HIT and positive",
"    <span class=\"nowrap\">",
"     anti-PF4/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"    </span>",
"    antibody levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/127\">",
"     127",
"    </a>",
"    ]. In this study the threshold value for considering the test to be positive was determined daily using a positive and negative control, with a median threshold value of 0.46 OD units and a range from 0.31 to 0.67 OD units. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median OD level for these patients was 0.85 (range: 0.31 to 4.0). Their overall rate of arterial or venous thrombosis was 23.3 percent, with a 30-day mortality of 16.7 percent.",
"     </li>",
"     <li>",
"      Logistic regression showed that increases in antibody levels were associated with significantly greater odds of thrombosis by 30 days (OR 1.9; 95% CI 1.5-2.6).",
"     </li>",
"     <li>",
"      A regression analysis of the data predicted that the proportions of patients with any clinically evident thrombosis were 19, 32, and 48 percent at optical densities of 1.0, 2.0, and 3.0, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, it has been suggested that the optical density of the test result, whether or not there was inhibition by high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and the cut-off for a positive result should all be reported by the laboratory, rather than stating that the test is either positive or negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/7,8,111,121,128\">",
"     7,8,111,121,128",
"    </a>",
"    ]. As an example, in a study where HIT was diagnosed solely on clinical grounds, the probability of clinical HIT for a patient with an optical density on an ELISA test of 1.0 was approximately 20 percent if the high-dose heparin confirmatory test was negative and approximately 80 percent if it was positive (",
"    <a class=\"graphic graphic_figure graphicRef70437 \" href=\"mobipreview.htm?18/10/18605\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Practical diagnostic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ELISA test is best used along with one of the functional assays rather than as a single test, since up to 10 to 20 percent of sample results may be discordant between the ELISA assay and the functional assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,104,129-132\">",
"     2,104,129-132",
"    </a>",
"    ]. In complex clinical settings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when the ELISA test is marginally positive, a functional assay can help to confirm or refute the diagnosis of HIT (",
"    <a class=\"graphic graphic_figure graphicRef70437 \" href=\"mobipreview.htm?18/10/18605\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    From a practical standpoint, one is often faced with the report of a positive ELISA assay without additional details. In the absence of a confirmatory functional assay, the diagnosis of HIT should be determined by a clinical assessment (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Pretest probability of HIT (the 4 T's)'",
"    </a>",
"    below). Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the clinical presentation is consistent with HIT and there are no alternate explanations for the thrombocytopenia, a positive ELISA assay should be considered as supportive of the diagnosis of HIT.",
"     </li>",
"     <li>",
"      There is the potential to over-diagnose HIT if any \"positive\" ELISA assay (ie, independent of the strength of the positive test) is considered \"diagnostic\" of HIT irrespective of the clinical scenario and the pretest probability (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/133\">",
"       133",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If, in the course of time, the pretest probability of the patient increases from a prior value, it is reasonable to repeat a previously negative ELISA test. A positive ELISA test under such circumstances is more likely to be associated with clinical HIT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pretest probability of HIT (the 4 T's)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A difficulty in establishing the diagnosis of HIT is that medical and surgical patients may have multiple causes for thrombocytopenia other than the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Furthermore, patients who do not have HIT may, on the basis of a false-positive test result, be inappropriately switched from heparin to much more expensive medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ) that also increase the risk of bleeding. Another potential problem with the over-diagnosis of HIT is that it limits the future use of heparin in these patients.",
"   </p>",
"   <p>",
"    In an attempt to address this problem, a pretest clinical score (called \"the 4 T's\") has been developed and prospectively validated in two centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count fall &gt;50 percent and nadir",
"      <span class=\"nowrap\">",
"       &ge;20,000/microL",
"      </span>",
"      &ndash; 2 points",
"     </li>",
"     <li>",
"      Platelet count fall 30 to 50 percent or nadir 10 to",
"      <span class=\"nowrap\">",
"       19,000/microL",
"      </span>",
"      &ndash; 1 points",
"     </li>",
"     <li>",
"      Platelet count fall &lt;30 percent or nadir",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL",
"      </span>",
"      &ndash; zero points",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Timing of platelet count fall",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clear onset between days 5 and 10 or platelet count fall at &le;1 day if prior",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      exposure within the last 30 days &ndash; 2 points",
"     </li>",
"     <li>",
"      Consistent with fall at 5 to 10 days but unclear (eg, missing platelet counts), onset after day 10, or fall &le;1 day with prior",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      exposure within 30 to 100 days &ndash; 1 point",
"     </li>",
"     <li>",
"      Platelet count fall at &lt;4 days without recent exposure &ndash; 0 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Thrombosis or other sequelae",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confirmed new thrombosis, skin necrosis, or acute systemic reaction after intravenous unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      bolus &ndash; 2 points",
"     </li>",
"     <li>",
"      Progressive or recurrent thrombosis, non-necrotizing (erythematous) skin lesions, or suspected thrombosis that has not been proven &ndash; 1 point",
"     </li>",
"     <li>",
"      None &ndash; zero points",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other causes for thrombocytopenia present",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      None apparent &ndash; 2 points",
"     </li>",
"     <li>",
"      Possible &ndash; 1 point",
"     </li>",
"     <li>",
"      Definite &ndash; zero points",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Test interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A score is determined for each of the four above categories, resulting in a total score from zero to 8. Pretest probabilities for HIT are, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zero to 3 &ndash; Low probability",
"     </li>",
"     <li>",
"      4 to 5 &ndash; Intermediate probability",
"     </li>",
"     <li>",
"      6 to 8 &ndash; High probability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the initial analysis, among 111 patients with a low pretest probability of HIT using this scoring system, only one had clinically significant HIT antibodies (0.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/135\">",
"     135",
"    </a>",
"    ]. In contrast, the overall rate of clinically significant HIT antibodies was 11.4 and 34 percent in those with intermediate and high scores, respectively.",
"   </p>",
"   <p>",
"    A meta-analysis of 3068 patients with clinically suspected HIT who were followed prospectively (eight trials) or evaluated retrospectively (five trials) found that the proportion of those with a low probability 4 Ts score who did not have HIT antibodies (ie, negative predictive value, NPV) was 0.998 (95% CI 0.97-1.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/136\">",
"     136",
"    </a>",
"    ]. This NPV of a low probability score remained high regardless of the party performing the scoring (ie, clinician or study coordinator), the patient population being studied (ie, medical or surgical), or the prevalence of HIT in the population. The proportions of those with an intermediate or high probability score who had HIT antibodies (ie, positive predictive value) were 0.14 and 0.64, respectively.",
"   </p>",
"   <p>",
"    We limit laboratory testing for HIT to patients with an intermediate or high 4 Ts pretest probability, since those with a low probability are at very low risk of having clinically significant HIT antibodies (ie, &lt;5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/8,119,136,137\">",
"     8,119,136,137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12976323\">",
"    <span class=\"h2\">",
"     Other pre-test probability models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other pre-test probability models have been proposed. Neither has been prospectively evaluated on a multicenter basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lillo-Le Louet model &ndash; This model is intended for use exclusively in the postcardiopulmonary bypass setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac surgery patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIT Expert Probability Score &ndash; This model is based on broad expert opinion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , the heparin analogue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , and heparinoids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    , are associated with a much lower incidence of HIT than unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/21,95\">",
"     21,95",
"    </a>",
"    ]. In a prospective study of postoperative orthopedic patients, the administration of a LMW heparin was associated with a lower incidence of heparin-dependent IgG antibodies (2.2 versus 7.8 percent with unfractionated heparin) and no cases of HIT (zero versus 2.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar observations were made in a multicenter study of two different LMW heparins in 499 patients who had undergone hip replacement; only one developed thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     Danaparoid",
"    </a>",
"    , an agent no longer available in the United States, has been used extensively to treat patients with HIT (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/140\">",
"     140",
"    </a>",
"    ]. There is an approximately 10 percent crossreactivity with standard HIT-IgG in vitro and 5 percent crossreactivity in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/141\">",
"     141",
"    </a>",
"    ]. The clinical relevance of this finding is unclear, since clinical sequelae resulting from danaparoid use are uncommon.",
"   </p>",
"   <p>",
"    In general, the best way to prevent HIT is the judicious use of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (eg, for a shorter period of time when used) or the substitution of LMW heparin, where appropriate (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Incidence and risk factors'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limiting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    duration to less than five days and starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    early to minimize the length of heparin use in patients requiring long-term anticoagulation are two often overlooked strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Initial intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first intervention in a patient with suspected HIT should be",
"    <strong>",
"     immediate",
"    </strong>",
"    cessation of all exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . This includes warning all personnel involved in the patient&rsquo;s care to avoid heparin (",
"    <a class=\"graphic graphic_algorithm graphicRef56493 \" href=\"mobipreview.htm?31/36/32334\">",
"     algorithm 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sources of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      flushes (eg, for arterial lines or heparin locks)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -bonded catheters",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -containing medications (eg, some forms of prothrombin complex concentrates, PCCs)",
"     </li>",
"     <li>",
"      Low molecular weight (LMW) heparins (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LMW heparins should be avoided since they may crossreact with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,142\">",
"     2,142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On making a diagnosis of HIT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    \"allergy\" should be included in the patient's record, and a sign should be posted at the bedside (or attached to all intravenous delivery devices) that the patient has HIT and should not receive any form of heparin, including heparin flushes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with a diagnosis of HIT should receive an alternate form of anticoagulation as long as there is no contraindication to anticoagulation (eg, active bleeding). This is due to the high subsequent risk of thrombosis in patients with HIT.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    cessation alone is often not sufficient, since these patients remain at risk for subsequent thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/142,144\">",
"     142,144",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective series of 62 patients with isolated thrombocytopenia caused by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , the subsequent 30-day risk of thrombosis was 53 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study evaluated 113 patients with HIT, in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was stopped early (mean 0.7 days) or late (mean 5 days) after the onset of thrombocytopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/145\">",
"       145",
"      </a>",
"      ]. The overall incidence of thrombosis was 45 and 34 percent in the early and late groups, respectively, with 61 and 40 percent of the thrombotic events occurring more than 24 hours after cessation of heparin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    should not be given to patients who have HIT until the thrombocytopenia resolves following the use of agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    or hirudin, and LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should not be substituted for unfractionated heparin after HIT develops. (See",
"    <a class=\"local\" href=\"#H2392980\">",
"     'Transition to warfarin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H87756545\">",
"     'Alternative anticoagulants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87756545\">",
"    <span class=\"h2\">",
"     Alternative anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop HIT will have an ongoing need for anticoagulation due to the HIT itself, and possibly due to the condition for which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was administered originally (",
"    <a class=\"graphic graphic_algorithm graphicRef56493 \" href=\"mobipreview.htm?31/36/32334\">",
"     algorithm 1",
"    </a>",
"    ). There are a number of recommended alternative anticoagulants to heparin in a patient with HIT: a direct thrombin inhibitor such",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    (not available in the United States); or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    (discontinued in May 2012, presumably due to lack of raw materials) (",
"    <a class=\"graphic graphic_table graphicRef73727 \" href=\"mobipreview.htm?39/9/40091\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,146-148\">",
"     2,146-148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a nonrandomized comparison study, the efficacies of therapeutic (rather than prophylactic) doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    in preventing death, amputation, or new thromboembolic complications in patients with HIT did not differ significantly, although the risk of bleeding appeared to be higher in patients treated with lepirudin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/142,149\">",
"     142,149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To date there have been no prospective randomized studies comparing the relative efficacy and toxicity of the available agents. However, because of their different modes of excretion and inactivation, patients with HIT and renal insufficiency are usually treated at our institution with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    , while those with hepatic impairment are usually treated with argatroban or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    (Angiomax), a hemodialyzable direct thrombin inhibitor and hirudin analog (previously called hirulog) has been successfully employed in patients with HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,150,151\">",
"     2,150,151",
"    </a>",
"    ], with reduced doses safely employed in patients with renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/152\">",
"     152",
"    </a>",
"    ], as well as in those with combined hepatic and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    has been approved by the FDA for patients with, or at risk of, HIT who are undergoing percutaneous coronary intervention, but not for HIT in other settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H11#H11\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    for HIT is approximately 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour, adjusted to achieve an aPTT 1.5 to 2.5 times baseline. Doses of 0.14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour in patients with hepatic dysfunction and 0.03 to 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour in patients with renal or combined hepatic and renal dysfunction have been successfully employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 45 percent of the anti-hirudin antibody positive patients (12 percent of all hirudin-treated patients), the dose of hirudin had to be reduced (mean dose reduction 45 percent, range: 17 to 90 percent) in order to keep the aPTT in the targeted therapeutic range. It was therefore suggested that daily monitoring of the aPTT be performed in all patients receiving prolonged treatment with this agent (ie, more than five days), in order to avoid bleeding complications due to this phenomenon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Argatroban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     Argatroban",
"    </a>",
"    is a direct thrombin inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/154\">",
"     154",
"    </a>",
"    ]. It is a small molecule that in contrast to hirudin, interacts with the active site of thrombin but does not make contact with exosites I or II. It has a short in vivo plasma half-life of 24 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/154\">",
"     154",
"    </a>",
"    ]; its effect is monitored by the aPTT, although dose-dependent increases also occur in the prothrombin time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/155\">",
"     155",
"    </a>",
"    ]. Steady-state anticoagulation is reached one to three hours after intravenous administration; after discontinuation, the aPTT returns to normal within two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/156\">",
"     156",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H22739310#H22739310\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Argatroban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three reports of multi-institutional phase III prospective trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    in HIT, as compared with historical controls, have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/157-159\">",
"     157-159",
"    </a>",
"    ]. These studies showed superior efficacy of argatroban in reducing subsequent thrombotic events and death due to thrombosis, with no difference in bleeding rates.",
"   </p>",
"   <p>",
"    As a result of these studies, the drug was approved by the FDA for both prophylaxis and treatment of thrombosis in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia. This agent has also been successfully employed in patients with a history of HIT needing acute anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/160\">",
"     160",
"    </a>",
"    ]. The drug is eliminated via a hepatobiliary route; dose adjustment is required in the presence of hepatic dysfunction but is not required in the presence of renal impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large case series are not available concerning the utility of this agent in patients with HIT. One report from a university hospital noted clinical outcomes in 27 patients with HIT; 63, 48, and 41 percent had renal failure, hepatic failure, or both, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/162\">",
"     162",
"    </a>",
"    ]. The median dose over the course of therapy was 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg/min",
"    </span>",
"    (range: 0.01 to 2.0). The following endpoints were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Death &mdash; Six patients (22 percent); these occurred mainly in patients with preexisting multi-organ failure",
"     </li>",
"     <li>",
"      Any bleeding &mdash; Six (22 percent)",
"     </li>",
"     <li>",
"      New thrombosis &mdash; Four (15 percent)",
"     </li>",
"     <li>",
"      Bleeding requiring transfusion &mdash; One (4 percent)",
"     </li>",
"     <li>",
"      Amputation required &mdash; None",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with normal hepatic function, the standard starting dose is 2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute by continuous intravenous infusion, adjusted to maintain the aPTT at 1.5 to 3 times baseline. Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    is mostly metabolized by the liver and excreted in bile, a conservative lower starting dose (eg, 0.5 to 1.2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) is appropriate in patients with hepatic dysfunction (eg, total serum bilirubin &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    &gt;25.5",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    as well as in those with combined",
"    <span class=\"nowrap\">",
"     hepatic/renal",
"    </span>",
"    dysfunction, heart failure, severe anasarca, or who are postcardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,163\">",
"     2,163",
"    </a>",
"    ]. In such patients it is prudent to check the aPTT at four-hour intervals after drug initiation or dose change to ensure that the desired level of anticoagulation is present.",
"   </p>",
"   <p>",
"    A small study in 24 patients has suggested that an even lower starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) may be appropriate in critically ill patients with multiple organ dysfunction syndrome and HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h4\">",
"     Transition to warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transition from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is discussed below. Since both warfarin and argatroban elevate the",
"    <span class=\"nowrap\">",
"     PT/INR,",
"    </span>",
"    institutional guidelines should be reviewed to determine the appropriate INR target when both agents are used in order to achieve an INR in the range of 2.0 to 3.0 when argatroban is discontinued. This target will differ according to the reagents used to determine the",
"    <span class=\"nowrap\">",
"     PT/INR",
"    </span>",
"    in each particular institution. (See",
"    <a class=\"local\" href=\"#H2392980\">",
"     'Transition to warfarin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pentasaccharide",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    has a theoretical role in treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevention of HIT, since the drug does not appear to interact with platelets or platelet factor 4. In one retrospective review of results from the Matisse trial, the use of fondaparinux as initial treatment for acute VTE in 10 patients with pre-existing platelet-activating HIT antibodies did not incite the development of HIT in any patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/165\">",
"     165",
"    </a>",
"    ]. In contrast, the use of unfractionated or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as initial treatment for acute VTE in four patients with pre-existing platelet-activating HIT antibodies resulted in the development of HIT in all four.",
"   </p>",
"   <p>",
"    Although not formally approved for this indication by the FDA, there are an increasing number of observational reports of patients with confirmed HIT being successfully managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in lieu of a direct thrombin inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/166-171\">",
"     166-171",
"    </a>",
"    ]. The 2012 ACCP Guidelines do mention the use of fondaparinux for suspected or confirmed HIT, but the evidence for using this agent was considered weak and it is not listed as among the suggested treatment choices for most cases of HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/1\">",
"     1",
"    </a>",
"    ]. However, we believe that the available data as well as its mechanism of action support the use of this agent if needed.",
"   </p>",
"   <p>",
"    The long half-life of this agent, its renal elimination, and the lack of an antidote are important considerations when considering the use of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/143\">",
"     143",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link&amp;anchor=H20#H20\">",
"     \"Therapeutic use of fondaparinux\", section on 'Heparin induced thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Danaparoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     Danaparoid",
"    </a>",
"    (Orgaran) is a heparinoid that includes predominantly dermatan sulfate and low-sulfated heparan sulfate. It had been approved by the Food and Drug Administration (FDA) in the United States for prophylaxis in patients undergoing hip-replacement surgery. However, as a result of shortage in drug substance, the manufacturer (Organon) has decided to discontinue providing this medication in the United States, although it is available in several other countries, including Canada.",
"   </p>",
"   <p>",
"    There is extensive experience using this agent in patients with HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/140,172\">",
"     140,172",
"    </a>",
"    ]. It has also been given to patients with HIT or a history of HIT who require cardiopulmonary bypass surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/173-175\">",
"     173-175",
"    </a>",
"    ]. Other than its effect as an alternative anticoagulant in patients with HIT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    , in therapeutic concentrations, has been shown to interfere with platelet factor 4-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    complex formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/176\">",
"     176",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a 10 percent crossreactivity between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    and the antibody responsible for HIT in vitro, but the clinical significance of this is uncertain given the apparent therapeutic benefit in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/140\">",
"     140",
"    </a>",
"    ]. However, in one study, persistence of, or recurrence of, thrombocytopenia without thrombosis was noted in 6.5 percent of patients with classical HIT who were switched from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to danaparoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/177\">",
"     177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    in HIT is a therapeutic dose (rather than a prophylactic dose), with an initial IV bolus of 2250 U, modified up or down according to body weight, followed by an IV infusion at the rate of 400",
"    <span class=\"nowrap\">",
"     U/hour",
"    </span>",
"    for four hours, 300",
"    <span class=\"nowrap\">",
"     U/hour",
"    </span>",
"    for the next four hours, and 200",
"    <span class=\"nowrap\">",
"     U/hour",
"    </span>",
"    thereafter. Doses are adjusted to achieve anti-Xa levels of 0.5 to 0.8 anti-Xa",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disadvantages of using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    are the need to measure anti-factor Xa levels to monitor its anticoagulant effect, its long half-life (25 &plusmn; 100 h) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/146\">",
"     146",
"    </a>",
"    ], renal elimination, and the absence of a reversing agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21256910\">",
"    <span class=\"h3\">",
"     Lepirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     Lepirudin",
"    </a>",
"    (Refludan) is a recombinant hirudin that had been approved by the FDA for treatment of HIT complicated by thrombosis. This agent has also been shown to be effective in preventing new thromboses in patients with isolated HIT and no clinically evident thromboembolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manufacturer of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    (Bayer HealthCare) has discontinued marketing this product as of May 31, 2012, and no further product is expected to be shipped to wholesalers in the United States, Canada, and the European Union after that date. These actions are not related to safety concerns and are presumably related to the lack of raw materials for its production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21256948\">",
"    <span class=\"h4\">",
"     Anti-hirudin antibody formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of 196 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    for HIT for a mean duration of 10 days, anti-hirudin IgG antibodies were detected in 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/179\">",
"     179",
"    </a>",
"    ]. Longer treatment duration with lepirudin (18.6 versus 11.8 days) was the only clinical variable associated with antibody formation. Deaths were significantly less common in antibody-positive patients (1.2 versus 14 percent); other end-points such as limb amputations, new thromboembolic complications, time course of platelet count normalization, and major bleeding complications did not differ between antibody-negative and antibody-positive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches (eg, arvin, thrombolysis, plasmapheresis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , intravenous immunoglobulin) are not effective for the initial treatment of HIT and should not be used in place of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A preliminary report of three patients suggests that a glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor in combination with a direct thrombin inhibitor may be effective when a thrombin inhibitor alone fails to relieve acute thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/180\">",
"       180",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are theoretical reasons why the new orally-active anticoagulants",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      should be effective treatments for patients with established HIT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/181,182\">",
"       181,182",
"      </a>",
"      ], although clinical experience with these agents in this off-label setting is virtually nonexistent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Platelet transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet transfusions are generally considered to be relatively contraindicated for the",
"    <strong>",
"     prevention",
"    </strong>",
"    of bleeding in patients with HIT, largely due to the theoretical possibility that they might precipitate thrombotic events (ie, \"add fuel to the fire\").",
"   </p>",
"   <p>",
"    In contrast, platelet transfusion for the",
"    <strong>",
"     treatment",
"    </strong>",
"    of bleeding may be appropriate. As an example, two reports of a total of 41 patients with HIT showed that platelet transfusions resulted in appropriate 24-hour post-transfusion platelet count increments in the majority, with cessation of bleeding in two-thirds of the bleeding patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/184,185\">",
"     184,185",
"    </a>",
"    ]. No thrombotic complications were noted in either report. A review of the literature revealed no case of a complication clearly attributable to platelet transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/184\">",
"     184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These authors, as well as the 2012 ACCP Guidelines, concluded that platelet transfusions can be considered in patients with HIT and overt bleeding or during the performance of an invasive procedure with a high bleeding risk, particularly if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been stopped for at least several hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392980\">",
"    <span class=\"h2\">",
"     Transition to warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    should be initiated in a patient with HIT only when both of the following have been accomplished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,82,145\">",
"     2,82,145",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has been stably anticoagulated with a thrombin-specific inhibitor,",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      The platelet count has increased to at least",
"      <span class=\"nowrap\">",
"       150,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There should be a minimum of five days of overlapping therapy before the thrombin inhibitor is discontinued. The",
"    <strong>",
"     initial",
"    </strong>",
"    use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone for a patient diagnosed with HIT should be avoided since warfarin therapy may increase the risk of venous limb gangrene in patients with deep vein thrombosis through its rapid lowering of protein C levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/82,186\">",
"     82,186",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the above two goals have been reached and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy is started, high initial doses (eg, &ge;10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    should be avoided to minimize the transient hypercoagulable state induced by the rapid decline in protein C levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,187\">",
"     2,187",
"    </a>",
"    ]. Accordingly, warfarin should be started at low maintenance doses of &le;5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (or phenprocoumon &le;6",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of warfarin\", section on 'Initial dose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H24#H24\">",
"     \"Therapeutic use of warfarin\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The target range for anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be an INR in the range of 2.0 to 3.0. The length of treatment with warfarin has not been defined in any prospective study, but in view of the high risk of thrombosis within 30 days of the diagnosis of HIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/80\">",
"     80",
"    </a>",
"    ], warfarin anticoagulation should probably be continued for at least two to three months, and for at least three to six months if a thrombotic event has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/62,188\">",
"     62,188",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     USE OF HEPARIN AFTER AN EPISODE OF HIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a",
"    <strong>",
"     history",
"    </strong>",
"    of HIT who require cardiopulmonary bypass (CPB) have been successfully anticoagulated with a brief course of treatment with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    without complications. This approach is based on the theory that a secondary immune response after re-exposure to heparin should not occur until at least three days after exposure. Thus, a brief exposure to heparin during CPB should not immediately elicit HIT antibodies. Furthermore, since the heparin would be rapidly cleared after the procedure, even if antibodies appeared, they would not be thrombogenic in the absence of heparin.",
"   </p>",
"   <p>",
"    This approach was applied in 10 patients with a history of HIT who required CPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/189\">",
"     189",
"    </a>",
"    ]. At the time of surgery all patients were negative for HIT antibodies according to a PF4 solid phase assay. There were no complications of surgery, no prolonged thrombocytopenia, and no increase in the serum concentration of HIT antibodies during a 10-day post-operative period.",
"   </p>",
"   <p>",
"    Thus, when managing such patients, the use of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    could be considered using the following guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2,69,189,190\">",
"     2,69,189,190",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prove, using a sensitive assay for platelet factor",
"      <span class=\"nowrap\">",
"       4/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      antibodies, that HIT antibodies are no longer detectable. These antibodies usually disappear at a median time of 50 to 90 days following the last exposure to heparin, but a safer interval is &gt;100 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/191\">",
"       191",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Early onset HIT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restrict the use of unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      to the operative procedure itself. Low molecular weight heparin is not recommended, due to its longer half-life compared with unfractionated heparin as well as the inability to fully reverse its effect with protamine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use alternative anticoagulants pre- and post-operatively if needed (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       Bivalirudin",
"      </a>",
"      has been approved by the FDA for patients with, or at risk of, HIT who are undergoing percutaneous coronary intervention. However, there are concerns about how best to monitor use of this agent and that its use may be associated with a high incidence of bleeding in patients undergoing CPB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/192\">",
"       192",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Bivalirudin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10335285\">",
"    <span class=\"h1\">",
"     URGENT USE OF ANTICOAGULANTS DURING AN EPISODE OF HIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;This issue is more complex if cardiopulmonary bypass (CPB) is urgently required in a patient with a past history of HIT in whom the platelet count has recovered but IgG antibodies to the platelet factor",
"    <span class=\"nowrap\">",
"     4/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"    </span>",
"    complex are still present (ie, \"subacute HIT\"). In a report of three patients with subacute HIT requiring urgent heart transplantation, re-exposure to unfractionated heparin was uneventful when it was shown that they tested negative by a sensitive",
"    <strong>",
"     functional",
"    </strong>",
"    assay using washed platelets (eg, heparin-induced platelet aggregation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/193\">",
"     193",
"    </a>",
"    ]. Heparin was discontinued and a direct thrombin inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    ) was used a few hours post-operatively in all three cases to prevent recurrence of thrombosis due to the re-exposure to heparin.",
"   </p>",
"   <p>",
"    Experience with intraoperative anticoagulation when cardiac or vascular surgery is urgently required in a patient with active HIT is similarly limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/1,194\">",
"     1,194",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For urgent cardiac surgery, the 2012 ACCP Guidelines suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      over other non-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulants and over heparin plus antiplatelet agents (Grade 2C).",
"     </li>",
"     <li>",
"      For urgent percutaneous coronary interventions, the Guidelines suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (Grade 2B) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      (Grade 2C) over other non-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When CPB is urgently required, HIT antibodies are present, a sensitive functional assay is not available, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is chosen as the anticoagulant, the use of intraoperative plasma exchange has been undertaken in order to reduce the titer of the HIT antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/195,196\">",
"     195,196",
"    </a>",
"    ]. Additional experience will be required before a recommendation can be made for such treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/59/40890/abstract/197\">",
"     197",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of any one of the following should raise the possibility of immune",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia (HIT) in a patient started on heparin therapy within the preceding 5 to 10 days; a patient receiving prolonged treatment with unfractionated or low molecular weight heparin; or a patient developing acute thrombocytopenia after being re-exposed to heparin (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Suspecting HIT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Otherwise unexplained thrombocytopenia",
"     </li>",
"     <li>",
"      Venous or arterial thrombosis associated with thrombocytopenia",
"     </li>",
"     <li>",
"      A platelet count that has fallen 50 percent or more from a prior value, even if absolute thrombocytopenia is not present",
"     </li>",
"     <li>",
"      Necrotic skin lesions at",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      injection sites",
"     </li>",
"     <li>",
"      Acute systemic (anaphylactoid) reactions occurring after IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      bolus administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All sources of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      should be discontinued",
"      <strong>",
"       immediately",
"      </strong>",
"      in a patient suspected of having HIT. The pretest probability of HIT should be determined based upon the 4 T&rsquo;s (thrombocytopenia, timing, thrombosis, other causes), interpreted within the clinical context. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pretest probability of HIT (the 4 T's)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low probability (0 to 3 points) &mdash; Causes for thrombocytopenia other than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      should be re-evaluated in those with a low pretest probability. Laboratory testing for HIT is not generally appropriate in this group.",
"     </li>",
"     <li>",
"      Intermediate or high probability (4 to 8 points) &mdash; Patients with intermediate or high pretest probability for HIT require anticoagulation with an alternative nonheparin anticoagulant, and urgent laboratory testing for HIT is indicated. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Initial intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of HIT should be considered established in a patient with intermediate or high pretest probability and a positive solid phase ELISA test for HIT. In complex clinical settings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when the ELISA test is marginally positive, a functional assay can help to confirm or refute the diagnosis of HIT, since up to 10 to 20 percent of sample results may be discordant between the ELISA and the functional assays (",
"      <a class=\"graphic graphic_figure graphicRef70437 \" href=\"mobipreview.htm?18/10/18605\">",
"       figure 3",
"      </a>",
"      ). Because the results of functional assays for HIT may be delayed for as long as one week, they are useful only for final confirmation of the diagnosis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Practical diagnostic issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Defining test positivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with intermediate or high pretest probability for HIT, we recommend the immediate use of an alternative nonheparin anticoagulant (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"       danaparoid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      , as available) unless there is a strong contraindication, such as bleeding (",
"      <a class=\"graphic graphic_algorithm graphicRef56493 \" href=\"mobipreview.htm?31/36/32334\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef73727 \" href=\"mobipreview.htm?39/9/40091\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A choice among these alternative nonheparin anticoagulants is largely made based upon the patient&rsquo;s renal and hepatic function and availability (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Initial intervention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Any of these agents can be used in patients whose renal and hepatic functions are both normal.",
"     </li>",
"     <li>",
"      We suggest that patients with abnormal hepatic function and normal renal function be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"       danaparoid",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (as available), while those with abnormal renal function and normal hepatic function receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      at standard doses (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients in whom both renal and hepatic function are abnormal we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      at reduced doses (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with HIT be anticoagulated for at least two to three months in the absence of a thrombotic event, and three to six months if such an event has occurred (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      can be started once the patient has been stabilized with a nonheparin anticoagulant and the platelet count has recovered to",
"      <span class=\"nowrap\">",
"       &ge;150,000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2392980\">",
"       'Transition to warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients transitioning to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , low initial doses of warfarin, rather than high \"loading\" doses, should be started once the patient is stably anticoagulated with a nonheparin alternative and the platelet count is above",
"      <span class=\"nowrap\">",
"       150,000/microL.",
"      </span>",
"      The nonheparin anticoagulant should be continued for at least five days along with warfarin and until the INR has reached the intended target range. (See",
"      <a class=\"local\" href=\"#H2392980\">",
"       'Transition to warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a history of HIT who require cardiopulmonary bypass can sometimes be anticoagulated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , provided that platelet factor",
"      <span class=\"nowrap\">",
"       4/heparin",
"      </span>",
"      antibodies (ie, HIT antibodies) are absent and the heparin exposure is limited to the operative procedure only. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Use of heparin after an episode of HIT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/1\">",
"      Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/2\">",
"      Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/3\">",
"      Chong BH, Castaldi PA. Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Aust N Z J Med 1986; 16:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/4\">",
"      Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost 1995; 21:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/5\">",
"      Stanton PE Jr, Evans JR, Lefemine AA, et al. White clot syndrome. South Med J 1988; 81:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/6\">",
"      Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006; 118:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/7\">",
"      Keeling D, Davidson S, Watson H, Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/8\">",
"      Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med 2006; 34:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/9\">",
"      Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/10\">",
"      Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/11\">",
"      Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/12\">",
"      Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/13\">",
"      Harbrecht U, Bastians B, Kredteck A, et al. Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology 2004; 62:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/14\">",
"      Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/15\">",
"      Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest 2007; 132:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/16\">",
"      Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108:2937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/17\">",
"      Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/18\">",
"      Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest 2007; 131:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/19\">",
"      Oliveira GB, Crespo EM, Becker RC, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/20\">",
"      Crespo EM, Oliveira GB, Honeycutt EF, et al. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J 2009; 157:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/21\">",
"      Stein PD, Hull RD, Matta F, et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009; 122:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/22\">",
"      Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/23\">",
"      Pohl C, Kredteck A, Bastians B, et al. Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. Neurology 2005; 64:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/24\">",
"      Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/25\">",
"      Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/26\">",
"      Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/27\">",
"      Yusuf AM, Warkentin TE, Arsenault KA, et al. Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. Thromb Haemost 2012; 107:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/28\">",
"      Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005; 106:3049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/29\">",
"      Heeger PS, Backstrom JT. Heparin flushes and thrombocytopenia. Ann Intern Med 1986; 105:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/30\">",
"      Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 1988; 7:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/31\">",
"      Muslimani AA, Ricaurte B, Daw HA. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol 2007; 82:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/32\">",
"      Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/33\">",
"      Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/34\">",
"      Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83:3232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/35\">",
"      Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/36\">",
"      Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92:3250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/37\">",
"      Visentin GP, Moghaddam M, Beery SE, et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/38\">",
"      Newman PM, Chong BH. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 1999; 107:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/39\">",
"      Sachais BS, Litvinov RI, Yarovoi SV, et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood 2012; 120:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/40\">",
"      Krauel K, P&ouml;tschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/41\">",
"      Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/42\">",
"      Greinacher A, P&ouml;tzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/43\">",
"      Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000; 96:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/44\">",
"      Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84:3691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/45\">",
"      Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002; 14:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/46\">",
"      Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J 2007; 153:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/47\">",
"      Chilver-Stainer L, L&auml;mmle B, Alberio L. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 2004; 91:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/48\">",
"      Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97:3300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/49\">",
"      Kasthuri RS, Glover SL, Jonas W, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fc&gamma;RI. Blood 2012; 119:5285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/50\">",
"      Kowalska MA, Krishnaswamy S, Rauova L, et al. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood 2011; 118:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/51\">",
"      Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001; 98:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/52\">",
"      Chudasama SL, Espinasse B, Hwang F, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood 2010; 116:6046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/53\">",
"      Cines DB, Rauova L, Arepally G, et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/54\">",
"      Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity. Blood 2007; 110:4253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/55\">",
"      Reilly MP, Taylor SM, Franklin C, et al. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J Thromb Haemost 2006; 4:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/56\">",
"      Carlsson LE, Lubenow N, Blumentritt C, et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003; 13:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/57\">",
"      Harris K, Nguyen P, Van Cott EM. Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol 2008; 129:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/58\">",
"      Arepally G, McKenzie SE, Jiang XM, et al. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/59\">",
"      Gruel Y, Pouplard C, Lasne D, et al. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004; 104:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/60\">",
"      Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/61\">",
"      Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113:4970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/62\">",
"      Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101:31.",
"     </a>",
"    </li>",
"    <li>",
"     Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Low-Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. Fundamental and Clinical Cardiology, Bounameaux H (Ed), Marcel Decker, New York 1994. p.75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/64\">",
"      Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998; 35:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/65\">",
"      Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/66\">",
"      Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/67\">",
"      Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/68\">",
"      Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/69\">",
"      Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/70\">",
"      Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/71\">",
"      Nader ND, Khadra WZ, Reich NT, et al. Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg 1999; 68:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/72\">",
"      Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010; 8:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/73\">",
"      Gruel Y, Pouplard C. Post-operative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocypenia after cardiac surgery. J Thromb Haemost 2010; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/74\">",
"      Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996; 128:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/75\">",
"      Schallmoser K, Drexler C, Rohde E, et al. The particle gel immunoassay as a rapid test to rule out heparin-induced thrombocytopenia? J Thorac Cardiovasc Surg 2009; 137:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/76\">",
"      Lillo-Le Lou&euml;t A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004; 2:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/77\">",
"      Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/78\">",
"      Hughes M, Hayward CP, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/79\">",
"      Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/80\">",
"      Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/81\">",
"      Levine RL, McCollum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest 2006; 130:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/82\">",
"      Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/83\">",
"      Comp PC, Elrod JP, Karzenski S. Warfarin-induced skin necrosis. Semin Thromb Hemost 1990; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/84\">",
"      Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/85\">",
"      LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/86\">",
"      Giossi A, Del Zotto E, Volonghi I, et al. Thromboembolic complications of heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 2012; 23:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/87\">",
"      White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy: including six cases of heparin--induced skin necrosis. Ann Surg 1979; 190:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/88\">",
"      Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997; 78:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/89\">",
"      Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/90\">",
"      Moore A, Lau E, Yang C, et al. Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. Am J Clin Oncol 2007; 30:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/91\">",
"      Tietge UJ, Schmidt HH, J&auml;ckel E, et al. Low molecular weight heparin-induced skin necrosis occurring distant from injection sites and without thrombocytopenia. J Intern Med 1998; 243:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/92\">",
"      Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/93\">",
"      Arthur CK, Grant SJ, Murray WK, et al. Heparin-associated acute adrenal insufficiency. Aust N Z J Med 1985; 15:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/94\">",
"      Warkentin TE, Hirte HW, Anderson DR, et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994; 97:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/95\">",
"      Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/96\">",
"      Spectre G, Kalish Y, Schliamser L, Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol 2008; 83:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/97\">",
"      Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/98\">",
"      Kelton JG, Warkentin TE. Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination. Am J Clin Pathol 1995; 104:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/99\">",
"      Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 1982; 60:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/100\">",
"      Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/101\">",
"      Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/102\">",
"      Harenberg J, Huhle G, Giese C, et al. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2000; 109:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/103\">",
"      Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/104\">",
"      Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/105\">",
"      Martinuzzo ME, Forastiero RR, Adamczuk Y, et al. Antiplatelet factor 4--heparin antibodies in patients with antiphospholipid antibodies. Thromb Res 1999; 95:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/106\">",
"      de Larra&ntilde;aga G, Martinuzzo M, Bocassi A, et al. Heparin-platelet factor 4 induced antibodies in patients with either autoimmune or alloimmune antiphospholipid antibodies. Thromb Haemost 2002; 88:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/107\">",
"      Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/108\">",
"      Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/109\">",
"      Schenk S, El-Banayosy A, Morshuis M, et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost 2007; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/110\">",
"      Alpert D, Mandl LA, Erkan D, et al. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008; 67:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/111\">",
"      Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/112\">",
"      Pauzner R, Greinacher A, Selleng K, et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 7:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/113\">",
"      Martin-Toutain I, Settegrana C, Ankri A. High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. J Thromb Haemost 2009; 7:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/114\">",
"      Verma AK, Levine M, Shalansky SJ, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/115\">",
"      Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/116\">",
"      Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/117\">",
"      Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/118\">",
"      Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/119\">",
"      Bakchoul T, Giptner A, Najaoui A, et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/120\">",
"      Pouplard C, Leroux D, Regina S, et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/121\">",
"      Whitlatch NL, Kong DF, Metjian AD, et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010; 116:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/122\">",
"      Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/123\">",
"      Selleng S, Schreier N, Wollert HG, Greinacher A. The diagnostic value of the anti-PF4/heparin immunoassay high-dose heparin confirmatory test in cardiac surgery patients. Anesth Analg 2011; 112:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/124\">",
"      Asmis LM, Segal JB, Plantinga LC, et al. Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 2008; 100:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/125\">",
"      Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/126\">",
"      Ruf KM, Bensadoun ES, Davis GA, et al. A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011; 105:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/127\">",
"      Baroletti S, Hurwitz S, Conti NA, et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med 2012; 125:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/128\">",
"      Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/129\">",
"      Nguy&ecirc;n P, Droull&eacute; C, Potron G. Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/130\">",
"      Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/131\">",
"      Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/132\">",
"      Vun CM, Evans S, Chesterman CN. Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. Br J Haematol 2001; 112:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/133\">",
"      Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/134\">",
"      Chan M, Malynn E, Shaz B, Uhl L. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hematol 2008; 83:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/135\">",
"      Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/136\">",
"      Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120:4160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/137\">",
"      Bryant A, Low J, Austin S, Joseph JE. Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol 2008; 143:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/138\">",
"      Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 8:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/139\">",
"      Plan&egrave;s A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/140\">",
"      Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/141\">",
"      Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects of in vivo thrombin and cross-linked fibrin generations, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG. Blood 1996; 88 (Suppl I):626a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/142\">",
"      Warkentin TE. Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost 2001; 85:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/143\">",
"      Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/144\">",
"      Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004; 104:3072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/145\">",
"      Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/146\">",
"      Danhof M, de Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/147\">",
"      Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematol 1999; 36:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/148\">",
"      Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/149\">",
"      Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/150\">",
"      Mann MJ, Tseng E, Ratcliffe M, et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005; 24:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/151\">",
"      Nikolsky E, Dangas GD. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost 2004; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/152\">",
"      Wisler JW, Washam JB, Becker RC. Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. J Thromb Thrombolysis 2012; 33:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/153\">",
"      Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006; 26:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/154\">",
"      Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/155\">",
"      Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/156\">",
"      Argatroban for treatment of heparin-induced thrombocytopenia. Med Lett Drugs Ther 2001; 43:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/157\">",
"      Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/158\">",
"      Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/159\">",
"      Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/160\">",
"      Matthai WH Jr, Hursting MJ, Lewis BE, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005; 116:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/161\">",
"      Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/162\">",
"      Kodityal S, Nguyen PH, Kodityal A, et al. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006; 21:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/163\">",
"      Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/164\">",
"      Beiderlinden M, Treschan TA, G&ouml;rlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007; 41:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/165\">",
"      Warkentin TE, Davidson BL, B&uuml;ller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/166\">",
"      Blackmer AB, Oertel MD, Valgus JM. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues. Ann Pharmacother 2009; 43:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/167\">",
"      Baroletti S, Labreche M, Niles M, et al. Prescription of fondaparinux in hospitalised patients. Thromb Haemost 2009; 101:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/168\">",
"      Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011; 9:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/169\">",
"      Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost 2011; 9:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/170\">",
"      Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/171\">",
"      Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010; 16:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/172\">",
"      Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/173\">",
"      Wilhelm MJ, Schmid C, Kececioglu D, et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996; 61:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/174\">",
"      Sodian R, Loebe M, Gorman KF, et al. Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients. ASAIO J 1997; 43:M430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/175\">",
"      Gillis S, Merin G, Zahger D, et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 1997; 98:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/176\">",
"      Krauel K, F&uuml;rll B, Warkentin TE, et al. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 6:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/177\">",
"      Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999; 115:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/178\">",
"      Doherty DC, Ortel TL, de Bruijn N, et al. \"Heparin-free\" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990; 73:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/179\">",
"      Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/180\">",
"      Walenga JM, Jeske WP, Wallis DE, et al. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999; 25 Suppl 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/181\">",
"      Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 2008; 143:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/182\">",
"      Krauel K, Hackbarth C, F&uuml;rll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/183\">",
"      Fieland D, Taylor M. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. Ann Pharmacother 2012; 46:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/184\">",
"      Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 2008; 48:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/185\">",
"      Refaai MA, Chuang C, Menegus M, et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/186\">",
"      Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/187\">",
"      Potzsch B, Unkrig C, Madlener K, et al. APC resistance and early onset of oral anticoagulation are high thrombotic risk factors in patients with heparin-associated thrombocytopenia (HAT). Ann Hematol 1996; 72 (Suppl I):A6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/188\">",
"      Watson HG, Keeling DM, BCSH Taskforce in Haemostasis and Thrombosis. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 135:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/189\">",
"      P&ouml;tzsch B, Kl&ouml;vekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/190\">",
"      Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 2000; 70:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/191\">",
"      Wanaka K, Matsuo T, Matsuo M, et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/192\">",
"      Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/193\">",
"      Selleng S, Haneya A, Hirt S, et al. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 2008; 112:4024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/194\">",
"      Warkentin TE, Pai M, Cook RJ. Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. J Thromb Haemost 2012; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/195\">",
"      Kajitani M, Aguinaga M, Johnson CE, et al. Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin induced thrombocytopenia: a case report. J Card Surg 2001; 16:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/196\">",
"      Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010; 110:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/59/40890/abstract/197\">",
"      Despotis GJ, Avidan MS. Plasma exchange for heparin-induced thrombocytopenia: is there enough evidence? Anesth Analg 2010; 110:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1369 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-9A95019A57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40890=[""].join("\n");
var outline_f39_59_40890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibody formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disease variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic and patient-specific interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Onset and degree of thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Delayed onset HIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Early onset HIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiac surgery patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Suspecting HIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Serotonin release assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Heparin-induced platelet aggregation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Solid phase immunoassay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Results in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Defining test positivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Practical diagnostic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pretest probability of HIT (the 4 T's)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Timing of platelet count fall",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Thrombosis or other sequelae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other causes for thrombocytopenia present",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Test interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12976323\">",
"      Other pre-test probability models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Initial intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87756545\">",
"      Alternative anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Argatroban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Transition to warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Danaparoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21256910\">",
"      - Lepirudin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21256948\">",
"      Anti-hirudin antibody formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Platelet transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2392980\">",
"      Transition to warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      USE OF HEPARIN AFTER AN EPISODE OF HIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10335285\">",
"      URGENT USE OF ANTICOAGULANTS DURING AN EPISODE OF HIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1369|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/36/32334\" title=\"algorithm 1\">",
"      Algorithm HIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1369|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/43/29375\" title=\"figure 1\">",
"      HIT mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/27/19901\" title=\"figure 2\">",
"      Platelet count and bleeding in ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/10/18605\" title=\"figure 3\">",
"      Predicting HIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1369|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/45/21211\" title=\"table 1\">",
"      Types of heparin thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/2/18475\" title=\"table 2\">",
"      Frequency heparin thrombopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/9/40091\" title=\"table 3\">",
"      ACCP guidelines Rx of HIT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_59_40891="Pediatric blood culture volume";
var content_f39_59_40891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric bacterial blood cultures: Recommended blood volume",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient weight",
"        <br/>",
"        (lb)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended blood volume per culture",
"        <br/>",
"        (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume of blood equal to 1 percent of patient's total blood volume",
"        <br/>",
"        (mL)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;19",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18-30",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        6-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-60",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        10-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-90",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        20-30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90-120",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;120",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Blood volume calculated by assuming 85 mL/kg in newborns and 73 mL/kg in other patients. Two 20 mL blood specimens collected from an 80 kg adult (40 mL total) represent approximately 0.7 percent of the patient's total blood volume.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Kaditis AG, O'Marcaigh AS, Rhodes KH, et al. Yield of positive blood cultures in pediatric oncology patients by a new method of blood culture collection. Pediatr Infect Dis 1996; 15:615.",
"       </li>",
"       <li>",
"        Specimen collection, transport, and processing: Bacteriology. In: Manual of Clinical Microbiology, 10th ed, Versalovic J, Carroll KC, Funke G, et al (Eds), ASM Press, Washington, DC 2007.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40891=[""].join("\n");
var outline_f39_59_40891=null;
var title_f39_59_40892="Sleep tonic muscle activity";
var content_f39_59_40892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of sleep on tonic muscle activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 190px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Integrated tensor palatini (TP) EMG activity, esophageal pressure (P esophageal) (negative is up in this figure), and inspiratory flow in a nonsnorer during wakefulness and sleep. Sleep is associated with a reduction in TP activity, an increase in esophageal pressure, and a reduction in airflow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Tangel, DJ, Mezzanotte, WS, White, DP, J Appl Physiol 1991; 70:2574.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40892=[""].join("\n");
var outline_f39_59_40892=null;
var title_f39_59_40893="AHT drug and HF ALLHAT";
var content_f39_59_40893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amlodipine, lisinopril, and increased risk of HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the ALLHAT trial, cumulative event rates for the development of heart failure (HF) according to primary treatment with chlorthalidone, amlodipine, or lisinopril. Compared to chlorthalidone, there were significant increases in the six year rate of HF with both amlodipine (10.2 versus 7.7 percent, relative risk 1.38, 95 percent CI 1.25 to 1.52) and lisinopril (8.7 versus 7.7 percent, relative risk 1.19 95 percent CI 1.07 to 1.31).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The ALLHAT Officers, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40893=[""].join("\n");
var outline_f39_59_40893=null;
var title_f39_59_40894="Algorithm for management of blunt aortic injury";
var content_f39_59_40894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of blunt aortic injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 478px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that depending upon the type of injury and the judgement of the surgeon, an aortic injury may be treated with endovascular repair rather than open thoracotomy.",
"    <div class=\"footnotes\">",
"     CT: computed tomography; CXR: chest x-ray; OR: operating room; TEE: transesophageal echocardiogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40894=[""].join("\n");
var outline_f39_59_40894=null;
var title_f39_59_40895="GAVE post bipolar probe endosc";
var content_f39_59_40895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thermal coagulation of gastric antral vascular ectasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance after bipolar probe thermal coagulation of gastric antral vascular ectasia (watermelon stomach). Coagulation with the bipolar probe eventually obliterated the vascular ectasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_59_40895=[""].join("\n");
var outline_f39_59_40895=null;
